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Rationale: Abdominal aortic aneurysm (AAA) is a complex disease with both genetic and environmental risk 
factors. Together, 6 previously identified risk loci only explain a small proportion of the heritability of AAA.
Objective: To identify additional AAA risk loci using data from all available genome-wide association studies.
Methods and Results: Through a meta-analysis of 6 genome-wide association study  data sets and a validation 
study totaling 10 204 cases and 107 766 controls, we identified 4 new AAA risk loci: 1q32.3 (SMYD2), 13q12.11 
(LINC00540), 20q13.12 (near PCIF1/MMP9/ZNF335), and 21q22.2 (ERG). In various database searches, we 
observed no new associations between the lead AAA single nucleotide polymorphisms and coronary artery disease, 
blood pressure, lipids, or diabetes mellitus. Network analyses identified ERG, IL6R, and LDLR as modifiers of 
MMP9, with a direct interaction between ERG and MMP9.
Conclusions: The 4 new risk loci for AAA seem to be specific for AAA compared with other cardiovascular 
diseases and related traits suggesting that traditional cardiovascular risk factor management may only have 
limited value in preventing the progression of aneurysmal disease.  
(Circ Res. 2017;120:341-353. DOI: 10.1161/CIRCRESAHA.116.308765.)
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■ matrix metalloproteinases ■ meta-analysis


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































342  Circulation Research  January 20, 2017
Nonstandard Abbreviations and Acronyms
AAA abdominal aortic aneurysm
CAD coronary artery disease
eQTL expression quantitative trait locus
GWAS genome-wide association study
IL interleukin
IPA ingenuity pathway analysis
LDLR low-density lipoprotein receptor
LRP1 low-density lipoprotein receptor related protein 1
SMYD2 SET and MYND domain containing 2 (SET domain-containing 
proteins, such as catalyze lysine methylation)
SNP single nucleotide polymorphism
TNF tumor necrosis factor
Abdominal aortic aneurysms (AAAs; MIM100070) are a significant cause of mortality and morbidity in the 
Western world. Although much less common than ischemic 
heart disease or stroke, AAA is responsible for ≈11 000 
deaths/y in the United States, with no clinical treatment oth-
er than expensive, high-risk surgery.1 The US Preventative 
Services taskforce recommends AAA screening by ultrasound 
for all men aged 65 to 75 years who have ever smoked.2 The 
UK NHS AAA Screening Program screens all men at the age 
of 65 years irrespective of smoking history yielding a preva-
lence of AAA (>29 mm) of 1.2%.3
Editorial, see p 259
AAA is an enigmatic complex disease. Although shar-
ing risk factors for, and often coexisting with atherosclerosis, 
AAA can be considered to be a distinct entity from atheroscle-
rosis. Smoking, a positive family history of AAA, and male 
sex have been consistently identified as the strongest risk fac-
tors for AAA. There is uncertainty over the influence of other 
traditional cardiovascular risk markers such as hypertension 
and hyperlipidemia. Furthermore, diabetes mellitus has been 
found to be negatively associated with AAA and is strongly 
protective against disease progression (AAA growth).1
Heritability of AAA is >0.7,4 and individuals with a first-
degree relative with AAA have a 2-fold higher risk of develop-
ing an AAA.5 Genome-wide association studies (GWAS) have 
identified 3 AAA risk loci on chromosomes 9 (DAB2IP6 [DAB2 
interacting protein]), 12 (LRP17 [low-density lipoprotein receptor 
related protein 1]), and 19 (LDLR8 [low-density lipoprotein re-
ceptor]). Further AAA risk loci on chromosomes 1 (SORT19 [sor-
tilin 1] and IL6R10 [interleukin 6 receptor]) and 9 (CDKN2BAS1/
ANRIL11 [also known as CDKN2B-AS1, CDKN2B antisense 
RNA 1]) were identified by candidate gene/locus approaches. 
Together, these explain only a small proportion of the heritability 
of AAA.
Overall, the high heritability estimates for AAA and the 
small number of loci identified suggest that there are further 
risk loci yet to be found. In the current study, we performed 
a meta-analysis of 6 available GWAS data sets for AAA on 
4972 cases and 99 858 controls and confirmed the findings 
within validation data sets of 5232 cases and 7908 controls. 
This resulted in identification of 4 novel validated loci for 
AAA. We followed up positive results with extensive bioin-
formatics analyses and used data available from various data-
bases to elucidate the potential biological significance of our 
findings to the pathobiology of AAA.
Methods
Detailed Methods are available in the Online Data Supplement.
Expanded Aneurysm Consortium
All known studies with AAA genome-wide genotyping (Online 
Methods; Online Table I) were invited to join the International 
Aneurysm Consortium. Additional samples (Online Methods; Online 
Table II) were used for the validation study. All AAA cases had an 
infrarenal aortic diameter of >30 mm. AAAs secondary to connec-
tive tissue diseases were excluded. The use of the samples in each 
study cohort was approved by local Ethics Committees or Institutional 
Review Boards.
What Is Known?
• Abdominal aortic aneurysm (AAA) has a prevalence of ≈1.5% in men 
aged >65 years.
• Positive family history of AAA is a strong risk factor for AAA; however, 
only 6 robust and independently validated AAA genetic loci have been 
identified to date.
What New Information Does This Article Contribute?
• Four novel genetic loci associated with AAA were identified.
• Pathway analysis highlighted the potential importance of lipoprotein 
metabolism, inflammation, and matrix metalloproteinases in AAA 
pathobiology.
• Potentially novel mechanisms, involving genes such as ERG, PLTP, and 
FGF9, were implicated.
AAA is a significant health burden, particularly among elderly 
males. It has a strong heritable component; however, previously 
identified risk loci explain only a small proportion of this effect. 
No current effective medical therapies that slow AAA growth 
exist, highlighting the need to better understand factors influ-
encing pathogenesis and disease progression. This study is 
the first meta-analysis of genome-wide association studies for 
AAA (10 204 cases). Four novel loci were identified and 5 of the 
6 previous AAA genetic associations were confirmed. The new 
loci showed no significant associations with other arterial disease 
phenotypes, potentially suggesting associations more specific to 
AAA than known loci (such as CDKN2BAS1, SORT1, and LDLR). 
Associations were consistent with known AAA pathobiology, im-
plicating lipoprotein metabolism, inflammation, and matrix me-
talloproteinases but also identified potentially novel mechanisms 
relating to genes such as ERG and FGF9. This study has identified 
novel, potentially disease-specific, genetic associations with AAA. 
Further functional studies, investigating the translational potential 
of these observations, will be required.
Novelty and Significance
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Meta-Analysis
The discovery phase of the meta-GWAS was conducted using the 
METAL (a tool for meta-analysis of genome-wide association scans) 
software package12 on the 6 cohorts detailed in Online Table I, com-
prising 4972 AAA cases and 99 858 controls. An effective sample 
number (N
eff) weighted analysis12 was conducted because of case/
control asymmetry within some of the contributing cohorts. Quality 
control included assessments for population stratification in each data 
set and adjustment was performed if necessary. The analysis of each 
contributing GWAS had been performed independently, and there was 
therefore no uniform analysis plan across all data sets. The individual 
GWAS data sets from Iceland and the Netherlands were adjusted for 
genomic inflation before inclusion in the meta-analysis. The over-
all meta-analysis was then adjusted for genomic inflation (λ; Online 
Table I; Online Figure I). An initial (λ-adjusted) discovery threshold 
of P<5×10−6 was used to identify single nucleotide polymorphisms 
(SNPs) for subsequent validation genotyping. SNPs with high hetero-
geneity (Phet <0.005 or I2>70%) were not taken forward for validation.
The lead SNPs [or their proxies in high linkage disequilibrium], 
identified in the discovery analyses, were then genotyped in a further 
8 independent cohorts with 5,232 cases and 7,908 controls (Online 
Table II). Allele association analysis of each individual validation 
study cohort was carried out using the SHEsis (software platform 
for analyses of linkage disequilibrium, haplotype construction, and 
genetic association at polymorphism loci) web-based software pack-
age.13 A combined (discovery-validation) fixed effect meta-analysis 
was performed using a Maentel–Haenzel method with the genome-
wide P-value significance threshold being set at 5×10−8. Random-
effects (Han-Eskin method14) meta-analysis was also performed 
to determine whether any results were sensitive to between-study 
heterogeneity.
SNP Lookup in GWAS for Other Traits 
Associated With AAA
GWAS data sets for other traits were searched for associations 
with the AAA-associated SNPs to determine whether the associa-
tions were unique to AAA or related to generalized cardiovascular 
disease. Results were obtained from meta-analyses of multiple pri-
mary GWAS data sets for each trait. Summary data for each AAA 
associated SNP (P value and effect size) were extracted. P values 
<5×10−8 were considered to be significant. Results were available for 
type 2 diabetes mellitus15 (DIAGRAM [a consortium called DIAbetes 
Genetics Replication And Meta-analysis] consortium; http://www.
diagram-consortium.org/index.html), coronary artery disease 
(CAD; CARDIoGRAM consortium (a consortium called Coronary 
ARtery DIsease Genome wide Replication and Meta-analysis)16; 
www.CARDIOGRAMPLUSC4D.ORG), lipids (the Global Lipids 
Genetics Consortium17; http://csg.sph.umich.edu/abecasis/public/lip-
ids2013), and blood pressure (the International Consortium for Blood 
Pressure18; http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.
cgi?study_id=phs000585.v1.p1).
Search for Other Associated Traits and Diseases 
Using GWAS Databases
The Phenotype-Genotype Integrator19 (http://www.ncbi.nlm.nih.
gov/gap/phegeni#GenomeView), the GWAS catalog (http://www.
gwascentral.org/index), and the NHLBI GRASP (The Genome-
wide Repository of Associations between SNPs and Phenotypes) 
catalog (GRASP v2.0; http://grasp.nhlbi.nih.gov/Overview.aspx)20 
were searched for diseases and traits associated with the lead SNPs 
at the AAA loci.
Phenome-Wide Association Study Analysis
We performed a phenome-wide association study (PheWAS)21,22 
exploring associations between the 9 AAA-associated SNPs and an 
extensive group of diagnoses to identify novel associations and un-
cover potential pleiotropy. For the PheWAS, we used data from the 
eMERGE (electronic Medical Records and Genomics) Network23 
with a total of 27 077 unrelated patients of European ancestry aged 
>19 years. We divided these samples into 2 data sets by propor-
tional sampling based on eMERGE site, sex, and genotyping plat-
form (13 559 and 13 518 individuals in sets 1 and 2, respectively). 
We calculated associations between the 9 AAA-associated SNPs 
and case or control status based on the extensive set of 9th edition of 
the International Statistical Classification of Diseases and Related 
Health Problems diagnoses (2408 and 2385 in sets 1 and 2, respec-
tively) where for a specific diagnosis, individuals with the diagnosis 
are considered cases. Associations were adjusted for sex, site, geno-
typing platform, and the first 3 principal components to account for 
global ancestry.
Annotation of AAA Associated SNPs Using the 
University of California Santa Cruz  Genome 
Browser, Pupasuite, and GWAS3D
Confirmed AAA-associated loci were manually annotated using the 
University of California Santa Cruz Genome Browser (http://genome.
ucsc.edu/cgi-bin/hgGateway) on the hg19 human genome assembly. 
For the Pupasuite analyses SNPs in linkage disequilibrium (r2>0.5) 
and with lead SNPs at the novel AAA risk loci identified were ex-
tracted from the 1000 Genomes data and then entered into Pupasuite 
v3.1.24 In addition, all known (novel and previously identified) AAA-
associated SNPs were entered into the GWAS3D (bioinformatics 
tool detecting human regulatory variants by integrative analysis of 
genome-wide associations, chromosome interactions, and histone 
modifications)25 web-portal (http://jjwanglab.org/gwas3d) to identify 
functional SNPs.
Bioinformatic Identification of Candidate AAA 
Genes and Pathways Using DEPICT (Data-Driven 
Expression-Prioritized Integration for Complex 
Traits)
An integrated gene function analysis was performed using the 
DEPICT tool (version 1.1).26 Two separate runs were performed 
using either all independent SNPs with discovery meta-GWAS 
P<5×10−6 or just those 9 SNPs that reached P<5×10−8 in the com-
bined analysis. Both nominal P values and false discovery rates were 
calculated.
Experimental Evidence for Functional Variants 
at AAA Loci
SNPs at loci confirmed to be associated with AAA were examined 
for functional effects using multiple methods (Online Methods). 
(1) To search for evidence of functional effects of SNPs at AAA 
associated loci 2 expression quantitative trait locus (eQTL) data 
sets based on publically available data, and a broad range of tis-
sues with relatively large sample sizes were examined. First, in-
dex and proxy SNPs were queried in a collected database of 
published expressed SNP results. The collected expressed SNP 
results met criteria for statistical thresholds for association with 
gene transcript levels as described in the original publications. 
Second, additional eQTL data were integrated from online sources 
including ScanDB (SNP and CNV Annotation Database), the 
Broad Institute The Genotype-Tissue Expression browser, and the 
Pritchard Laboratory (eqtl.uchicago.edu). (2) To search for vascu-
lar tissue-specific effects, eQTL data were also obtained from the 
ASAP (Advanced Study of Aortic Pathology) data set27 and RNA-seq 
(whole-genome RNA-sequence generated by high-throughput meth-
ods) data were from the Stockholm-Tartu Atherosclerosis Reverse 
Network Engineering Task (STARNET) database28 (http://www.
mountsinai.org/profiles/johan-bjorkegren). (3) Because some genes 
at AAA loci were associated with monocyte function and AAA is 
known to be an inflammatory disease,29 data from an eQTL analysis 
of peripheral blood monocytes were obtained from the Cardiogenics 
Consortium (http://www.cardiogramplusc4d.org/). (4) Finally to 
search for effects in AAA tissue specifically, mRNA expression pro-
files of all the GWAS3D predicted distal targets, as well as SNP prox-
imity implicated genes, were examined using a previously published 
genome-wide expression data set on human aorta (GSE57691),30 
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from which 49 AAA samples were compared with 10 organ donor 
control aortic samples. Transcription factor (TF) binding data were 
also obtained from a previous study,31 which described chromatin-
immunoprecipitation (ChIP)-chip for TFs ELF1, ETS2, RUNX1, and 
STAT5 using human aortic tissue in AAAs and healthy control aorta.
Network Analysis
We investigated whether most of the loci could be connected into 
a single network through intermediate nodes and interactions. A 
network integrating most of the loci would suggest mechanisms 
by which the loci could act in concert, whether synergistically or 
antagonistically, to affect the phenotype. The network(s) would 
also provide hypotheses for future investigation. Using the genes 
harboring AAA-associated SNPs as a starting set, we analyzed po-
tential interactions between the proteins and known intermediates 
(proteins, noncoding RNA, and metabolites) using 2 independent 
analysis tools, Ingenuity Pathway Analysis (IPA) tool version 9.0 
(Qiagen’s Ingenuity Systems, Redwood City, CA; www.ingenu-
ity.com) and Consensus PathDB (http://cpdb.molgen.mpg.de/
CPDB).32,33 The analyzed gene set had 14 genes because 2 of the 
9 AAA loci included clusters of 3 genes and tumor necrosis factor 
(TNF) was added because of the recent literature demonstrating 
the strong effect of SMYD2 (SET and MYND domain containing 2 
[SET domain-containing proteins, such as catalyze lysine methyla-
tion]) on interleukin-6 (IL6) and TNF production34,35 (see Online 
Table XIV for SNP annotations and Online Methods).
Results
Meta-Analysis of 6 GWAS Data sets for AAA 
Followed by a Validation Study Reveals 4 New 
AAA Susceptibility Loci
The meta-analysis of 6 GWAS data sets (4972 AAA cases; 
99 858 controls; Online Table I) revealed 19 loci of interest 
(P<1×10−6, Online Tables III and IV; Figure 1). Lead SNPs 
from these loci, including the 6 AAA risk loci reported pre-
viously, were analyzed in a validation study of 5232 AAA 
cases and 7908 controls (Online Tables II, V, VI, and VII). 
Four new loci were independently significant (P<0.05) in the 
validation cohort, had a direction of effect consistent with the 
discovery cohort and when combined with the discovery co-
hort had a P value that surpassed a genome-wide significance 
(5×10−8): 1q32.3 (SMYD2), 13q12.11 (LINC00540 [long 
intergenic nonprotein coding RNA 540]), 20q13.12 (near 
PCIF1 [C-terminal inhibiting factor 1 of a protein called pan-
creatic and duodenal homeobox 1]/MMP9 [matrix metallo-
proteinase 9]/ZNF335 [zinc finger protein 335]), and 21q22.2 
(ERG [v-ets avian erythroblastosis virus E26 oncogene ho-
molog]; Table 1; Online Tables V, VI, and VII; Figure 2). All 
previously reported associations with AAA were confirmed at 
genome-wide significance (Table 1; Online Table VII; Online 
Figure II) with the exception of 12q13.3 (LRP1), where the 
lead SNP identified in this meta-analysis and tested in our 
validation study only demonstrated a borderline association 
with AAA in the combined analysis (P=6.4×10−7). There was 
evidence of significant heterogeneity in the results observed 
for rs1795061 (near SMYD2) and rs2836411 (ERG) (Online 
Table VII). A random-effects model sensitivity analysis (Han-
Eskin14 method) demonstrated minimal effect on the results 
for these 2 loci (Online Table VIII). The lead SNPs at 2 loci 
that were both below the threshold for genome-wide signifi-
cance under the fixed-effects model (rs6516091, 20p12.3, near 
FERMT1 and rs5954362, Xq27.2, SPANXA1) were significant 
Figure 1. Whole-genome association plot for the primary meta-analysis of genome-wide association studies of abdominal 
aortic aneurysm (AAA). Data represent a meta-analysis of 4972 AAA cases and 99 858 controls. The horizontal line indicates the P 
value threshold of 5×10−6 used to select loci for validation studies. The 9 subsequently validated AAA loci are indicated along with the 
previously identified LRP1 locus, which fell to P=6.4×10–7 in the combined discovery/ validation analysis (Online Tables III and IV). 
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in the random-effects model. However, because both demon-
strated extreme heterogeneity (I2 ≥ 0.7), we did not consider 
these to be newly identified loci for AAA and these were ex-
cluded from further analysis.
New AAA Loci Seem to be Specific for AAA
To assess whether the loci identified in our meta-analysis were 
specific to AAA or were also associated with diseases or risk 
factors known to be associated with AAA, we looked up re-
sults from GWAS of CAD,6 hypertension,18 and lipid traits.17 
We also obtained results for diabetes mellitus15 to determine 
whether there was a reverse effect at these loci because diabe-
tes mellitus is a negative risk factor for AAA and negatively 
influences AAA growth.1 Other than the known associations 
at 1p13.3 (SORT1), 9p21 (CDKN2BAS1/ANRIL) with CAD, 
1p13.3 (SORT1) with high-density lipoprotein/LDL, and 
19p13.2 (LDLR) with LDL, we observed no new associations 
between the lead SNPs at any of the AAA risk loci we had 
identified and these traits (Figure 3; Online Table IX). In par-
ticular, no association was observed between diabetes mellitus 
and these SNPs. Literature searching revealed an association 
between rs4845625 at 1q21.3 (IL6R) and CAD, but this was 
not in high linkage disequilibrium with the lead SNP geno-
typed in our study at this locus (R2=0.54).36
We also searched GWAS Central (database proving integra-
tive visualization of and access to GWAS data) and Phenotype-
Genotype Integrator and performed a GRASP37 analysis for 
any associations of the lead AAA SNPs with traits other than 
those listed above. We identified additional genome-wide sig-
nificant associations between 1q21.3/IL6R (rs4129267) and 
C-reactive protein/asthma, and nominal associations between 
1p13.3/SORT1 (rs602633), 21q22.2/ERG (rs2836411), and 
19p13.2/LDLR (rs6511720) and height (Online Tables X, XI, 
and XII), a potential risk factor for AAA.38
We also performed a PheWAS21,22 in the eMERGE 
data sets exploring the association between the 9 AAA-
associated SNPs and an extensive group of diagnoses to 
identify novel associations and uncover potential pleiotropy. 
We considered identification of previously known associa-
tions, such as rs602633 associated with hyperglyceridemia 
and rs10757274 associated with CAD, to be indications that 
the PheWAS approach was robust. The PheWAS results 
demonstrated the known associations with CAD and lipid 
levels but did not identify any novel disease associations 
(Online Table XIII).
Annotation of SNPs at AAA Loci
Annotation did not identify any nonsynonymous variants in 
high linkage disequilibrium (R2>0.5) with the lead SNPs at 
the AAA risk loci (Online Tables XIV and XV). Based on 
GWAS3D analysis, all 9 lead SNPs were associated with TF-
binding site affinity variants (Online Tables XVI and XVII). 
Eight SNPs had potential long-range interactions with distal 
genomic regions (Figure 4). GWAS3D analysis also provided 
potential mechanistic insight for intergenic AAA variants such 
as rs9316871 (13q12.11) that had significant predicted regu-
latory variant interaction with FGF9 (fibroblast growth fac-
tor 9; 13q12.11). In addition, although the AAA association 
with rs599839 (1p13.3) showed strong long-range chromatin 
interaction with SORT1 (as previously reported specifically 
in AAA9), it also had predicted distal interactions with other 
genes including BCAR3 (breast cancer antiestrogen resistance 
3; 1p22.1) and NOTCH2 (notch 2 member of type 1 trans-
membrane protein family; 1p12-p11).
DEPICT Gene Pathway Prediction
DEPICT identified 633 and 482 gene enrichment sets with 
nominal P<0.05 using the discovery meta-GWAS SNP set 
Table 1. List of AAA Associated Loci Surpassing a Genome-Wide Significance Threshold After Combining GWAS data (4972 cases 
and 99 858 controls) and Validation Data (5232 cases and 7908 controls)
SNP
      Discovery Phase Validation Phase Combined
Chr Position Nearest Gene(s) Min_All* Maj_All* MAF OR P Value I2 OR P Value I2 OR 95% CI P Value I2





T G* 0.199 0.845 3.12×10−08 29.4 0.920 9.83×10−3 55.7 0.879 0.842–0.918 6.58×10−9 54.5





A G* 0.462 0.832 2.71×10−13 10.0 0.774 1.02×10−21 64.2 0.806 0.778–0.834 1.54×10−33 55.6
  rs10985349 9 124425243 DAB2IP T* C 0.195 1.185 2.01×10−7 18.1 1.155 2.30×10−5 3.9 1.171 1.118–1.226 2.40×10−11 9.2
  rs6511720 19 11202306 LDLR T G* 0.096 0.743 8.60×10−13 0 0.868 6.02×10−4 68.2 0.804 0.759–0.851 7.90×10−14 61.0
Novel AAA risk loci
  rs1795061 1 214409280 SMYD2 T* C 0.337 1.154 3.26×10−8 47.9 1.105 3.49×10−4 70.3 1.131 1.090–1.174 8.80×10−11 61.9





T* C 0.179 1.232 1.88×10−10 0 1.213 2.00×10−8 16.5 1.223 1.168–1.281 2.13×10−17 0.0
  rs2836411 21 39819830 ERG T* C 0.369 1.149 2.51×10−8 30.1 1.072 1.13×10−2 28.3 1.113 1.074–1.154 5.80×10−9 42.2
For all loci shown the direction of effect was consistent across all studies in the discovery phase. Full details are shown in Online Tables III, IV, V, VI, and VII. Results 
shown for the discovery, validation and combined analyses are all Maentel–Haenzel fixed effect meta-analysis method. AAA indicates abdominal aortic aneurysm; CI, 
confidence interval; MAF, minor allele frequency; and OR, odds ratio.
*Effect allele.
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(P<5×10−6) and top 9 SNPs from the combined analysis, re-
spectively. Only one of the gene sets (decreased long bone 
epiphyseal plate size) had a false discovery rate of <0.2. Gene 
set descriptions included multiple functional classes relevant 
to vascular biology, ie, transforming growth factor-β regula-
tion, lipoprotein metabolism, inflammation-induced extra-
cellular matrix remodeling (regulatory factor X1), vascular 
smooth muscle cell function, vascular injury including hem-
orrhage, immune cell function (particularly T and B cells), 
acute phase response including IL6 secretion, apoptosis, hy-
perglycemia and the phosphatidylinositol-4,5-bisphosphate 
3-kinase catalytic subunit alpha, c-Jun N-terminal kinase, and 
mitogen-activated kinase-like protein cascades. In addition, 
there were multiple gene sets associated with long bone size 
and epiphyseal plate formation (Table 2; Online Table XVIII 
and Online Data File).
Functional Effects of SNPs at AAA Loci
The lookup of SNPs at AAA loci in studies of functional effects 
included multitissue eQTL studies, vascular/monocyte-specif-
ic eQTL, and AAA-specific studies (mRNA expression and 
chromatin-immunoprecipitation-chip). These analyses revealed 
several potential functional associations (Online Tables XI, 
XX, XXI, and XXII; Online Figure III).27,39 Of most relevance 
to AAA, eQTLs were observed for rs3827066 (20q13.3) and 
PLTP (phospholipid transfer protein) expression in aortic tissue 
and for rs4129267 (1q21.3) and IL6R expression in mammary 
artery. RNA-Seq data also demonstrated independent eQTLs in 
mammary artery for 2 of the novel AAA associations we have 
identified: rs2836411 and ERG expression and rs9316871 and 
FGF9 expression. All eQTLs, with the exception of rs9316871 
and FGF9 were also seen in tissues other than arterial samples.
Several GWAS3D-predicted distal interacting genes had 
significantly different mRNA expression between AAA and 
control samples (Table 3; Online Table XXIII and Figure 
IV).30 For example, BCAR3 had decreased mRNA expression 
in AAA tissue (as did SORT1 itself). In addition, although the 
closest gene to rs9316871, a long intergenic noncoding RNA 
(LINC00540), was not part of the mRNA data set, the pre-
dicted distal target FGF9 had significantly increased mRNA 
expression in AAA tissue (Online Table XXIII).
Chromatin-immunoprecipitation-chip data from human 
AAA tissue31 revealed TF-binding sites in 5 genes (SMYD2, 
SORT1, CDKN2BAS1/ANRIL, ERG, and DAB2IP), which 
harbor AAA risk loci, but none of these binding sites included 
Figure 2. Regional association plots for 4 new abdominal aortic aneurysm (AAA) genome-wide significant loci at 1q32.3, 
13q12.11, 20q13.12, and 21q22.2. New AAA genome-wide significant loci at 1q32.3 (near SMYD2), 13q12.11 (LINC00540), 20q13.12 
(near MMP9/ZNF335), and 21q22.2 (ERG). −log10 (Pfixed) values for single nucleotide polymorphisms (SNPs) from the AAA discovery 
meta-analysis of 4972 cases and 99 858 controls were plotted against their genomic positions using LocusZoom (1000Genomes, EUR, 
November 2014). The peak SNP in each region is labeled (purple diamond), whereas the color indicates LD (r2) with the peak.
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the lead SNP tested for association with AAA (Online Table 
XXIV).
Network Analysis Reveals a Central Role for Matrix 
Metalloproteinase 9
Network analysis using both IPA and Consensus PathDB 
demonstrated similar results (Online Figures V and VI). Both 
analyses revealed a central role for MMP9 in AAA, with IPA 
identifying direct interactions (physical contact between 2 
molecules such as binding or phosphorylation) between ERG, 
IL6R and LDLR, and MMP9, and Consensus PathDB iden-
tifying a direct interaction between ERG and MMP9 with 
secondary interactions (interactions without physical contact, 
such as signaling events) between both SMYD2 and LDLR, 
and MMP9. On removing TNF from the analysis (which had 
been added based on the strong effect of SMYD2 on IL6 and 
TNF production34,35), the genes at AAA loci each remained in 
independent subnetworks. Inclusion of transforming growth 
factor-B1, implicated in thoracic aneurysms and Marfan syn-
drome, instead of TNF failed to coalesce the subnetworks. 
The long noncoding RNA ANRIL (CDKN2BAS1), our stron-
gest hit in the genome (Figure 1), has been reported in nu-
merous studies as a GWAS hotspot and a candidate gene for 
CAD, intracranial aneurysms, and diverse cardiometabolic 
disorders40; however, this was not represented in either the IPA 
or Consensus PathDB networks.
Discussion
The present study is the largest genetic association study of 
AAA performed to date, utilizing 6 GWAS data sets for AAA 
with a total of 4972 cases and 99 858 controls. Furthermore, 
we used an independent validation set of 5232 AAA cases 
and 7908 controls and then performed a pooled analysis of all 
10 204 cases and 107 766 controls. We confirmed the associa-
tion of 5 previously reported loci and identified 4 new loci as-
sociated with AAA at genome-wide levels of significance. In 
contrast to previously identified loci, lead SNPs at the newly 
identified loci did not demonstrate evidence of cross-pheno-
type association with other cardiometabolic phenotypes. In 
summary, the genetic evidence to date mirrors that seen in the 
epidemiological literature where it is clear that AAA and other 
forms of cardiovascular diseases are seen as distinct but over-
lapping phenotypes.
Previous genetic discoveries in AAA have pointed to in-
flammation and immune function (IL6R and CDKN2BAS1/
ANRIL) and low-density lipoprotein metabolism (SORT1 and 
LDLR) as important mediators of AAA development. The 
genes at the novel AAA loci identified here are relevant to 
aneurysm biology, but their precise roles require further in-
vestigation. MMP9 is within the 20q13.12 locus and matrix 
degradation via MMP9 is known to play a key role in the 
development of AAA, evidenced by the observation of high 
levels of MMP9 in end-stage disease specimens.41 This is also 
an important finding given the development of novel pharma-
cotherapies that target inflammation and matrix degradation 
pathways such as tofacitinib (a novel Janus kinase inhibitor). 
Although it is tempting to assume that MMP9 is the causal 
association at this locus, there are, however, other candidate 
genes at this locus. Examination of the region and the asso-
ciation pattern with AAA (Figure 2) shows that the strongest 
signals are seen upstream of MMP9 and are separated from 
MMP9 by a recombination hotspot. Closer to the strongest 
association signal are ZNF335 and PCIF1. There is no litera-
ture evidence for any potential link for ZNF335 to AAA and 
the only identified genetic association of ZNF335 is with ce-
liac disease.42 Although rs181914932 is upstream and more 
proximal to PCIF1, it has been associated with the activity of 
PLTP,43 an adjacent gene in the same locus. Our eQTL analy-
ses demonstrated an association between the lead SNP we as-
sessed at this locus (rs3827066) and PLTP expression in aortic 
tissue (Online Tables XX and XXI). We have also shown that 
PLTP expression is significantly higher in aneurysmal aortic 
Figure 3. Association between the lead single nucleotide 
polymorphisms (SNP) at the abdominal aortic aneurysm risk 
loci and association P values for other cardiovascular risk 
factors/traits (Online Table IX). CAD indicates coronary artery 
disease; DBP, diastolic blood pressure; DM, diabetes mellitus; 
HDL, high-density lipoprotein; LDL, low-density lipoprotein; SBP, 
systolic blood pressure; and TG, triglyceride.
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tissue than in control aorta (Online Table XXIII and Figure 
IV). PLTP plays a role in cholesterol transport. These data 
strengthen the evidence, particularly when taken together with 
the SORT1 and LDLR associations confirmed here, that aber-
rations of lipid metabolism play a key role in the development 
of AAA.
The other novel AAA loci identified here contain 
LINC00540, ERG, and SMYD2. LINC00540 is a long noncod-
ing RNA with no currently known function; however, both 
our GWAS3D and eQTL analyses independently suggested 
an association with FGF9, which was also differentially ex-
pressed within AAA tissue. ERG encodes a TF that is nor-
mally present in hematopoietic and endothelial cells. ERG has 
a role in vascular endothelial growth factor/mitogen-activated 
kinase-like protein–mediated vascular development,44 as well 
as regulating angiogenesis, which is known to play a role in 
the development of AAA.45,46 ERG also plays a role in the em-
bryonic development of the aorta,44 and it has been hypoth-
esized that in utero aortic development has a role in the later 
development of an AAA.47 In prostate cancer, ERG has been 
shown to regulate the expression of MMP9.48 Taken together 
this limited evidence points to several potential roles by which 
ERG may influence the development of AAA and, along with 
our significant eQTL observations, strongly suggest that fur-
ther work in this area is warranted.
The role of SMYD2 in AAA is less clear. SMYD2 regu-
lates HSP90 (heat shock protein 90) methylation,49 and the 
inhibition of heat shock protein 90 has been shown to reduce 
AAA formation in murine models,50 suggesting this as a pos-
sible link between SMYD2 and AAA. SMYD2 also plays a 
role in the differentiation of embryonic stem cells,51 again 
suggesting a possible role for aberrations of in utero aortic 
development influencing the risk of aortic disease later in life.
The integrated gene function analysis tool DEPICT 
identified numerous pathways that are potentially relevant 
to aneurysm pathogenesis (Table 2). In particular, we note 
with interest that the strongest predicted set was associated 
with long bone epiphyseal plate formation, which is pos-
sibly consistent with previous studies reporting tall stature 
as a risk factor for AAA52 and conversely short stature with 
occlusive CAD.53,54
Our network analyses using 2 different bioinformatics 
tools also revealed a central role for MMP9 in AAA, with IPA 
identifying direct interactions between ERG, IL6R and LDLR, 
and MMP9, and Consensus PathDB identifying a direct inter-
action between ERG and MMP9 with secondary interactions 
between both SMYD2 and LDLR and MMP9. These results 
suggest that the novel loci could act in concert, either syn-
ergistically or antagonistically, to affect the AAA phenotype, 
and provide hypotheses for future investigation using animal 
and cell culture models.
In this study, we did not replicate the association previ-
ously identified between LRP1 and AAA.7 The samples from 
the original study that identified this association were in-
cluded in this analysis, suggesting that this may have been 
a false-positive association. However, there is evidence sup-
porting LRP1 as a biologically plausible candidate pathway 
for AAA.55,56 Variants at, or close to, LRP1 are also associated 
with other vascular/related phenotypes (aortic dissection,57 
migraine,58 and lipid traits17). Because we observed a degree 
Figure 4. Circle plot showing the lead 
single nucleotide polymorphism (SNP) 
distal interaction regions based on the 
9 replicated abdominal aortic aneurysm 
genome-wide association study SNPs. 
Top variants with highest regulatory 
signals and distal interaction regions are 
shown on the outer circle (significant 
regulatory variants are labeled with I). The 
inner circle shows genes and genomic 
loci, whereas the distal interactive 
signals are shown with red lines (width 
corresponds to intensity of interaction). 
Note the long-range interactions, such 
as that between variants associated with 
IL6R (rs4845620, 1q21.3) and TYW1B 
(7q11.23).
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of heterogeneity at this locus in our analysis (Online Table 
VII), we consider that further investigation of this locus re-
mains warranted despite our findings.
Our GWAS3D genome analysis predicted potential nov-
el biological pathways in AAA pathogenesis. For example, 
FGF9 was shown to have a possible distal interaction with 
the intergenic SNP rs9316871. FGF9, although not previously 
considered a strong candidate in AAA pathogenesis, was nev-
ertheless at least partially validated by its increased mRNA 
expression in AAA tissue (Table 3). In AAA, both the medial 
and adventitial layers of the vessel wall are significantly more 
vascularized compared with nonaneurysmal tissue,59 and it 
is therefore interesting to note that FGF9 has been shown to 
enhance angiogenesis and neovascularization within mouse 
models of myocardial infarction.60
The main strength of this study is the inclusion of all cur-
rently available worldwide GWAS data sets for AAA and for-
mation of an expanded International Aneurysm Consortium. 
We acknowledge several limitations in our work. The over-
all numbers of samples included in our analysis are lower 
than for more common traits such as diabetes mellitus15 and 
CAD.16 We also did not have an adequate number of females 
in our sample set to perform sex-specific analyses that may 
Table 2. DEPICT Gene Enrichment Sets Based on the Top 10 
Validated Loci
Original Gene Set ID
Original Gene Set 
Description
DEPICT Nominal P 
Value
MP:0006396* Decreased long bone 
epiphyseal plate size
1.14×10−9
GO:0034381 Plasma lipoprotein 
particle clearance
5.22×10−7
ENSG00000132005 RFX1 PPI subnetwork 2.28×10−6




ENSG00000122641 INHBA PPI subnetwork 1.79×10−3
MP:0002764 Short tibia 1.79×10−3
ENSG00000169047 IRS1 PPI subnetwork 2.21×10−3
GO:0050431 Transforming growth 
factor beta binding
2.47×10−3
MP:0005590 Increased vasodilation 3.45×10−3
GO:0071813 Lipoprotein particle 
binding
3.51×10−3
GO:0005178 Integrin binding 4.08×10−3
ENSG00000133056 PIK3C2B PPI 
subnetwork
4.40×10−3
MP:0005095 Decreased T cell 
proliferation
4.84×10−3
ENSG00000149257 SERPINH1 PPI 
subnetwork
5.79×10−3
ENSG00000034152 MAP2K3 PPI 
subnetwork
6.58×10−3
ENSG00000017427 IGF1 PPI subnetwork 7.51×10−3
GO:0043406 Positive regulation of 
MAP kinase activity
7.65×10−3






MP:0004883 Abnormal vascular 
wound healing
8.15×10−3
ENSG00000106992 AK1 PPI subnetwork 8.69×10−3
MP:0003419 Delayed endochondral 
bone ossification
8.98×10−3




ENSG00000170581 STAT2 PPI subnetwork 9.79×10−3
GO:0043277 Apoptotic cell 
clearance
9.98×10−3
MP:0001828 Abnormal T—ell 
activation
0.01








GO:0007254 JNK cascade 0.01
GO:0014910 Regulation of smooth 
muscle cell migration
0.02




ENSG00000105851 PIK3CG PPI 
subnetwork
0.02
GO:0050900 Leukocyte migration 0.03
MP:0003957 Abnormal nitric oxide 
homeostasis
0.03
GO:0006953 Acute-phase response 0.03
ENSG00000206240 HLA-DRB1 PPI 
subnetwork
0.03











This table is a truncated version of the full list available in the Online Table 
XVIII. DEPICT indicates Data-Driven Expression-Prioritized Integration for 
Complex Traits.
*The gene sets that had a false discovery rate of <0.2.
Table 2. Continued
Original Gene Set ID
Original Gene Set 
Description
DEPICT Nominal P 
Value
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have been informative given the strong sexual dimorphism 
exhibited by AAA.61 We recognize this limitation, but the 
current focus of AAA screening programs on men alone2,3 
and the much reduced prevalence of AAA in women means 
that collecting adequate samples for such analyses is likely 
to be challenging. Some of the contributing GWAS studies 
such as the Aneurysm Consortium GWAS were derived from 
multicenter sample collections that led to intercohort hetero-
geneity in clinical phenotyping of the case groups. Together 
with the limited covariate data available for the control 
groups in the GWAS studies that used population control 
samples, this led to an inability to reliably adjust for clinical 
covariates in our overall analysis. Given these limitations, 
and in particular about the numbers of samples available for 
analysis in AAA, alternative approaches for investigating the 
genetic cause of AAA need to be considered. The natural 
history of AAA with a long latent period (if detected early), 
during which patients are monitored by serial imaging stud-
ies, offers the opportunity to study disease progression as a 
continuous trait, leveraging additional power over discrete 
trait approaches for the limited sample sizes available.37
In conclusion, our meta-GWAS and the bioinformat-
ics analyses, applying multiple techniques, has highlighted 
several potentially novel mechanisms of AAA pathobiology. 
These will require direct investigation in future studies to con-
firm their role in the development and progression of AAA.
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INDIVIDUAL GWAS STUDIES 
 
All known studies with AAA genome-wide genotyping data were invited to join the International 
Aneurysm Consortium effort.  All studies agreed to participate in the meta-GWAS, with cohort case 
control descriptions and inclusion/exclusion criteria having been previously reported1-3 (Online Table 
I). All AAA cases shared a common definition of infra-renal aortic diameter ≥30 mm. Patients with 
connective tissue disease associated AAAs (e.g. Marfan, Ehlers-Danlos, Loeys-Dietz) were excluded 
from the study. Each GWAS was based on a case-control analysis of AAA modelled as a discrete trait. 
The statistical analysis of the Aneurysm Consortium and New Zealand GWAS datasets was repeated 
specifically for this study and therefore was harmonized using identical imputation and analysis 
methods. Data from the remaining cohorts consisted of summary data obtained from previously 
performed analyses. 
The use of the samples in each study cohort was approved by the local Ethics Committees or 
Institutional Review Boards. 
 
DISCOVERY AND VALIDATION COHORT DESCRIPTIONS (Online Tables I and II) 
 
a) Discovery Cohorts 
 
Aneurysm Consortium (AC) AAA GWAS dataset:  The Aneurysm Consortium recruited cases of AAA 
from centres across the United Kingdom and Western Australia.  Cases were defined as an infra-
renal aortic diameter ≥ 30 mm proven on ultrasound or computerized tomography (CT) scan. 
Controls were taken from the WTCCC2 common control group1, 4 and were therefore unscreened for 
AAA.  
Data were from 1,866 cases with AAA and 5,435 unscreened controls from the Wellcome Trust Case 
Control Consortium 2 (WTCCC2) study consisting of samples from the 1958 British Birth Cohort and 
from the UK National Blood Service. DNA samples were processed at the Wellcome Trust Sanger 
Institute (WTSI). Genomic DNA was quantified by PicoGreen assay, and quality control (QC) assured 
by both agarose gel electrophoresis and Sequenom iPLEX genotyping of 29 SNPs and 4 sex-specific 
markers. Genotyping for the discovery study was performed using Illumina 1.2M (controls) or 670K 
(AAA) BeadChips. Raw intensity data were normalized using BeadStudio and genotypes were called 
concurrently from the combined case-control data set using the Illuminus algorithm5. 
As part of the original Aneurysm Consortium GWAS individual sample QC had been performed as 
follows. QC was first performed by exclusion of SNPs with call rates < 0.98 and those that 
demonstrated significant deviation from Hardy-Weinberg equilibrium in the control group (P<5x10-
4). Duplicate samples and those that failed genotyping (sample call rates <0.98) were also excluded 
from further analysis. Genotyping cluster plots for all SNPs with P< 1x10-4 were visually inspected to 
exclude from further analysis positive associations generated by erroneous genotyping or calling. 
Checks for population stratification were performed by PLINK6 identical by state clustering and 
extreme outliers were removed from the analysis.  
Imputation was performed using IMPUTE 2.2 run on the BCISNPmax database platform (version 3.5, 
BCI Platforms, Espoo, Finland). The reference haplotypes were based on the 1000 Genomes June 
2011 release. Imputed calls were filtered by quality score (excluding those <0.9) to restrict to higher 
quality imputed SNPs. 
Following imputation further QC filtering was performed, excluding SNPs with call rates < 0.98 and 
those that demonstrated significant deviation from Hardy-Weinberg equilibrium in the control group 
(P<5x10-4).  Duplicate samples and those that failed genotyping (sample call rate <0.98) were also 




New Zealand (NZ) Vascular Genetics Study AAA GWAS dataset:  The Vascular Research Consortium 
of New Zealand recruited New Zealand men and women with a proven history of AAA (infra-renal 
aortic diameter ≥ 30 mm proven on ultrasound or CT scan).  Approximately 80% had undergone 
surgical AAA repair (typically AAA’s > 50-55 mm in diameter).  The vast majority of cases (>97%) 
were of Anglo-European ancestry.  The control group underwent an abdominal ultrasound scan to 
exclude (>25 mm) concurrent AAA and Anglo-European ancestry was required for inclusion.  
Controls were also screened for peripheral artery disease (PAD; using ankle brachial index), carotid 
artery disease (ultrasound) and other cardiovascular risk factors. 
Two separate GWAS were performed using New Zealand samples.  NZ GWAS 1 consisted of 608 AAA 
patients (474 male) and 612 elderly controls (450 male), genotyped using the Affymetrix SNP 6 
GeneChip array.  All samples had call rates >0.95 (mean 0.992).  NZ GWAS 2 consisted of 397 AAA 
patients (332 male) and 384 elderly controls (308 male), genotyped using the Illumina Infinium 
Omni2.5 BeadChip array.  All samples had call rates >0.95 (mean 0.990).  All NZ genomic DNA 
samples exceeded manufacturer’s quality and quantity requirements having undergone pre-
assessment by Nanophotometer (Implen GmbH, München, Germany) and agarose gel 
electrophoresis. 
Imputation was conducted separately on NZ GWAS 1 and 2 data sets using the same methods as 
used for the Aneurysm Consortium datasets.  IMPUTE 2.2 was run on the BCISNPmax database 
platform (version 3.5, BCI Platforms, Espoo, Finland). The reference haplotypes were based on the 
1000 Genomes June 2011 release.  Imputed calls were filtered by quality score (excluding those 
<0.9) to restrict to higher quality imputed SNPs. The genomic inflation factors (λ) were 1.07 and 
1.05, respectively (MAF >0.05). 
Both NZ GWAS 1 and 2 data sets underwent QC filtering, excluding SNPs with call rates < 0.98 and 
those that demonstrated significant deviation from Hardy-Weinberg equilibrium in the control group 
(P<5x10-4).  Duplicate samples and those that failed genotyping (sample call rate <0.98) were also 
excluded from further analysis. Association testing was carried out in PLINK6. 
 
US (PA) GWAS dataset: AAA patients were enrolled through the Department of Vascular Surgery at 
Geisinger Medical Center, Danville, Pennsylvania, USA as previously reported2, 7. To identify cases 
and controls from the electronic medical records, an ePhenotyping algorithm was developed8. 
Briefly, Structured Query Language (SQL) was used to script the algorithm utilizing “Current 
Procedural Terminology” (CPT) and “International Classification of Diseases” (ICD-9) codes as well as 
demographic and encounter data to classify individuals as case, control, or excluded. AAA cases were 
defined as having an AAA repair procedure (case Type 1), or at least one appropriate specialty 
encounter (vascular clinic) with a ruptured AAA (case Type 2), or at least two specialty encounters 
with an unruptured AAA (case Type 3). Controls were neither cases nor those excluded, had an 
encounter within the past 5 years, and had never been assigned an ICD9 code of 441.*, where * is a 
1 or 2 digit code. Individuals were excluded if 1) they had a thoracic aortic aneurysm or a rare 
heritable disease with aortic manifestation; 2) they were younger than 40 or older than 89 years, 3) 
they had a single encounter with a code without mention of rupture (441.4), or 4) they had not had 
an encounter within the past 5 years. Rare heritable diseases were excluded because the goal of the 
current study was to identify non-syndromic AAA. Controls under 40 years might yet manifest an 
AAA, while cases under 40 years of age and without rare syndromic forms of aortic aneurysms are 
likely due to trauma. The AAA algorithm can be downloaded from www.PheKb.org. The algorithm 
was validated on a subset of individuals by manual chart review, and implemented at eMERGE 




AAA cases had infrarenal aortic diameter ≥ 30 mm as revealed by abdominal imaging. Approximately 
20% of individuals with AAA had a family history of AAA.  A control group was obtained through the 
Geisinger MyCode® Project, a cohort of Geisinger Clinic patients recruited for genomic studies.  The 
MyCode® controls were matched for age distribution and sex to the Geisinger Vascular Clinic AAA 
cases.  Based on electronic medical records, controls had no ICD-9 codes for AAA in their records, 
but they were not screened by ultrasonography for AAA.  Both cases and controls from the Geisinger 
Clinic were of European descent.  
The Geisinger cohort used for this study was a subset of a larger cohort comprising 3,264 samples 
from 3,149 individuals with three phenotypes: 922 putative AAA cases, 981 obesity cases and 1,246 
controls. Samples were genotyped on the Illumina HumanOmniExpress-12v1.0 genotyping platform 
at the University of Pittsburgh Genomics and Proteomics Core Laboratories. Genotypes were called 
using the Illumina GenomeStudio v2010.3 software. QC consisted of a number of steps: 
identification of cross-contamination and removal of specimens, call rate of samples (> 0.98 SNPs 
called), sex consistency between annotated sex and genotyped sex, SNP discordance between 
replicate sample pairs, SNP call rate (> 0.95 calls in all specimens), SNP minor allele frequency (> 
0.01), SNP Hardy-Weinberg equilibrium (P >1x 10-4), and selection of replicates to retain based on 
sex-specific Mahalanobis distance (< 4.1) and Illumina P10.GC (> 0.71). Cross-contamination of 
samples was detected by excess heterozygosity and excess relatedness (related to more than half of 
other samples at Pi-hat > 0.0625); four samples were removed prior to other QC steps. After the QC 
steps above, related individuals (pairwise Pi-hat > 0.15) were removed, retaining the individual and 
specimen with the highest call rate. A second round of QC was applied using the above SNP and 
sample criteria to ensure consistency after removal of SNPs and individuals. In addition, the SNP 
criteria were analyzed per chromosome to ensure that there were no systematic differences (no 
differences detected). Lastly, principle component analysis (PCA) was used to determine if there 
were any batch effects during genotyping (no evidence for batch effects). Of the 3,264 samples, 153 
were removed for one or more of the QC reasons above. Of the 731,306 SNPs, 95,369 were 
removed; 2,012 were discordant, 13,107 had a low call rate, 78,086 had a MAF < 0.01, and 14,056 
had a HWE P <1x 10-4 (9,047 SNPs were removed for more than one reason).  
 
The final meta-analysis cohort comprised only those individuals who were identified as definitive 
AAA cases or controls using the rigorous ePhenotyping algorithm described above. 
Imputation was performed as previously described9. Briefly: SNPs were re-mapped to the Genome 
Reference Consortium Human build 37 (GRCh37) and the program liftOver run to ensure mapping 
consistency. Subsequently all SNPs were mapped from the Illumina TOP notation to the plus (+) 
strand.  Strand was checked using SHAPEIT2 (version r2.644)10. Next the data were phased using 
SHAPEIT2. Imputation was performed using IMPUTE2 (version 2.3.0)11. Chromosomes were divided 
into 6 MB segments with 250 kbp overlap between segments. A total of 5,719,283 SNPs with an info 
score of ≥ 0.9 were used for analysis.  
Association analysis without adjustment was performed using PLINK (v1.09)6 and the imputed SNPs. 
The eMERGE Network Imputed GWAS for 41 Phenotypes (the dbGaP eMERGE Phase 1 and 2 Merged 
data Submission) accession number is: phs000888.v1.p1 which includes the Geisinger AAA data. 
 
Iceland, deCODE Genetics AAA GWAS dataset:  Icelandic individuals with AAA (defined as infra-renal 
aortic diameter ≥ 30 mm) were recruited from a registry of individuals who were admitted at 
Landspitali University Hospital, in Reykjavik, Iceland, 1980 – 2006.  AAA patients were either 
followed up or treated by intervention for emergency repair of symptomatic or ruptured AAA or for 
an elective repair by surgery or endovascular intervention.  In total, whole genome data from 557 
subjects with AAA, enrolled as part of the cardiovascular disease (CVD) genetics program at deCODE, 
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were included in the metaGWAS.  The Icelandic controls used (n=89,235) were selected from 
individuals who have participated in various GWA studies and who were recruited as part of genetic 
programs at deCODE.  Individuals with known CVD were excluded as controls2 but controls were 
unscreened for AAA. 
The Icelandic case and control samples were assayed with the Illumina HumanHap300, 
HumanHapCNV370 or HumanHap610 bead chips (Illumina, SanDiego, CA, USA). Only SNPs present 
on all chips were included in the analysis and SNPs were excluded if they had (a) call rates < 95% in 
cases or controls, (b) MAF<0.01 in the controls, or (c) showed significant deviation from HWE in the 
controls (P < 1x10-4). These criteria were applied separately to genotype data from each of the chip 
types used and SNPs that showed significant deviation (P < 0.0001 in an ANOVA test) in frequency 
between the chips were excluded from the analysis. Any samples with a call rate < 0.98 were 
excluded from the analysis. The final analysis included 293,677 SNPs present on all three chips. 
For case-control association analysis, we used a standard likelihood ratio statistic, implemented in 
the NEMO software12, to calculate two-sided P values and ORs for each individual allele, assuming a 
multiplicative model for risk13. 
Familial imputation: For the Icelandic data set, we extended the classical case-control association 
analysis to include in silico genotypes of affected individuals who were not genotyped but who had 
genotyped relatives14 among the 40,000 Icelanders (about 13% of all living Icelanders) genotyped 
with the Illumina SNP chips at deCODE Genetics. For every ungenotyped affected individual, we 
calculated the probability distribution of the genotypes of his or her relatives, given his or her four 
possible phased genotypes. In practice, we included only genotypes of the affected individual's 
parents, children, siblings, half-siblings (and the half-sibling's parents), grandparents, grandchildren 
(and the grandchildren's parents) and spouses. The contribution of the ungenotyped affected 
individuals through this familial imputation to the effective sample size of the affected individuals, 
na,eff, was estimated using the Fisher information. 
Genomic control: Some of the individuals in the Icelandic case-control groups are related to each 
other, causing the χ2 test statistic to have a mean >1 and median >0.455. We estimated the 
genome-wide inflation factor λg as the average of the 293,677 χ2 statistics to adjust for both 
relatedness and potential population stratification14. 
 
The Netherlands AAA GWAS dataset: The AAA sample set from Utrecht was recruited in 2007-2009 
from 8 centres in The Netherlands2, mainly when individuals visited their vascular surgeon in the 
clinic or, in rare cases, during hospital admission for elective or emergency AAA surgery.  An AAA 
was defined as an infrarenal aorta ≥ 30 mm. The sample set comprised 89.9% males, with a mean 
AAA diameter of 58.4 mm, 61.7% had been operated on, of which 8.1 % were after rupture. The 
Dutch controls used in the AAA GWAS were recruited as part of the Nijmegen Biomedical Study and 
the Nijmegen Bladder Cancer Study (see http://dceg.cancer.gov/icbc/membership.html). 
Genotyping was performed on Illumina HumanHap610 chips.2 As controls, we included 2,791 Dutch 
subjects who were recruited as part of the Nijmegen Biomedical Study (n=1,832) and the Nijmegen 
Bladder Cancer Study (n=1,278)15, 16 These controls were genotyped on Illumina CNV370 Duo 
BeadChips. 
QC: We performed QC using PLINK version 1.076. After removal of SNPs with A/T or C/G alleles and 
SNPs that were not called in any individual, we performed sample QC and SNP QC.  
Sample QC was performed after merging cases and controls, using a subset of common, high-quality 
SNPs (as defined by SNPs without deviation from HWE (P>0.001), with high MA) (>0.2) and with low 
rate of missing genotypes (<0.01)). Linkage disequilibrium (LD) pruning (r2>0.5) was performed. 
Subjects were removed based on the following three criteria: missing genotypes (subjects with call 
6 
 
rates < 0.95 were removed), heterozygosity (subjects were excluded if the inbreeding coefficient 
deviated more than 3 standard deviations from the mean) and cryptic relatedness (by calculating 
identity-by-descent (IBD) for each pair of individuals). In each pair with an IBD proportion of >20%, a 
subject was excluded, if it exhibited distant relatedness with more than one individual. For case-
control pairs, we removed the control subject. In the case-case or control-control pairs, the subject 
with the lowest call rate was excluded.  
Using these common, high-quality SNPs, we performed PCA using EIGENSTRAT on the remaining 
study subjects and HapMap-CEU subjects. We excluded SNPs from three regions with known long-
distance LD: the major histocompatibility (MHC) region (chr6: 25.8-36 Mbp), the chromosome 8 
inversion (chr8: 6-16 Mbp) and a chromosome 17 region (chr17: 40-45 Mbp). We created PC plots 
with the first four PCs, using R version 2.11.17 Based on visual inspection of these plots, we excluded 
subjects that appeared to be outliers with respect to the CEU or the study population. After outlier 
removal, we recomputed PCs for them to be included as covariates in the logistic regression models. 
After sample QC, we excluded SNPs with more than 2% missing genotypes, MAF < 0.01, missing 
genotype rate higher than MAF, and HWE deviation (P<0.001). Because cases and controls had been 
genotyped separately, we performed these QC steps in each study cohort separately and again after 
merging cases and controls. We also removed SNPs with a differential degree of missing genotypes 
between cases and controls (P<1x10-5; chi-squared test). 
Imputation: We performed genotype imputation using the pre-phasing/imputation stepwise 
approach implemented in IMPUTE2 and SHAPEIT (chunk size of 3 Mb and default parameters)10, 18. 
The imputation reference set consisted of 2,184 phased haplotypes from the full 1000 Genomes 
Project data set (February 2012; 40,318,253 variants). All genomic locations are given in NCBI Build 
37/UCSC hg19 coordinates. After imputation, SNPs with an imputation accuracy score < 0.6 or MAF < 
0.005 were excluded.  
Association testing: Association testing was carried out in PLINK6 using imputed SNP dosages. We 
included as covariates the first four PCs. We calculated genomic inflation factors (λGC), defined as the 
ratio of the median of the empirically observed distribution of the test statistic to the expected 
median19. 
 
b) Validation Cohorts 
 
Aneurysm Consortium (AC) validation cohort: The same inclusion/exclusion criteria and recruitment 
sites were used as for the Aneurysm Consortium AAA GWAS. The lead SNPs (or their high LD 
proxies), identified in the discovery analysis, were genotyped at The Wellcome Trust Sanger Insitute, 
Cambridge, UK using Sequenom iPLEX platform. Allele frequency summary results (odds ratio and 
95% confidence interval) were generated using Chi-squared tests as implemented in the SHEsis web-
based software package20 (available: http://analysis.bio-x.cn/SHEsisMain.htm). Deviation from HWE 
was estimated and results are shown in Online Table VI. 
 
New Zealand (NZ) Validation cohort:  NZ validation cohort participants were recruited from the 
same sites as those in the GWAS.  Case and control inclusion/exclusion criteria were identical to that 
of the NZ AAA GWAS, with all controls having been screened by ultrasound. 
The lead SNPs (or their high LD proxies), identified in the discovery analysis, were genotyped at the 
Vascular Research Group, University of Otago using the TaqMan (LifeTechnologies) platform. Allele 
frequency summary results (odds ratio and 95% confidence interval) were generated using Chi-
squared tests as implemented in the SHEsis web-based software package20. Deviation from HWE 




Belgium and Canada validation cohorts: These sample-sets, in which all individuals were of 
European descent, included individuals with AAA who were admitted either for emergency repair of 
ruptured AAA or for an elective surgery to the University Hospital of Liege (Liege, Belgium) and to 
Dalhousie University Hospital (Halifax, Canada).  AAA was defined as an infrarenal aortic diameter ≥ 
30 mm.  Details of these case-control sets have been reported previously21, 22. Approximately 40% of 
individuals with AAA had a family history of AAA. Control samples (51% males) were obtained from 
spouses of individuals with AAA or from individuals admitted to the same hospitals for reasons other 
than AAA. Controls had no known AAA, but they were not screened by ultrasonography for AAA. 
The lead SNPs (or their high LD proxies), identified in the discovery analysis, were genotyped in the 
Tromp-Kuivaniemi Laboratory at Geisinger Health System using TaqMan (LifeTechnologies) platform. 
Allele frequency summary results (odds ratio and 95% confidence interval) were generated using 
Chi-squared tests as implemented in the SHEsis web-based software package20. Deviation from HWE 
was estimated and results are shown in Online Table VI. 
 
eMERGE phase II (US) validation cohort: This cohort consisted of 338 AAA cases and 1,696 controls 
with GWAS data9 available from Mayo Clinic, Marshfield Clinic, Mount Sinai School of Medicine , 
Vanderbilt University, Northwestern University and Group Health Research Institute. The cases and 
controls were ascertained from the electronic medical records23 using an ePhenotyping algorithm8 as 
described above. The samples had been genotyped in various GWAS and then imputed (see above). 
Allele frequency summary results (odds ratio and 95% confidence interval) were generated using 
Chi-squared tests as implemented in the SHEsis web-based software package20. Deviation from HWE 
was estimated and results are shown in Online Table VI. The eMERGE Network Imputed GWAS for 
41 Phenotypes (the dbGaP eMERGE Phase 1 and 2 Merged data Submission) accession number is: 
phs000888.v1.p1 which includes these data. 
 
US Validation 2 cohort: A second US case/control  validation cohort was derived from the Mayo 
Vascular Disease Biorepository24 (Mayo VDB; http://www.mayo.edu/research/labs/cardiovascular-
biomarkers/vascular-diseases-biorepository), the Presbyterian University Hospital in Pittsburgh25, 
Vanderbilt University (BioVU®)26, Marshfield Clinic (Personalized Medicine Research Project®)27, 
Mount Sinai School of Medicine (BioMe®)28, and Northwestern University (NUgene®)29. The cases and 
controls at  Mayo Clinic, Vanderbilt University, Marshfield Clinic, Mount Sinai School of Medicine, 
and Northwestern University were phenotypically ascertained using the same ePhenotyping 
algorithm8 described above, whereas the AAA cases from the Presbyterian University Hospital in 
Pittsburgh were patients who had undergone elective or emergency surgery for AAA25. 
The lead SNPs (or their high LD proxies), identified in the discovery analysis, were genotyped in the 
Tromp-Kuivaniemi Laboratory at Geisinger Health System using TaqMan (LifeTechnologies) platform. 
Allele frequency summary results (odds ratio and 95% confidence interval) were generated using 
Chi-squared tests as implemented in the SHEsis web-based software package20. Deviation from HWE 
was estimated and results are shown in Online Table VI. 
 
Italy validation cohort: This group consisted of 761 AAA cases and 520 controls. AAA cases were 
individuals referred to the Vascular Surgery Unit of the University of Florence. Familial and 
inflammatory AAAs were excluded from the study. All control subjects (n=520) had a negative 
personal and family history of AAA and were of comparable age and sex distribution to that of the 
AAA patients. A more detailed description of the study populations has been previously published30. 
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The lead SNPs (or their high LD proxies), identified in the discovery analysis, were genotyped in the 
Giusti Laboratory at University of Florence using TaqMan (LifeTechnologies) platform. Allele 
frequency summary results (odds ratio and 95% confidence interval) were generated using Chi-
squared tests as implemented in the SHEsis web-based software package20. Deviation from HWE 
was estimated and results are shown in Online Table VI. 
 
Poland validation cohort: This group consisted of 481 AAA cases scheduled for surgery at the 
Department of General and Vascular Surgery of the Poznan University of Medical Sciences in the 
years 1999–2011. The control group, consisting of 487 subjects matched for age (±5 years) and sex 
to the AAA patients, was selected during the same time from the Poznan district31.  The collection of 
samples was approved by the Bioethics Committee of the Poznan University of Medical Sciences. 
The diagnosis of AAA was evaluated by computed tomography angiography or magnetic resonance 
angiography. Based on physical examination supplemented with ultrasound duplex color scanning, 
the coexistence of PAD was recognized in 60.3% of the AAA patients. All patients were treated 
pharmacologically with statins, antiplatelet drugs and other drugs (antihypertensive or antidiabetic), 
depending on their clinical condition. The exclusion criteria for the controls included known 
aneurysms and PAD.  
The lead SNPs (or their high LD proxies), identified in the discovery analysis, were genotyped in the 
Tromp-Kuivaniemi Laboratory at Geisinger Health System using TaqMan (LifeTechnologies) platform. 
Allele frequency summary results (odds ratio and 95% confidence interval) were generated using 
Chi-squared tests as implemented in the SHEsis web-based software package20. Deviation from HWE 




META-ANALYSIS of GWAS datasets 
 
The discovery analysis consisted of the six cohorts with GWAS data detailed above, comprising 4,972 
AAA cases and 99,858 controls, that were genotyped with a variety of genome-wide SNP arrays 
(Online Table I). All cohorts underwent QC filtering using the manufacturers’ array-specific 
guidelines but with consistently applied inclusion criteria of SNP or sample call rates >95% and HWE 
P>5x10-5 in controls1-3, 7.  Each cohort then underwent imputation (9see above). Following imputation 
SNPs were quality controlled by quality score (Q>0.9) and MAF>0.05 in controls filtering, resulting in 
a common set of 5,363,770 SNPs across all discovery phase participants. 
To obtain data for combination in the meta-analysis each case-control cohort was first analysed 
individually. Logistic regression models were used with AAA as a binary outcome in each cohort. 
Summary data [sample size, P-value, effect size (or log odds ratio), and the effect allele], unadjusted 
for covariates, for each SNP were combined in the meta-analysis. 
The metaGWAS analysis was conducted using the METAL software package32 on the BCISNPmax 
database platform (version 3.5, BCI Platforms, Espoo, Finland). METAL was implemented using the 
sample size scheme with weighting based on the effective sample size [Neff=4/(1/Ncases +1/Ncontrols)]. 
This approach was preferred over an inverse-variance weighted meta-analysis due to the 
disproportionate number of controls in some of the contributing cohorts and the fact that effect 
standard errors were not available in the data provided from Iceland and the United States 
(Geisinger) (Online Table I). The GWAS datasets from Iceland and the Netherlands were adjusted for 
genomic inflation prior to inclusion in the meta-analysis. The overall meta-GWAS analysis was 
adjusted for genomic inflation (λ) in each cohort (Online Table I; Online Figure I). An initial (λ-
adjusted) discovery threshold of P<5x10-6 was used to identify SNPs for subsequent validation 
genotyping. 
The lead SNPs (or their high LD proxies), identified in the discovery analysis, were then genotyped in 
a further 8 independent cohorts (Online Table II). Each cohort’s allele frequency summary results 
(odds ratio and 95% confidence interval) were generated using Chi-squared tests as implemented in 
the SHEsis web-based software package. Combined (discovery+validation) fixed effect meta-analysis 
was performed using a Maentel–Haenzel method with the genome-wide P-value significance 
threshold being set at 5x10-8. The Maentel-Haenzel method was chosen since SNPs from the 
discovery and validation studies that were being combined demonstrated effects in the same 
direction and with low/medium heterogeneity. A sensitivity analyses of the combined 
(discovery+validation) study data were also performed using a random-effects model33. The results 
from the discovery phase are presented in Table 1; Online Tables III and IV; Figures 1 and 2; and 
Online Figures I and II. The validation results are presented in Table 1 and Online Tables V and VI. 
Results from the combined analyses are presented in Table 1 and Online Table VII. Results from the 







Online Figure I.  Q-Q plot for the AAA meta-GWAS, showing (A) all 5.3 M SNPs with MAF>0.05 and 
(B) excluding the six previously identified loci (all SNPs within 100 kb of the peak variant associated 
with SORT1, IL6R, CDKN2BAS1, DAB2IP, LDLR, LRP1), generated from a comparison of 4,972 cases 
and 99,858 controls from 6 separate GWAS. The red arrow indicates the (λ-adjusted) P<5x10-6 
discovery threshold (362 SNPs in plot A). 
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Online Table I. Genome-wide association study (GWAS) cohort details. Individual level data were not available to calculate overall median age. 
 
GWAS cohorts 





















NZ 1 608 78 75 612 74 69 12.2 6.0 1,220 Affymetrix SNP6 1.07 None 
NZ 2 397 84 77 384 80 67 8.0 3.9 781 Illumina Omni2.5 1.05 None 
Aneurysm Consortium  1,846 98 72 5,605 49 52 37.1 18.1 5,555 Illumina 670 1.15 None 
Netherlands 840 90 68 2,791 60 51 16.9 8.2 2,583 Illumina 300/370/610 1.11 Lambda 
US (PA)  724 99 77 1,231 68 68 14.6 7.1 1,824 Illumina OmniExpress 1.06 None 
Iceland deCODE  557 77 72 89,235 44 60 11.2 5.5 2,214 Illumina 300/370/610 0.70 Lambda 
Total 4,972  N/A 99,858  N/A 100 48.7% 14,176    
 
Online Table II. Independent validation cohort details 
 
Validation cohorts 













validation (AC) 1,236 84 72 2,196 93 68 23.6 12.1 3,163 Sequenom 
NZ validation 753 81 77 1,237 67 68 14.4 7.4 1,872 Taqman 
Italy validation 761 79 73 520 78 72 14.5 7.5 1,236 Taqman 
Poland validation 481 86 69 487 72 59 9.2 4.7 968 Taqman 
eMERGE US validation 1 338 80 82 1696 80 82 6.5 3.3 1127 Imputed data fromvarious GWAS platforms 
US validation 2 1,176 82 73 1,371 64 68 22.5 11.5 2,532 Taqman 
Belgium validation 339 91 N/A 265 68 N/A 6.5 3.3 595 Taqman 
Canada validation 148 75 N/A 136 79 N/A 2.8 1.5 283 Taqman 
Total 5,232  N/A 7,908  N/A 100 51.3% 11,777  
*Combined (GWAS + Validation) analysis consisted of 10,204 AAA cases and 107,766 controls.
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Online Table III: Summary of results for the lead SNPs at 19 putative AAA associated loci (P<5x10-6) in the meta-analysis of 6 primary AAA GWAS datasets with a total of 
4,972 AAA cases and 99,858 controls (see Online Table I for details on these cohorts). The results were based on an Neffective weighted METAL analysis. The order of cohorts 
in the direction column is the same as that in Online Table I [NZ 1, NZ 2, Aneurysm Consortium, Netherlands, US (PA), Iceland (deCODE)]. See Online Table IV for MAF 
values for cases and controls separately. 
 
      Neffective weighted analysis 
Chr SNP Position Gene Risk allele 
Other 
allele Direction P Phet I
2 
1 rs602633 109821511 Near PSRC1 CELSR2 SORT1 T G ------ 1.72x10-07 0.097 46.3 
1 rs12133641 154428283 IL6R A G ++++++ 1.67x10
-10 0.903 0.0 
1 rs4129267 proxySNP 154426264 IL6R T C ------ 9.26x10-10 0.886 0.0 
1 rs1795061 214409280 near SMYD2 T C ++++++ 1.80x10-07 0.069 51.2 
2 rs13382862 20882449 near C2orf43 and GDF7 A G ------ 3.03x10-08 0.878 0.0 
4 rs10029392 5616048 EVC2 T G ++++++ 4.60x10-06 0.147 38.8 
5 rs12659791 74757758 COL4A3BP T C -----+ 2.28x10-06 0.105 45.1 
6 rs3176334 36648364 CDKN1A C T ------ 1.45x10-06 0.627 0.0 
6 rs733590 proxySNP 36645203 CDKN1A T C ------ 8.74x10-06 0.584 0.0 
8 rs3110425 107649626 OXR1 T C ------ 3.25x10-06 0.895 0.0 
9 rs10757274 22096055 CDKN2BAS1/ANRIL A G ------ 2.32x10-13 0.520 0.0 
9 rs10985349 124425243 DAB2IP T C ++++++ 8.98x10-07 0.181 34.0 
12 rs1385526 57532749 LRP1 C G ------ 1.31x10-09 0.597 0.0 
13 rs9316871 22861921 LINC00540 A G ++++++ 5.95x10-06 0.143 39.4 
15 rs17189674 89040591 DET1 A G ++++++ 1.05x10-06 0.663 0.0 
19 rs6511720 11202306 LDLR T G ------ 5.71x10-12 0.679 0.0 
19 rs12980543 56096197 ZNF579 A G ++++++ 2.30x10-06 0.301 17.4 
19 rs11084402 proxySNP 56093365 ZNF579 T C ++++++ 4.33x10-06 0.218 29.0 
20 rs6516091 6050622 near FERMT1 A G +++++- 3.82x10-09 0.027 60.5 
20 rs58749629 44571317 near PCIF1 ZNF335 MMP9 A G ++++++ 7.97x10-10 0.473 0.0 
20 rs3827066 proxySNP 44586023 near PCIF1 ZNF335 MMP9 T C ++++++ 9.18x10-10 0.729 0.0 
21 rs2836411 39819830 ERG T C +++++- 1.53x10-07 0.103 45.5 
X rs5954362 140673423 SPANXA1 G C --- 2.73x10




Online Table IV: Individual cohort data from the 6 primary AAA GWAS studies, combined using the Maentel–Haenzel fixed effect method, for the lead SNPs at the 19 
putative AAA loci identified in the meta-analysis of GWAS. See Online Table I for details on these cohorts. This table spans this and the following 6 pages. 
 
CHR SNP POSITION Region Cohort OR (95% CI) P Case/ Control MAFAAA MAFControl 
1 rs602633 109821511 Near PSRC1 CELSR2 SORT1  NZ GWAS 1 0.653 (0.535 - 0.797) 2.59E-05 608/ 612 0.1743 0.2442 
   NZ GWAS 2 0.874 (0.680 - 1.125) 0.2952 397/ 384 0.1870 0.2083 
   Aneurysm Consortium GWAS 0.864 (0.785 - 0.950) 0.002639 1846/ 5605 0.1942 0.2181 
   Netherlands GWAS 0.899 (0.778 - 1.038) 0.1458 840/ 2791 0.2151 0.2336 
   US (PA) GWAS 0.793 (0.680 - 0.925) 0.003166 724/ 1231 0.1843 0.2217 
   Iceland deCODE GWAS 0.916 (0.783 - 1.073) 0.2768 557/ 89235 0.1944 0.2085 
   OR (95% CI) Z-score P-value df (Q) HetI
2 HetPval 
   Combined 0.845 (0.796 - 0.897) -5.534 3.1E-08 5 29.4 0.215 
    
1 rs12133641 154428283 IL6R NZ GWAS 1 0.841 (0.715 - 0.989) 0.03596 608/ 612 0.3881 0.43 
 rs4129267 proxy 154426264 NZ GWAS 2 0.838 (0.683 - 1.027) 0.08904 397/ 384 0.3687 0.4108 
   Aneurysm Consortium GWAS 0.878 (0.813 - 0.948) 8.50E-04 1846/ 5605 0.3762 0.4072 
   Netherlands GWAS 0.818 (0.723 - 0.924) 0.001291 840/ 2791 0.3475 0.3936 
   US (PA) GWAS 0.817 (0.720 - 0.927) 0.001744 724/ 1231 0.3455 0.3925 
   Iceland deCODE GWAS 0.879 (0.775 - 0.997) 0.04487 557/ 89235 0.3857 0.4169 
   OR (95% CI) Z-score P-value df (Q) HetI
2 HetPval 
   Combined 0.854 (0.813 - 0.896) -6.382 1.7E-10 5 0 0.945 
    
1 rs1795061 214409280 near SMYD2 NZ GWAS 1 1.033 (0.868 - 1.229) 0.716 608/ 612 0.3224 0.3153 
   NZ GWAS 2 1.364 (1.087 - 1.713) 0.007383 397/ 384 0.3456 0.2791 
   Aneurysm Consortium GWAS 1.135 (1.048 - 1.229) 0.001908 1846/ 5605 0.3342 0.3067 
   Netherlands GWAS 1.075 (0.943 - 1.225) 0.2806 840/ 2791 0.2952 0.2784 
   US (PA) GWAS 1.324 (1.163 - 1.507) 2.16E-05 724/ 1231 0.3517 0.2907 
   Iceland deCODE GWAS 1.133 (0.997 - 1.287) 0.0559 557/ 89235 0.4247 0.3954 
   OR (95% CI) Z-score P-value df (Q) HetI
2 HetPval 
   Combined 1.154(1.097 - 1.214) 5.527 3.3E-07 5 47.9 0.087 
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CHR SNP POSITION Region Cohort OR (95% CI) P Case/ Control MAFAAA MAFControl 
2 rs13382862 20882449 C2orf43  and GDF7 NZ GWAS 1 0.886 (0.742 - 1.057) 0.1787 608/ 612 0.3424 0.3701 
   NZ GWAS 2 0.766 (0.618 - 0.948) 0.01432 397/ 384 0.3307 0.3922 
   Aneurysm Consortium GWAS 0.865 (0.799 - 0.937) 3.78E-04 1846/ 5605 0.3359 0.3689 
   Netherlands GWAS 0.862 (0.763 - 0.974) 0.0176 840/ 2791 0.3430 0.3761 
   US (PA) GWAS 0.855 (0.750 - 0.974) 0.01851 724/ 1231 0.3255 0.3609 
   Iceland deCODE GWAS 0.892 (0.782 - 1.016) 0.08629 557/ 89235 0.3420 0.3683 
   OR (95% CI) Z-score P-value df (Q) HetI
2 HetPval 
   Combined 0.863 (0.820 - 0.907) -5.75 8.8E-09 5 0 0.942 
    
4 rs10029392 5616048 EVC2 NZ GWAS 1 2.071 (1.444 - 2.968) 5.47E-05 608/ 612 0.0801 0.0404 
   NZ GWAS 2 1.199 (0.733 - 1.961) 0.4692 397/ 384 0.0467 0.0393 
   Aneurysm Consortium GWAS 1.306 (1.081 - 1.578) 0.005588 1846/ 5605 0.0436 0.0338 
   Netherlands GWAS 1.180 (0.869 - 1.601) 0.2894 840/ 2791 0.0396 0.0358 
   US (PA) GWAS 1.166 (0.882 - 1.542) 0.28 724/ 1231 0.0517 0.0447 
   Iceland deCODE GWAS 1.402 (1.033 - 1.904) 0.03019 557/ 89235 0.0587 0.0445 
   OR (95% CI) Z-score P-value df (Q) HetI
2 HetPval 
   Combined 1.331 (1.1851 - 1.495) 4.825 1.4E-06 5 32.1 0.195 
    
5 rs12659791 74757758 COL4A3BP NZ GWAS 1 1.284 (0.837 - 1.970) 0.2512 608/ 612 0.1763 0.1429 
   NZ GWAS 2 1.067 (0.808 - 1.409) 0.6466 397/ 384 0.1549 0.1466 
   Aneurysm Consortium GWAS 1.304 (1.181 - 1.440) 1.59E-07 1846/ 5605 0.1785 0.1428 
   Netherlands GWAS 1.216 (1.040 - 1.421) 0.01392 840/ 2791 0.1710 0.1480 
   US (PA) GWAS 1.077 (0.909 - 1.278) 0.3911 724/ 1231 0.1510 0.1417 
   Iceland deCODE GWAS 0.986 (0.819 - 1.188) 0.8844 557/ 89235 0.1264 0.1279 
   OR (95% CI) Z-score P-value df (Q) HetI
2 HetPval 
   Combined 1.192 (1.115 - 1.274) 5.151 2.6E-07 5 45.5 0.102 
           
           
           
15 
 
CHR SNP POSITION Region Cohort OR (95% CI) P Case/ Control MAFAAA MAFControl 
6 rs733590 proxy 36648364 CDKN1A NZ GWAS 1 1.027 (0.870 - 1.213) 0.7498 608/ 612 0.3550 0.3489 
   NZ GWAS 2 1.108 (0.896 - 1.371) 0.3434 397/ 384 0.3405 0.3178 
   Aneurysm Consortium GWAS 1.128 (1.040 - 1.224) 0.003699 1846/ 5605 0.3612 0.3339 
   Netherlands GWAS 1.228 (1.085 - 1.391) 0.001181 840/ 2791 0.4027 0.3552 
   US (PA) GWAS 1.160 (1.024 - 1.315) 0.01962 724/ 1231 0.4052 0.3699 
   Iceland deCODE GWAS 1.056 (0.925 - 1.206) 0.42 557/ 89235 0.3449 0.3329 
   OR (95% CI) Z-score P-value df (Q) HetI
2 HetPval 
   Combined 1.127 (1.072 - 1.186) 4.665 3.1E-06 5 0 0.546 
    
8 rs3110425 107649626 OXR1 NZ GWAS 1 0.909 (0.769 - 1.075) 0.2639 608/ 612 0.3460 0.3679 
   NZ GWAS 2 0.852 (0.692 - 1.048) 0.1284 397/ 384 0.3469 0.3842 
   Aneurysm Consortium GWAS 0.883 (0.816 - 0.955) 0.001861 1846/ 5605 0.3310 0.3613 
   Netherlands GWAS 0.865 (0.764 - 0.980) 0.02225 840/ 2791 0.3340 0.3680 
   US (PA) GWAS 0.954 (0.840 - 1.085) 4.68E-01 724/ 1231 0.3650 0.3760 
   Iceland deCODE GWAS 0.849 (0.752 - 0.959) 0.012 557/ 89235 0.3480 0.3870 
   OR (95% CI) Z-score P-value df (Q) HetI
2 HetPval 
   Combined 0.885 (0.843 - 0.93) -4.873 1.1E-06 5 0 0.784 
    
9 rs10757274 22096055 ANRIL/ CDKN2B-AS1 NZ GWAS 1 0.814 (0.694 - 0.955) 0.01152 608/ 612 0.4553 0.5066 
   NZ GWAS 2 0.922 (0.755 - 1.125) 0.4232 397/ 384 0.4484 0.4686 
   Aneurysm Consortium GWAS 0.842 (0.781 - 0.908) 7.91E-06 1846/ 5605 0.4707 0.5137 
   Netherlands GWAS 0.742 (0.660 - 0.834) 6.31E-07 840/ 2791 0.4746 0.5465 
   US (PA) GWAS 0.883 (0.782 - 0.997) 0.04425 724/ 1231 0.4793 0.5104 
   Iceland deCODE GWAS 0.838 (0.739 - 0.949) 0.005418 557/ 89235 0.5111 0.555 
   OR (95% CI) Z-score P-value df (Q) HetI
2 HetPval 
   Combined 0.832 (0.793 - 0.872) -7.612 2.7E-14 5 9.9 0.352 
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CHR SNP POSITION Region Cohort OR (95% CI) P Case/ Control MAFAAA MAFControl 
9 rs10985349 124425243 DAB2IP NZ GWAS 1 1.326 (1.078 - 1.630) 0.007382 608/ 612 0.2053 0.1631 
   NZ GWAS 2 1.443 (1.112 - 1.872) 0.005649 397/ 384 0.2091 0.1549 
   Aneurysm Consortium GWAS 1.159 (1.038 - 1.294) 0.008684 1846/ 5605 0.1666 0.1471 
   Netherlands GWAS 1.036 (0.890 - 1.206) 0.6491 840/ 2791 0.2192 0.2110 
   US (PA) GWAS 1.223 (1.050 - 1.425) 0.009782 724/ 1231 0.2055 0.1746 
   Iceland deCODE GWAS 1.212 (1.027 - 1.429) 0.02253 557/ 89235 0.2427 0.2130 
   OR (95% CI) Z-score P-value df (Q) HetI
2 HetPval 
   Combined 1.185 (1.112 - 1.264) 5.198 2.0E-07 5 18.1 0.296 
    
12 rs1385526 57532749 LRP1 NZ GWAS 1 0.863 (0.728 - 1.024) 0.09069 608/ 612 0.3165 0.3491 
   NZ GWAS 2 0.820 (0.659 - 1.021) 0.07616 397/ 384 0.3043 0.3478 
   Aneurysm Consortium GWAS 0.798 (0.737 - 0.865) 3.19E-08 1846/ 5605 0.3125 0.3629 
   Netherlands GWAS 0.893 (0.788 - 1.011) 0.07384 840/ 2791 0.3182 0.3452 
   US (PA) GWAS 0.902 (0.790 - 1.030) 0.1277 724/ 1231 0.3047 0.3269 
   Iceland deCODE GWAS 0.904 (0.796 - 1.028) 0.1233 557/ 89235 0.3945 0.4186 
   OR (95% CI) Z-score P-value df (Q) HetI
2 HetPval 
   Combined 0.851 (0.809 - 0.895) -6.295 3.1E-10 5 0 0.613 
    
13 rs9316871 22861921 LINC00540 NZ GWAS 1 0.979 (0.804 - 1.190) 0.8279 608/ 612 0.2048 0.2083 
   NZ GWAS 2 0.678 (0.530 - 0.869) 0.002047 397/ 384 0.1755 0.2388 
   Aneurysm Consortium GWAS 0.823 (0.750 - 0.903) 3.92E-05 1846/ 5605 0.1923 0.2244 
   Netherlands GWAS 0.891 (0.770 - 1.030) 0.1191 840/ 2791 0.1931 0.2104 
   US (PA) GWAS 0.880 (0.760 - 1.020) 0.08905 724/ 1231 0.2103 0.2324 
   Iceland deCODE GWAS 0.969 (0.821 - 1.143) 0.7052 557/ 89235 0.1763 0.1809 
   OR (95% CI) Z-score P-value df (Q) HetI
2 HetPval 
   Combined 0.864 (0.815 - 0.917) -4.850 1.23E-06 5 33.2 0.187 
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CHR SNP POSITION Region Cohort OR (95% CI) P Case/ Control MAFAAA MAFControl 
15 rs17189674 89040591 DET1 NZ GWAS 1 1.227 (0.966 - 1.559) 0.09398 608/ 612 0.1410 0.1180 
   NZ GWAS 2 1.595 (1.140 - 2.230) 0.006056 397/ 384 0.1273 0.0838 
   Aneurysm Consortium GWAS 1.241 (1.096 - 1.406) 6.51E-04 1846/ 5605 0.1123 0.0925 
   Netherlands GWAS 1.194 (0.991 - 1.438) 0.06165 840/ 2791 0.1314 0.1148 
   US (PA) GWAS 1.109 (0.916 - 1.344) 0.2889 724/ 1231 0.1167 0.1064 
   Iceland deCODE GWAS 1.181 (0.983 - 1.418) 0.07515 557/ 89235 0.1645 0.1448 
   OR (95% CI) Z-score P-value df (Q) HetI
2 HetPval 
   Combined 1.216 (1.128 - 1.311) 5.091 3.6E-07 5 0 0.742 
    
19 rs6511720 11202306 LDLR NZ GWAS 1 0.611 (0.403 - 0.927) 0.01942 608/ 612 0.04043 0.06452 
   NZ GWAS 2 0.717 (0.514 - 1.001) 0.05007 397/ 384 0.08564 0.11550 
   Aneurysm Consortium GWAS 0.764 (0.676 - 0.863) 1.48E-05 1846/ 5605 0.09778 0.12430 
   Netherlands GWAS 0.650 (0.529 - 0.797) 3.74E-05 840/ 2791 0.08240 0.12150 
   US (PA) GWAS 0.742 (0.608 - 0.905) 0.003207 724/ 1231 0.09655 0.12590 
   Iceland deCODE GWAS 0.855 (0.684 - 1.068) 0.1668 557/ 89235 0.07480 0.08720 
   OR (95% CI) Z-score P-value df (Q) HetI
2 HetPval 
   Combined 0.743 (0.685 - 0.806) -7.151 8.6E-13 5 0 0.829 
    
19 rs12980543 56096197 ZNF579 NZ GWAS 1 1.011 (0.832 - 1.227) 0.9147 608/ 612 0.2170 0.2152 
 rs11084402 proxy 56093365 NZ GWAS 2 1.280 (1.006 - 1.628) 0.04423 397/ 384 0.2418 0.1995 
   Aneurysm Consortium GWAS 1.077 (0.984 - 1.180) 0.1091 1846/ 5605 0.2153 0.2030 
   Netherlands GWAS 1.217 (1.051 - 1.409) 0.00854 840/ 2791 0.2159 0.1824 
   US (PA) GWAS 1.273 (1.094 - 1.481) 0.001733 724/ 1231 0.2131 0.1754 
   Iceland deCODE GWAS 1.281 (1.059 - 1.549) 0.01071 557/ 89235 0.1734 0.1430 
   OR (95% CI) Z-score P-value df (Q) HetI
2 HetPval 
   Combined 1.152 (1.086 - 1.223) 4.669 3.0E-06 5 33.2 0.187 
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CHR SNP POSITION Region Cohort OR (95% CI) P Case/ Control MAFAAA MAFControl 
20 rs6516091 6050622 near FERMT1 NZ GWAS 1 1.263 (0.991 - 1.609) 0.05848 608/ 612 0.1381 0.1126 
   NZ GWAS 2 1.271 (0.931 - 1.734) 0.13 397/ 384 0.1297 0.1050 
   Aneurysm Consortium GWAS 1.399 (1.261 - 1.551) 1.73E-10 1846/ 5605 0.1655 0.1242 
   Netherlands GWAS 1.187 (0.994 - 1.416) 0.05749 840/ 2791 0.1298 0.1150 
   US (PA) GWAS 1.186 (0.987 - 1.426) 0.06916 724/ 1231 0.1290 0.1110 
    Iceland deCODE GWAS 0.968 (0.783 - 1.197) 0.7619 557/ 89235 0.0938 0.0966 
   OR (95% CI) Z-score P-value df (Q) HetI
2 HetPval 
   Combined 1.262 (1.177 - 1.354) 6.525 6.8E-11 5 56.2 0.044 
    
20 rs58749629 44571317 Near MMP9/ZNF335 NZ GWAS 1 1.062 (0.846 - 1.333) 0.6044 608/ 612 0.1503 0.1427 
 rs3827066 proxy 44586023 NZ GWAS 2 1.101 (0.847 - 1.430) 0.4723 397/ 384 0.1827 0.1688 
   Aneurysm Consortium GWAS 1.237 (1.119 - 1.368) 2.97E-05 1846/ 5605 0.1743 0.1457 
   Netherlands GWAS 1.287 (1.099 - 1.506) 0.001752 840/ 2791 0.1761 0.1414 
   US (PA) GWAS 1.246 (1.067 - 1.456) 0.005513 724/ 1231 0.1972 0.1647 
   Iceland deCODE GWAS 1.325 (1.094 - 1.606) 0.003994 557/ 89235 0.1492 0.1193 
   OR (95% CI) Z-score P-value df (Q) HetI
2 HetPval 
   Combined 1.233 (1.156 - 1.314) 6.371 1.9E-10 5 0 0.444 
    
21 rs2836411 39819830 ERG NZ GWAS 1 1.313 (1.113 - 1.548) 0.001228 608/ 612 0.3980 0.3350 
   NZ GWAS 2 1.076 (0.876 - 1.321) 0.4862 397/ 384 0.3823 0.3652 
   Aneurysm Consortium GWAS 1.132 (1.048 - 1.223) 0.00155 1846/ 5605 0.3814 0.3525 
   Netherlands GWAS 1.204 (1.065 - 1.361) 0.002983 840/ 2791 0.4016 0.3611 
   US (PA) GWAS 1.232 (1.086 - 1.397) 0.001164 724/ 1231 0.3821 0.3342 
   Iceland deCODE GWAS 1.000 (0.878 - 1.139) 0.9964 557/ 89235 0.3330 0.3331 
   OR (95% CI) Z-score P-value df (Q) HetI
2 HetPval 
   Combined 1.149 (1.095 - 1.207) 5.573 2.5E-08 5 30.1 0.209 
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CHR SNP POSITION Region Cohort OR (95% CI) P Case/ Control MAFAAA MAFControl 
X RS5954362 140673423 SPANXA1 NZ GWAS 1 0.750 (0.556 - 1.007) 0.05496 474/ 450 0.2372 0.2930 
   NZ GWAS 2 0.862 (0.586 - 1.269) 0.4522 332/ 308 0.2310 0.2584 
   Aneurysm Consortium GWAS 0.584 (0.499 - 0.685) 1.81E-11 1815/ 2736 0.1894 0.2856 
   OR (95% CI) Z-score P-value df (Q) HetI
2 HetPval 






Online Table V: Summary of results for the combined (using the Maentel–Haenzel fixed effect method) validation study cohorts for the lead SNPs at putative AAA 
associated loci. The SNPs with P<5x10-6 in the meta-analysis of 6 primary AAA GWAS datasets were genotyped in 8 different validation cohorts for a total of 5,232 AAA cases 
and 7,908 controls (see Online Table II for details on these cohorts). Results including MAFs for cases and controls in each individual cohort are shown in Online Table VI. 
Where a proxy SNP was typed the original lead SNP from the discovery study is shown above the proxy SNP typed in the validation study. 
 
 
Chr SNP Position Gene Risk allele 
Other 
allele P Direction Phet I
2 
1 rs602633 109821511 Near PSRC1 CELSR2 SORT1 T G 0.01 ---++--- 0.027 55.8 
1 rs12133641 154428283 IL6R A G     
 rs4129267 proxySNP 154426264 IL6R T C 1.81x10-4 +------- 0.294 17.2 
1 rs1795061 214409280 near SMYD2 T C 3.49x10-4 +-++++++ 0 70.3 
2 rs13382862 20882449 near C2orf43 and GDF7 A G 0.360 ---++++- 0.278 19.2 
4 rs10029392 5616048 EVC2 T G 0.267 +-+---++ 0.195 29.2 
5 rs12659791 74757758 COL4A3BP T C 0.966 -+-+---+ 0.749 0.0 
6 rs3176334 36648364 CDKN1A C T     
 rs733590 proxySNP 36645203 CDKN1A T C 0.789 +++-+-+- 0.754 0.0 
8 rs3110425 107649626 OXR1 T C 0.261 +-+++--+ 0.268 20.4 
9 rs10757274 22096055 CDKN2BAS1/ANRIL A G 1.02x10-21 -------- 0.001 64.2 
9 rs10985349 124425243 DAB2IP T C 2.30x10-5 -+++++++ 0.4 3.9 
12 rs1385526 57532749 LRP1 C G 0.622 ---+++-+ 0.33 12.8 
13 rs9316871 22861921 LINC00540 A G 8.28x10-5 -----+-- 0.795 0.0 
15 rs17189674 89040591 DET1 A G 0.744 --++-++- 0.102 41.5 
19 rs6511720 11202306 LDLR T G 6.02x10-4 ------++ 0.003 68.2 
19 rs12980543 56096197 ZNF579 A G     
 rs11084402 proxySNP 56093365 ZNF579 T C 0.364 +-+++++- 0.12 38.9 
20 rs6516091 6050622 near FERMT1 A G 0.867 +-+---++ 0.104 41.1 
20 rs58749629 44571317 near PCIF1 ZNF335 MMP9 A G     
 rs3827066 proxySNP 44586023 near PCIF1 ZNF335 MMP9 T C 2.00x10-8 ++++++++ 0.3 16.5 
21 rs2836411 39819830 ERG T C 0.011 +++-++++ 0.203 28.3 
X rs5954362 140673423 SPANXA1 G C 0.172 -+-+-- 0.005 73.2 
21 
 
Online Table VI: Results of validation for the lead SNPs (combined using the Maentel–Haenzel fixed effect method) at putative AAA loci identified in the meta-analysis of 
GWAS. The SNPs with P<5x10-6 in the meta-analysis of 6 primary AAA GWAS datasets were genotyped in 8 different validation cohorts for a total of up to 5,232 AAA cases 
and 7,908 controls (see Online Table II for details on these cohorts). This table spans this and the following 5 pages. Where a proxy SNP is indicated the results are for that 
proxy SNP. 
 
Chromosome SNP POSITION Region Cohort OR (95% CI) Case/control MAFAAA MAFControl HWEControl HWEAAA
     
1 rs602633 109821511 Near PSRC1 CELSR2 SORT1 AC 0.885 (0.781-1.002) 1236/2196 0.191 0.211 0.079 0.799
    US2 0.864 (0.757-0.987) 1157/1374 0.211 0.236 0.724 0.248
    NZ 0.933 (0.794-1.095) 753/1237 0.201 0.213 0.473 0.183
    Italy 1.201 (0.995-1.449) 718/636 0.220 0.190 0.200 0.210
    Poland 1.133 (0.904-1.421) 443/474 0.218 0.197 0.652 0.995
    eMERGE 0.784 (0.639-0.963) 330/1648 0.203 0.245 0.005 0.248
    Belgium 0.8 (0.591-1.082) 302/216 0.192 0.229 0.198 0.959
    Canada 0.803 (0.533-1.211) 126/118 0.230 0.271 0.881 0.870
     
    OR (95% CI) Z-score P-value df (Q) HetPVal I-squared
    Combined: 0.92 (0.863-0.98) -2.582 0.010 7 0.027 55.770
     
     
1 rs12133641 154428283 IL6R AC 1.001 (0.904-1.108) 1236/2196 0.386 0.386 0.706 0.293
 rs4129267 proxy 154426264  US2 0.879 (0.783-0.986) 1137/1324 0.369 0.400 0.798 0.689
    NZ 0.835 (0.732-0.954) 753/1237 0.377 0.420 0.155 0.022
    Italy 0.897 (0.765-1.052) 714/585 0.364 0.390 0.286 0.179
    Poland 0.925 (0.768-1.114) 480/481 0.353 0.371 0.731 0.000
    eMERGE 0.927 (0.781-1.099) 345/1724 0.354 0.371 0.137 0.840
    Belgium 0.767 (0.606-0.971) 334/256 0.361 0.424 0.440 0.410
    Canada 0.761 (0.541-1.072) 139/133 0.381 0.447 0.025 0.427
     
    OR (95% CI) Z-score P-value df (Q) HetPVal I-squared
    Combined: 0.904 (0.857-0.953) -3.743 1.81E-04 7 0.294 17.200
     
     
1 rs1795061 214409280 Near SMYD2 AC 1.171 (1.053-1.302) 1236/2196 0.332 0.298 0.869 0.360
    US2 0.91 (0.808-1.024) 1172/1386 0.301 0.321 0.469 0.892
    NZ 1.077 (0.939-1.236) 753/1237 0.336 0.319 0.060 0.026
    Italy 1.434 (1.21-1.698) 761/558 0.340 0.264 0.226 0.071
    Poland 1.025 (0.848-1.239) 470/487 0.332 0.326 0.823 0.025
    eMERGE 1.088 (0.915-1.294) 340/1679 0.347 0.328 0.216 0.991
    Belgium 1.28 (0.996-1.646) 335/260 0.327 0.275 0.605 0.583
    Canada 1.32 (0.916-1.905) 132/132 0.352 0.292 0.075 0.364
     
    OR (95% CI) Z-score P-value df (Q) HetPVal I-squared
    Combined: 1.105 (1.046-1.168) 3.576 3.49E-04 7 0.000 70.300
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2 rs13382862 20882449 near C2orf43 and GDF7 AC 0.942 (0.85-1.045) 1236/2196 0.358 0.372 0.224 0.156
    US2 0.94 (0.836-1.057) 1109/1386 0.346 0.360 0.103 0.291
    NZ 0.87 (0.759-0.997) 753/1237 0.335 0.366 0.140 0.741
    Italy 1.109 (0.931-1.321) 727/558 0.287 0.266 0.158 0.345
    Poland 1.099 (0.906-1.332) 450/452 0.366 0.344 0.465 0.098
    eMERGE 1.083 (0.913-1.285) 335/1645 0.388 0.369 0.970 0.918
    Belgium 1.024 (0.794-1.319) 310/256 0.310 0.305 0.821 0.209
    Canada 0.998 (0.705-1.413) 142/131 0.370 0.370 0.720 0.021
     
    OR (95% CI) Z-score P-value df (Q) HetPVal I-squared
    Combined: 0.975 (0.923-1.029) -0.915 0.360 7 0.278 19.156
     
     
     
4 rs10029392 5616048 EVC2 AC 1.014 (0.814-1.263) 1698/2209 0.044 0.043 0.655 0.110
    US2* 0.876 (0.678-1.132) 1169/1387 0.046 0.052 0.217 0.088
    NZ* 1.233 (0.92-1.651) 753/1237 0.057 0.047 0.809 0.106
    Italy 0.767 (0.588-0.999) 678/556 0.088 0.112 0.423 0.709
    Poland* 0.809 (0.6-1.092) 472/481 0.091 0.110 0.074 0.963
    eMERGE 0.921 (0.642-1.321) 343/1707 0.054 0.058 0.998 0.006
    Belgium* 1.09 (0.545-2.18) 335/225 0.030 0.027 0.652 0.573
    Canada* 2.2 (0.754-6.422) 133/130 0.041 0.019 0.823 0.091
     
    OR (95% CI) Z-score P-value df (Q) HetPVal I-squared
    Combined: 0.94 (0.843-1.049) -1.111 0.267 7 0.195 29.200
     
     
5 rs12659791 74757758 COL4A3BP AC 0.963 (0.839-1.105) 1236/2196 0.149 0.154 0.071 0.307
    US2 1.063 (0.91-1.242) 1151/1371 0.153 0.145 0.398 0.663
    NZ 0.959 (0.802-1.148) 753/1237 0.152 0.158 0.149 0.581
    Italy 1.051 (0.83-1.332) 732/439 0.151 0.145 0.484 0.177
    Poland 0.976 (0.771-1.236) 486/488 0.169 0.172 0.002 0.553
    eMERGE 0.979 (0.773-1.241) 345/1723 0.138 0.140 0.818 0.807
    Belgium 0.91 (0.669-1.237) 339/266 0.156 0.169 0.298 0.126
    Canada 1.62 (0.898-2.921) 105/91 0.167 0.110 0.239 0.953
     
    OR (95% CI) Z-score P-value df (Q) HetPVal I-squared
    Combined: 0.998 (0.929-1.073) -0.043 0.966 7 0.749 0.000
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Chromosome SNP POSITION Region Cohort OR (95% CI) Case/control MAFAAA MAFControl HWEControl HWEAAA
     
     
     
6 rs3176334 36648364 CDKN1A AC 1.042 (0.94-1.156) 1236/2196 0.356 0.347 0.523 0.412
 rs733590 proxy 36645203  US2 1.006 (0.897-1.127) 1157/1374 0.379 0.378 0.871 0.072
    NZ 1.026 (0.894-1.178) 753/1237 0.333 0.327 0.268 0.428
    Italy 0.978 (0.831-1.149) 733/546 0.371 0.376 0.163 0.992
    Poland 1.021 (0.846-1.232) 455/453 0.398 0.393 0.702 0.557
    eMERGE 0.893 (0.748-1.066) 318/1599 0.357 0.383 0.525 0.391
    Belgium 1.127 (0.888-1.43) 331/254 0.394 0.366 0.776 0.917
    Canada 0.84 (0.585-1.205) 142/132 0.296 0.333 0.361 0.150
     
    OR (95% CI) Z-score P-value df (Q) HetPVal I-squared
    Combined: 1.007 (0.955-1.063) 0.2678 0.789 7 0.754 0.000
     
     
8 rs3110425 107649626 OXR1 AC 1.079 (0.974-1.196) 1225/2167 0.374 0.356 0.111 0.315
    US2 0.933 (0.826-1.053) 987/1323 0.355 0.371 0.568 0.248
    NZ 1.088 (0.949-1.247) 704/1174 0.382 0.361 0.107 0.279
    Italy 1.058 (0.878-1.275) 532/445 0.359 0.346 0.883 0.226
    Poland 1.214 (0.999-1.475 449/457 0.363 0.319 0.770 0.164
    eMERGE 0.942 (0.794-1.118) 342/1711 0.360 0.373 0.971 0.448
    Belgium 0.910 (0.713-1.163) 313/246 0.356 0.378 0.558 0.672
    Canada 1.036 (0.725-1.481) 126/118 0.230 0.271 0.881 0.870
     
    OR (95% CI) Z-score P-value df (Q) HetPVal I-squared
    Combined: 1.032 (0.977-1.090) 1.124 0.261 7 0.268 20.420
     
9 rs10757274 22096055 ANRILCDKN2BAS1/ AC 0.831 (0.752-0.917) 1236/2196 0.456 0.502 0.273 0.163
    US 0.748 (0.67-0.836) 1162/1382 0.451 0.523 0.099 0.622
    NZ 0.885 (0.777-1.007) 753/1237 0.466 0.497 0.561 0.038
    Italy 0.63 (0.527-0.753) 540/464 0.371 0.484 0.236 0.052
    Poland 0.679 (0.565-0.816) 451/468 0.463 0.560 0.616 0.551
    eMERGE 0.68 (0.576-0.804) 336/1696 0.435 0.530 0.333 0.922
    Belgium 0.959 (0.757-1.214) 313/248 0.455 0.466 0.333 0.977
    Canada 0.674 (0.468-0.97) 117/117 0.427 0.526 0.535 0.320
     
    OR (95% CI) Z-score P-value df (Q) HetPVal I-squared
    Combined: 0.774 (0.735-0.816) -9.575 1.02E-21 7 0.001 64.200
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9 rs10985349 124425243 DAB2IP AC 0.998 (0.876-1.135) 1236/2196 0.179 0.179 0.878 0.696
    US2 1.208 (1.051-1.387) 1171/1385 0.211 0.181 0.625 0.165
    NZ 1.266 (1.072-1.495) 753/1237 0.199 0.164 0.865 0.720
    Italy 1.227 (0.975-1.544) 729/620 0.138 0.115 0.061 0.327
    Poland 1.182 (0.947-1.476) 485/488 0.215 0.189 0.322 0.228
    eMERGE 1.215 (0.969-1.523) 299/1544 0.189 0.161 0.346 0.381
    Belgium 1.139 (0.848-1.53) 338/266 0.192 0.173 0.682 0.220
    Canada 1.304 (0.861-1.975) 149/134 0.221 0.179 0.177 0.116
     
     OR (95% CI) Z-score P-value df (Q) HetPVal I-squared 
    Combined: 1.155 (1.081-1.235) 4.233 2.30E-05 7 0.400 3.900
     
     
12 rs1385526 57532749 LRP1  AC 0.983 (0.886-1.092) 1236/2196 0.339 0.343 0.293 0.297
    US2 0.905 (0.804-1.019) 1161/1382 0.306 0.328 0.668 0.221
    NZ 0.918 (0.801-1.052) 753/1237 0.333 0.352 0.160 0.840
    Italy 1.135 (0.942-1.366) 509/493 0.351 0.323 0.072 0.392
    Poland 1.058 (0.875-1.28) 453/480 0.359 0.346 0.083 0.580
    eMERGE 1.124 (0.944-1.339) 342/1695 0.336 0.311 0.695 0.170
    Belgium 0.966 (0.749-1.244) 324/246 0.306 0.313 0.744 0.647
    Canada 1.031 (0.706-1.506) 132/120 0.311 0.304 0.181 0.607
     
    OR (95% CI) Z-score P-value df (Q) HetPVal I-squared
    Combined: 0.986 (0.933-1.042) -0.493 0.622 7 0.330 12.800
     
     
13 rs9316871 22861921 LINC00540 AC 0.905 (0.801-1.023) 1236/2196 0.199 0.216 0.094 0.193
    US2 0.845 (0.738-0.966) 1176/1384 0.202 0.231 0.624 0.052
    NZ 0.834 (0.711-0.978) 753/1237 0.195 0.225 0.210 0.727
    Italy 0.925 (0.776-1.102) 621/646 0.262 0.278 0.178 0.107
    Poland 0.884 (0.721-1.085) 469/483 0.251 0.274 0.222 0.038
    eMERGE 1.008 (0.828-1.226) 345/1724 0.223 0.222 0.049 0.954
    Belgium 0.79 (0.592-1.053) 330/251 0.185 0.223 0.854 0.920
    Canada 0.798 (0.515-1.235) 133/125 0.177 0.212 0.004 0.271
     
    OR (95% CI) Z-score P-value df (Q) HetPVal I-squared
    Combined: 0.883 (0.83-0.94) -3.936 8.28E-05 7 0.795 0.000
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15 rs17189674 89040591 DET1 AC 0.889 (0.763-1.036) 1236/2196 0.115 0.128 0.264 0.949
    US2 0.934 (0.781-1.116) 1170/1381 0.104 0.110 0.000 0.846
    NZ 1.301 (1.065-1.588) 753/1237 0.130 0.103 0.499 0.429
    Italy 1.115 (0.862-1.441) 616/872 0.127 0.116 0.113 0.276
    Poland 0.912 (0.686-1.212) 488/489 0.105 0.113 0.559 0.260
    eMERGE 1.072 (0.815-1.411) 320/1649 0.108 0.101 0.553 0.114
    Belgium 1.214 (0.849-1.737) 340/266 0.125 0.105 0.973 0.403
    Canada 0.927 (0.557-1.542) 201/137 0.113 0.120 0.105 0.944
     
    OR (95% CI) Z-score P-value df (Q) HetPVal I-squared
    Combined: 1.014 (0.935-1.099) 0.327 0.744 7 0.102 41.500
     
19 rs6511720 11202306 LDLR AC 0.969 (0.826-1.136) 1236/2196 0.107 0.110 0.144 0.384
    US2 0.93 (0.792-1.092) 1166/1383 0.132 0.141 0.000 0.000
    NZ 0.849 (0.69-1.045) 753/1237 0.103 0.119 0.737 0.454
    Italy 0.566 (0.436-0.736) 667/567 0.079 0.132 0.736 0.242
    Poland 0.607 (0.454-0.812) 477/479 0.087 0.136 0.944 0.132
    eMERGE 0.933 (0.709-1.227) 320/1639 0.108 0.101 0.553 0.114
    Belgium 1.162 (0.817-1.653) 336/260 0.129 0.113 0.102 0.079
    Canada 1.025 (0.63-1.67) 141/133 0.138 0.135 0.676 0.231
     
    OR (95% CI) Z-score P-value df (Q) HetPVal I-squared
    Combined: 0.868 (0.801-0.941) -3.431 6.02E-04 7 0.003 68.200
     
     
     
19 rs12980543 56096197 near ZNF579 AC 1.033 (0.913-1.169) 1217/2169 0.205 0.199 0.239 0.604
 rs11084402 proxy 56093365 near ZNF579 US2 0.889 (0.771-1.025) 1164/1386 0.176 0.193 0.216 0.988
    NZ 1.113 (0.953-1.3) 737/1217 0.230 0.212 0.665 0.832
    Italy 1.075 (0.871-1.326) 648/503 0.196 0.185 0.124 0.203
    Poland 1.014 (0.802-1.281) 474/485 0.177 0.176 0.737 0.780
    eMERGE 1.145 (0.935-1.402) 344/1723 0.209 0.188 0.967 0.200
    Belgium 1.293 (0.97-1.722) 337/262 0.223 0.181 0.068 0.140
    Canada 0.73 (0.486-1.096) 135/125 0.207 0.264 0.130 0.142
     
    OR (95% CI) Z-score P-value df (Q) HetPVal I-squared
    Combined: 1.03 (0.966-1.099) 0.908 0.364 7.000 0.120 38.900
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20 rs6516091 6050622 near FERMT1 AC 1.112 (0.961-1.287) 1236/2196 0.136 0.124 0.911 0.431
    US2 0.901 (0.768-1.057) 1173/1384 0.132 0.144 0.625 0.149
    NZ 1.094 (0.9-1.33) 753/1237 0.131 0.121 0.682 0.424
    Italy 0.834 (0.667-1.043) 715/589 0.137 0.160 0.357 0.152
    Poland 0.824 (0.619-1.096) 485/488 0.100 0.119 0.363 0.002
    eMERGE 0.94 (0.741-1.192) 343/1716 0.137 0.145 0.047 0.511
    Belgium 1.355 (0.947-1.939) 339/266 0.133 0.102 0.065 0.153
    Canada 1.089 (0.671-1.768) 149/137 0.138 0.128 0.857 0.415
     
    OR (95% CI) Z-score P-value df (Q) HetPVal I-squared
    Combined: 0.994 (0.921-1.072) -0.167 0.867 7 0.104 41.100
     
20 rs58749629 44571317 near PCIF1 ZNF335 MMP9 AC 1.076 (0.94-1.233) 1236/2196 0.160 0.151 0.688 0.617
 rs3827066 proxy 44586023 near PCIF1 ZNF335 MMP9 US2 1.197 (1.035-1.385) 1171/1384 0.185 0.160 0.510 0.814
    NZ 1.372 (1.153-1.632) 753/1237 0.185 0.142 0.132 0.899
    Italy 1.263 (1.05-1.518) 709/579 0.256 0.214 0.380 0.275
    Poland 1.373 (1.092-1.728) 487/486 0.210 0.163 0.958 0.907
    eMERGE 1.077 (0.86-1.348) 345/1713 0.159 0.150 0.160 0.926
    Belgium 1.291 (0.956-1.743) 340/265 0.196 0.158 0.280 0.733
    Canada 1.469 (0.983-2.197) 146/132 0.260 0.193 0.023 0.028
     
    OR (95% CI) Z-score P-value df (Q) HetPVal I-squared
    Combined: 1.213 (1.134-1.298) 5.616 2.00E-08 7 0.300 16.500
     
     
21 rs2836411 39819830 ERG AC 1.05 (0.947-1.164) 1236/2196 0.367 0.355 0.409 0.483
    US2 1.085 (0.966-1.218) 1171/1382 0.350 0.331 0.073 0.877
    NZ 1.171 (1.023-1.339) 753/1237 0.387 0.351 0.733 0.258
    Italy 0.898 (0.757-1.065) 706/625 0.263 0.285 0.088 0.332
    Poland 1.125 (0.935-1.354) 482/484 0.380 0.352 0.990 0.769
    eMERGE 1.045 (0.88-1.241) 345/1724 0.349 0.339 0.485 0.797
    Belgium 1.01 (0.797-1.281) 339/264 0.358 0.356 0.224 0.715
    Canada 1.457 (1.04-2.041) 150/137 0.440 0.350 0.422 0.314
     
    OR (95% CI) Z-score P-value df (Q) HetPVal I-squared
    Combined: 1.072 (1.016-1.131) 2.533 0.011 7 0.203 28.300
     
     
X rs5954362 140673423 SPANXA1 Males only  
    NZ 0.816 (0.636-1.047) 585/762 0.248 0.288
    Belgium 1.301 (0.972-1.741) 319/183 0.310 0.257
    Canada 0.536 (0.294-0.978) 155/32 0.272 0.411
    eMERGE 1.189 (1.044-1.353) 1145/1134 0.311 0.276
    Poland 0.948 (0.759-1.186) 426/355 0.286 0.297
     
    OR (95% CI) Z-score P-value df (Q) HetPVal I-squared
    Combined: 1.069 (0.972-1.175) 1.366 0.172 4 0.005 73.200




Online Table VII: Combined results from GWAS meta-analysis and validation studies. Shaded rows indicate validated AAA risk loci that are also shown in Table 1 in the main 
text. A fixed effect meta-analysis was performed using a Maentel–Haenzel method with the genome-wide P-value significance threshold being set at 5x10-8. 
 
*Loci previously identified as associated with AAA. 
     Meta-GWAS (lambda adjusted) Combined validation studies Combined meta-analysis and validation
Chr SNP Position Gene Minor allele Other allele MAF P-value Direction HetPVal OR L95 U95 Z-score P-value OR L95 U95 Z-score P-value df HetPVal 
1* rs602633 109821511 Near PSRC1 CELSR2 SORT1 T G 0.199 1.72x10-07 ------ 0.097 0.920 0.863 0.980 -2.582 9.83x10-03 0.879 0.842 0.918 -5.801 6.58x10-09 13 7.60x10-03 5
1* rs12133641 154428283 IL6R A G 1.67x10-10 ++++++ 0.903   
1 rs4129267 (proxy) 154426264 IL6R T C 0.370 9.26x10-10 ------ 0.886 0.904 0.857 0.953 -3.743 1.81x10-04 0.876 0.846 0.908 -7.232 4.76x10-13 13 0.478 
1 rs1795061 214409280 near SMYD2 T C 0.336 1.79x10-07 ++++++ 0.069 1.105 1.046 1.168 3.576 3.49x10-04 1.131 1.090 1.174 6.486 8.80x10-11 13 1.14x10-03 6
2 rs13382862 20882449 near C2orf43 and GDF7 A G 0.341 3.03x10-08 ------ 0.878 0.975 0.923 1.029 -0.915 3.60x10-01 0.913 0.880 0.947 -4.845 1.3x10-06 13 8.01x10-02 3
4 rs10029392 5616048 EVC2 T G 0.052 4.60x10-06 ++++++ 0.147 0.940 0.843 1.049 -1.111 2.67x10-01 1.107 1.022 1.198 2.496 1.25x10-02 13 6.51x10-04 6
5 rs12659791 74757758 COL4A3BP T C 0.159 2.28x10-06 --+--- 0.105 0.998 0.929 1.073 -0.043 9.66x10-01 1.098 1.046 1.153 3.752 1.8x10-04 13 1.69x10-02 5
6 rs3176334 36648364 CDKN1A T C 1.50x10-06 ------ 0.627   
6 rs733590 (proxy) 36645203 CDKN1A T C 0.367 8.74x10-06 ------ 0.584 1.007 0.955 1.063 0.2678 7.89x10-01 1.070 1.031 1.110 3.588 3.33x10-04 13 0.183 2
9* rs10757274 22096055 CDKN2BAS1/ANRIL A G 0.351 2.32 x10-13 ------ 0.520 0.774 0.735 0.816 -9.575 1.02x10-21 0.806 0.778 0.834 -12.069 1.54x10-33 13 5.94x10-03 5
9* rs10985349 124425243 DAB2IP T C 0.462 8.98x10-07 ++++++ 0.181 1.155 1.081 1.235 4.233 2.30x10-05 1.171 1.118 1.226 6.682 2.4x10-11 13 3.52x10-01
12* rs1385526 57532749 LRP1 C G 0.195 1.31x10-09 ------ 0.597 0.986 0.933 1.042 -0.493 6.22x10-01 0.910 0.877 0.944 -4.980 6.4x10-07 13 9.38x10-03 5
13 rs9316871 22861921 LINC00540 A G 0.328 5.95x10-06 ++++++ 0.143 0.883 0.830 0.940 -3.936 8.28x10-05 0.873 0.837 0.911 -6.227 4.8x10-10 13 0.488
15 rs17189674 89040591 DET1 A G 0.201 1.05x10-06 ++++++ 0.663 1.014 0.935 1.099 0.327 7.44x10-01 1.118 1.058 1.181 3.957 7.59x10-05 13 1.71x10-02 5
19* rs6511720 11202306 LDLR T G 0.122 5.71x10-12 ------ 0.679 0.868 0.801 0.941 -3.431 6.02x10-04 0.804 0.759 0.851 -7.472 7.9x10-14 13 1.53x10-03 6
19 rs12980543 56096197 near ZNF579 A G  2.30x10-06 ++++++ 0.301             
19 rs11084402 proxy 56093365 near ZNF579 T C 0.206 4.33x10-06 ++++++ 0.218 1.030 0.966 1.099 0.908 3.64x10-01 1.095 1.048 1.144 4.050 5.1x10-05 13 0.019 4
20 rs6516091 6050622 near FERMT1 A G 0.135 3.82x10-09 ++-+++ 0.027 0.994 0.921 1.072 -0.167 8.67x10-01 1.131 1.074 1.190 4.680 2.9x10-06 13 4.01x10-05 7
20 rs58749629 44571317 near PCIF1 ZNF335 MMP9 A G  7.97x10-10 ++++++ 0.760             
20 rs3827066 proxy 44586023 near PCIF1 ZNF335 MMP9 T C 0.179 9.18x10-10 ++++++ 0.729 1.213 1.134 1.298 5.616 2.00x10-08 1.223 1.168 1.281 8.486 2.1x10-17 13 0.552 
21 rs2836411 39819830 ERG T C 0.369 1.53x10-07 ++-+++ 0.103 1.072 1.016 1.131 2.533 1.13x10-02 1.113 1.074 1.154 5.823 5.8x10-09 13 4.83x10-02 4




Online Table VIII: Sensitivity analysis comparing results from the combined GWAS meta-analysis and validation studies using a fixed effects model with a random-effects 
model. Results for loci surpassing the threshold for genome-wide significance are shown in bold. *Loci previously identified as associated with AAA  
 
    Fixed effects model Random effects model
Chr SNP Position Gene Minor allele 
Other 
allele MAF df HetPVal I
2  OR (95% CI) P-value  OR (95% CI) P-value  
1* rs602633 109821511 Near PSRC1 CELSR2 SORT1 T G 0.199 13 7.60x10-03 54.5 0.879 (0.842 - 0.918) 6.58x10-09 0.881 (0.822 - 0.943) 3.18x10-9
1* rs12133641 154428283 IL6R A G
1 rs4129267 (proxy) 154426264 IL6R T C 0.370 13 0.478 0.0 0.876 (0.846 - 0.908) 4.76x10-13 0.876 (0.846 - 0.908) 1.03x10-12
1 rs1795061 214409280 near SMYD2 T C 0.336 13 1.14x10-03 61.9 1.131 (1.090 - 1.174) 8.80x10-11 1.142 (1.07 - 1.218) 3.47x10-12
2 rs13382862 20882449 near C2orf43 and GDF7 A G 0.341 13 8.01x10-02 37.1 0.913 (0.880 - 0.947) 1.3x10-06 0.921 (0.877 - 0.968) 2.05x10-6
4 rs10029392 5616048 EVC2 T G 0.052 13 6.51x10-04 63.6 1.107 (1.022 - 1.198) 1.25x10-02 1.120 (0.973 - 1.289) 1.88x10-4
5 rs12659791 74757758 COL4A3BP T C 0.159 13 1.69x10-02 50.1 1.098 (1.046 - 1.153) 1.8x10-04 1.071 (0.993 - 1.156) 8.18x10-6
6 rs3176334 36648364 CDKN1A T C
6 rs733590 (proxy) 36645203 CDKN1A T C 0.367 13 0.183 25.2 1.070 (1.031 - 1.11) 3.33x10-04 1.064 (1.017 - 1.112) 5.06x10-4
9* rs10757274 22096055 CDKN2BAS1/ANRIL A G 0.351 13 5.94x10-03 55.6 0.806 (0.778 - 0.834) 1.54x10-33 0.797 (0.753 - 0.843) 1.21x10-33
9* rs10985349 124425243 DAB2IP T C 0.462 13 3.52x10-01 9.2 1.171 (1.118 - 1.226) 2.4x10-11 1.174 (1.117 - 1.233) 4.47x10-11
12* rs1385526 57532749 LRP1 C G 0.195 13 9.38x10-03 53.4 0.910 (0.877 - 0.944) 6.4x10-07 0.930 (0.877 - 0.986) 6.541x10-8
13 rs9316871 22861921 LINC00540 A G 0.328 13 0.488 0.0 0.873 (0.837 - 0.911) 4.8x10-10 0.873 (0.837 - 0.911) 9.98x10-10
15 rs17189674 89040591 DET1 A G 0.201 13 1.71x10-02 50.0 1.118 (1.058 - 1.181) 7.59x10-05 1.120 (1.031 - 1.217) 1.26x10-5
19* rs6511720 11202306 LDLR T G 0.122 13 1.53x10-03 61.0 0.804 (0.759 - 0.851) 7.9x10-14 0.795 (0.72 - 0.878) 7.19x10-15
19 rs12980543 56096197 near ZNF579 A G
19 rs11084402 (proxy) 56093365 near ZNF579 T C 0.206 13 0.019 49.4 1.095 (1.048 - 1.144) 5.1x10-05 1.101 (1.031 - 1.176) 2.51x10-5
20 rs6516091 6050622 near FERMT1 A G 0.135 13 4.01x10-05 70.0 1.131 (1.074 - 1.19) 2.9x10-06 1.088 (0.983 - 1.203) 6.58x10-10
20 rs58749629 44571317 near PCIF1 ZNF335 MMP9 A G
20 rs3827066 (proxy) 44586023 near PCIF1 ZNF335 MMP9 T C 0.179 13 0.552 0.0 1.223 (1.168 - 1.281) 2.1x10-17 1.223 (1.168 - 1.281) 6.12x10-17
21 rs2836411 39819830 ERG T C 0.369 13 4.83x10-02 42.2 1.113 (1.074 - 1.154) 5.8x10-09 1.112 (1.057 - 1.17) 7.07x10-9







































Five of the 6 previously identified AAA loci at 1p13.3 (SORT1), 1q21.3 (IL6R), 9p21 (CDKN2BAS1/ANRIL), 9q33 (DAB2IP) and 19p13.2 (LDLR) were replicated in this meta-
GWAS and validation analysis.  Although the previously reported1 12q13 (LRP1) locus (lower right panel) reached the discovery threshold (P=1.1x10-9), it fell below the 
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SNP LOOKUP IN GWAS FOR OTHER TRAITS ASSOCIATED WITH AAA 
 
Data for AAA associated SNPs (those passing the genome-wide association threshold after 
combination of the results of the meta-analysis and validation studies) were obtained from GWAS 
datasets for other traits associated with AAA to determine if the associations were unique to AAA or 
related to generalized CVD (Online Table IX and Figure 3). All results were from meta-analyses of 
multiple primary GWAS datasets for each trait. Summary results for each AAA associated SNP (P-
value and effect size) were extracted.  Results for type 2 diabetes34 were obtained from the 
DIAGRAM consortium (http://www.diagram-consortium.org/index.html ), CAD data from the 
CARDIoGRAM consortium35 (www.CARDIOGRAMPLUSC4D.ORG ), lipid trait data from the Global 
Lipids Genetics Consortium36 (http://csg.sph.umich.edu/abecasis/public/lipids2013 ) and blood 




Online Table IX: Results of lookup of AAA associated SNPs in GWAS of other cardiovascular traits (See also below).  CAD: Coronary Artery Disease; HDL: High-density 
Lipoprotein; LDL: Low-density Lipoprotein; TG: Triglyceride; DBP: Diastolic Blood Pressure; SBP: Systolic Blood Pressure. 
 





































       OR (95%CI) n cases n controls P      
1 109821511 rs602633 1p13.3 CELSR2/SORT1 T  1.05 (1.01 - 1.1) 9580 53810 0.025      
1 154426264 rs4129267 1q21.3 IL6R T 0.96 (0.93 - 1.00) 12171 56862 0.037  
9 22096055 rs10757274 9p21 ANRIL A 0.96 (0.94 - 1.00) 12171 56862 0.041  
9 124425243 rs10985349 9q33.2 DAB2IP T 1.03 (0.98 - 1.07) 12171 56862 0.210  
19 11202306 rs6511720 19p13.2 LDLR T  1.02 (0.96 - 1.10) 8558 52735 0.480      
                 





       OR n cases n controls P      
1 109821511 rs602633 1p13.3 CELSR2/SORT1 T 0.90 (0.87 - 0.93) 20375 61324 2.16x10-9  
1 154426264 rs4129267 1q21.3 IL6R T 0.95 (0.93 - 0.98) 20784 58718 0.001  
9 22096055 rs10757274 9p21 ANRIL A  0.78 (0.74 - 0.82) 21932 62260 1.44x10-22      
9 124425243 rs10985349 9q33.2 DAB2IP T  1.04 (1.00 - 1.09) 14133 36016 0.036      
19 11202306 rs6511720 19p13.2 LDLR T 0.88 (0.83 - 0.94) 8948 47471 1.61x10-04  
        














      beta (SE) n P beta (SE) n P beta (SE) n P 
1 109821511 rs602633 1p13.3 CELSR2/SORT1 T 0.0073 (0.0051) 94311 0.077 -0.0066 (0.0057) 89888 0.230 -0.0129 (0.005) 91013 0.032 
1 154426264 rs4129267 1q21.3 IL6R T  0.0328 (0.0041) 185599 3.50x10-14 -0.1591 (0.0044) 171593 1.50x10-261 -0.0121 (0.004) 176361 0.003 
9 22096055 rs10757274 9p21 ANRIL A  -0.0047 (0.0048) 92706 0.371 0.0036 (0.0051) 83064 0.524 0.0012 (0.0047) 86702 0.907 
9 124425243 rs10985349 9q33.2 DAB2IP T -0.006 (0.0068) 86409 0.435 0.0067 (0.0075) 82099 0.557 -0.0039 (0.0066) 83111 0.944 
19 11202306 rs6511720 19p13.2 LDLR T 0.0249 (0.0057) 184617 6.32x10-05 -0.2209 (0.0061) 170608 3.85x10-262 -0.0084 (0.0056) 175280 0.104 
        
















       beta (SE) n P beta (SE) n P    
1 109821511 rs602633 1p13.3 CELSR2/SORT1 T  0.0704 (0.0665) 66347 0.289 -0.0568 (0.1044) 66352 0.586    
1 154426264 rs4129267 1q21.3 IL6R T  0.0257 (0.0748) 66774 0.731 0.0100 (0.1180) 66781 0.932    
9 22096055 rs10757274 9p21 ANRIL A NA NA NA NA NA NA 
9 124425243 rs10985349 9q33.2 DAB2IP T -0.0020 (0.0807) 58126 0.980 0.1229 (0.1283) 58171 0.338 
19 11202306 rs6511720 19p13.2 LDLR T  -0.0171 (0.1134) 48183 0.880 -0.0963 (0.1792) 48153 0.591    
                  



































       OR (95%CI) n cases n controls P      
1 214409280 rs1795061 1q32.3 near SMYD2 T  1.04 (1.00 - 1.08) 9580 53810 0.044      
13 22861921 rs9316871 13q12.11 LINC00540 G 1 (0.96 - 1.04) 11902 53152 0.940  
20 44586023 rs3827066 20q13.12 Near MMP9/ZNF335 T 1.00 (0.95 - 1.06) 9580 53810 0.890  
21 39819830 rs2836411 21q22.2 ERG T  1.01 (0.97 - 1.04) 12171 56862 0.720      
                 





       OR n cases n controls P      
1 214409280 rs1795061 1q32.3 near SMYD2 T  0.99 (0.96 - 1.02) 20441 61399 0.533      
13 22861921 rs9316871 13q12.11 LINC00540 G 1.00 (0.97 - 1.03) 21588 59365 0.974  
20 44586023 rs3827066 20q13.12 Near MMP9/ZNF335 T 1.07 (1.03 - 1.12) 19108 59177 5.48x10-04  
21 39819830 rs2836411 21q22.2 ERG T  1.02 (0.99 - 1.05) 21424 59122 0.205      
                 














       beta (SE) n P beta (SE) n P beta (SE) n P 
1 214409280 rs1795061 1q32.3 near SMYD2 T 0.0075 (0.0054) 94311 0.119 0.0023 (0.0059) 89888 0.572 -0.0047 (0.0052) 91013 0.501 
13 22861921 rs9316871 13q12.11 LINC00540 G -0.0013 (0.0058) 90317 0.883 0.006 (0.0063) 85936 0.417 0.0018 (0.0058) 86976 0.563 
20 44586023 rs3827066 20q13.12 Near MMP9/ZNF335 T 0.0208 (0.0048) 185539 2.96x10-05 -0.0092 (0.0052) 171507 0.103 -0.0156 (0.0047) 176203 0.003 
21 39819830 rs2836411 21q22.2 ERG T  -0.0047 (0.005) 92801 0.402 -0.0082 (0.0055) 88414 0.269 0.0054 (0.0049) 89466 0.566 
                 
















       beta (SE) n P beta (SE) n P    
1 214409280 rs1795061 1q32.3 near SMYD2 T 0.0320 (0.0691) 63232 0.643 0.0047 (0.1084) 63243 0.965 
13 22861921 rs9316871 13q12.11 LINC00540 G 0.0429 (0.0734) 69617 0.559 -0.0201 (0.1163) 69623 0.863 
20 44586023 rs3827066 20q13.12 Near MMP9/ZNF335 T -0.0397 (0.0878) 59823 0.651 -0.0276 (0.1380) 59806 0.842 




SEARCH FOR OTHER ASSOCIATED TRAITS AND DISEASES USING GWAS DATABASES 
 
The Phenotype-Genotype Integrator38 (http://www.ncbi.nlm.nih.gov/gap/phegeni#GenomeView) 
and the GWAS catalog (http://www.gwascentral.org/index) were searched for diseases and traits 
associated with the lead SNPs at the AAA loci. In addition, we searched NHLBI GRASP catalog (GRASP 
v2.0; http://grasp.nhlbi.nih.gov/Overview.aspx)39, 40 to find any further associations. The results 
obtained using the Phenotype-Genotype Integrator are shown in Online Table X, the search results 
from the GWAS catalog are presented in Online Table XI, and those using GRASP in Online Table XII. 
PheGenI includes results from the NHGRI/EBI catalog. GRASP (Genome-Wide Repository of 
Associations Between SNPs and Phenotypes) is the largest GWAS results database in terms of 
coverage. It includes all available genetic association results from papers, their supplements and 
web-based content meeting the following guidelines: 
• All associations with P<0.05 from GWAS defined as >= 25,000 markers tested for 1 or more 
traits. 
• Study exclusion criteria: CNV-only studies, replication/follow-up studies testing <25K 
markers, non-human only studies, article not in English, gene-environment or gene-gene 
GWAS where single SNP main effects are not given, linkage only studies, aCGH/LOH only 
studies, heterozygosity/homozygosity (genome-wide or long run) studies, studies only 
presenting gene-based or pathway-based results, simulation-only studies, studies which we 
judge as redundant with prior studies since they do not provide significant inclusion of new 




Online Table X: Results from the GWAS database search using the tool called Phenotype-Genotype 
Integrator (http://www.ncbi.nlm.nih.gov/gap/phegeni#GenomeView). All lead SNPs at the AAA loci 
were used for the search, but only two of the SNPs (rs4129267 and rs6511720) had hits. 
 
Chr Location SNP Gene Trait Location in gene P-Value Source PubMed ID 
1 154426264 rs4129267 IL6R Receptors, Interleukin-6 intron 2.00x10-57 NHGRI 18464913 
    C-Reactive Protein intron 2.00x10-48 NHGRI 21300955 
    Asthma intron 2.00x10-08 NHGRI 21907864 
    Maximal Midexpiratory Flow Rate intron 7.00x10-06 NHGRI 17903307 
19 11202306 rs6511720 LDLR Cholesterol, LDL intron 4.00x10-117 NHGRI 20686565 
    Cholesterol intron 7.00x10-97 NHGRI 20686565 
    Cholesterol, LDL intron 2.00x10-51 NHGRI 18193044 
    Cholesterol, LDL intron 2.00x10-26 NHGRI 19060906 
    Cholesterol, LDL intron 4.00x10-26 NHGRI 18193043 
    1-Alkyl-2-acetylglycerophosphocholine Esterase intron 3.00x10-11 NHGRI 22003152 
    Cholesterol, LDL intron 5.00x10-11 NHGRI 21943158 




Online Table XI: Results of the dbGAP SNP lookup using the GWAS Catalog available at http://www.gwascentral.org/index. The total number of results in the GWAS Catalog 
(“n results in dbGAP”) and the number of associations with P<1x10-3 (column labelled “n P<1x10-3”) are shown. Details on the associations with P<1x10-3 for each SNP are 
described. 
 
SNP Chromosome Position Gene(s) n results in dbGAP n P<1x10-3 P-value Phenotype Study 
rs602633 1 109821511 PSRC1-CELSR2-SORT1 16 3 4.80x10-14 LDL cholesterol levels Meta-analysis of plasma lipid concentrations (HGVST214)
      5.70x10-14 Serum LDL cholesterol levels GWAS of LDL-cholesterol concentrations (HGVST227) 
      0.0001862 Height GWAS of height (HGVST634) 
rs4129267 1 154426264 IL6R 77 6 2.00x10-57 Protein quantitative trait loci GWAS of protein quantitative trait loci (HGVST264) 
     2.00x10-48 C-reactive protein level GWAS of C-reactive protein levels (HGVST728)
      2.00x10-08 Asthma Unspecified analysis (HGVRS1753) 
      7.39x10-06 Percent predicted forced expiratory flow GWAS of pulmonary function phenotypes in the Framingham Heart Study 
(HGVST212) 
      1.92x10-05 Asthma; Total asthma sample fixed effects (HGVRS1509) GWAS of asthma (HGVST631) 
      0.00014411 Asthma; Total asthma sample random 
effects(HGVRS1257) 
GWAS of asthma (HGVST631) 
rs1795061 1 214409280 SMYD2 19 0
rs10757274 9 22096055 ANRIL 6 2 8.00x10-45 Coronary heart disease GWAS of Coronary heart disease (HGVST1380)
      3.70x10-06 Coronary heart disease GWAS of Coronary heart disease (HGVST57) 
rs10985349 9 124425243 DAB2IP 19 0    
rs9316871 13 22861921 LINC00540 101 2 0.0007248 Schizophrenia GWAS of schizophrenia (HGVST903) 
     0.00084 Crohn's disease GWAS of Crohn's disease (HGVST680)
rs6511720 19 11202306 LDLR 57 14 2x10-51 LDL cholesterol Meta-analysis of lipid concentrations (HGVST203)
     4.2x10-26 LDL cholesterol levels Meta-analysis of plasma lipid concentrations (HGVST214)
      2x10-26 LDL cholesterol GWAS of HDL cholesterol, triglycerides and LDL cholesterol (HGVST235) 
     0.00026672 Serum cholesterol GWAS of serum cholesterol levels in a British population (HGVST312)
     0.0005127 Height GWAS of height (HGVST634)
      0.0000001 Carotid intima media thickness, plaque GWAS of carotid intima media thickness (HGVST923) 
      3x10-11 Lipoprotein-associated phospholipase A2 activity and 
mass (Activity concentrations) 
GWAS of lipoprotein-associated phospholipase A2 activity and mass (HGVST931) 
     5x10-11 Cardiovascular disease risk factors (LDL) GWAS of cardiovascular disease risk factors (HGVST956)
     0.000000004 Metabolite levels GWAS of Metabolite levels (HGVST1409)
      2x10-31 Lipid metabolism phenotypes (LDL-C.assay, whole) GWAS of Lipid metabolism phenotypes (HGVST1667) 
      3x10-18 Lipid metabolism phenotypes (APOB.assay, fasting) GWAS of Lipid metabolism phenotypes (HGVST1667) 
     1x10-25 Lipid metabolism phenotypes (LDL-C.assay, fasting) GWAS of Lipid metabolism phenotypes (HGVST1667)
     5x10-25 Lipid metabolism phenotypes (APOB.assay, whole) GWAS of Lipid metabolism phenotypes (HGVST1667)
rs3827066 20 44586023 PCIF1-ZNF335-MMP9 15 0    




Online Table XII: Previously reported associations of the lead SNPs from AAA loci identified from an analysis of GRASP v2.0 (http://grasp.nhlbi.nih.gov/Overview.aspx). The 
Phenotypes, P values and sample sizes are those reported in the original publication that is referenced under ‘Phenotype’ in the table. The SNP, chromosome, position and 
genes are those from this analysis that were entered into GRASP v2.0 as a query. This table spans 3 pages. 
 
SNP CHR Position Gene Phenotype P value Ancestry Total Total Replication Total 
          
rs602633 1 109821511 PSRC1-CELSR2-SORT1 LDL cholesterol41 4.80x10-14 European 8656 11399 20055 
    LDL cholesterol in serum42 5.70x10-14 European 11685 5036 16721 
    LDL cholesterol43 7.60x10-41 European 19840 20623 40463 
    LDL cholesterol44 3.10x10-08 European 5059 0 5059 
    APOB (apolipoprotein B)44 2.20x10-07 European 5059 0 5059 
    Coronary artery disease (CAD)45 9.00x10-08 Unspecified 8319 10707 19026 
    LDL cholesterol change with statins46 8.40x10-08 European 3928 0 3928 
    LDL cholesterol46 8.40x10-08 European 3928 0 3928 
    Total cholesterol change with statins46 5.50x10-06 European 3928 0 3928 
    Total cholesterol46 5.50x10-06 European 3928 0 3928 
    LDL cholesterol47 4.90x10-164 Mixed 100184 39875 140059 
    Total cholesterol47 3.90x10-127 Mixed 100184 39875 140059 
    HDL cholesterol47 5.20x10-07 Mixed 100184 39875 140059 
    Height48 1.90x10-04 European 133653 50074 183727 
    LDL cholesterol49 2.90x10-06 African 8090 8849 16939 
    LDL cholesterol50 1.20x10-22 European 11683 0 11683 
    LDL cholesterol (baseline)51 5.00x10-08 European 5244 0 5244 
    Lp-PLA2 activity52 1.40x10-16 European 13664 0 13664 
    Total cholesterol53 5.90x10-65 European 66240 25282 91522 
    LDL cholesterol53 6.90x10-65 European 66240 25282 91522 
    HDL cholesterol53 1.30x10-07 European 66240 25282 91522 
    Coronary artery disease (CAD)54 4.70x10-26 Mixed 194427 15613 210040 
    Coronary artery disease (CAD) age <=5054 2.80x10-20 Mixed 194427 15613 210040 
    Coronary artery disease (CAD) (males)54 1.30x10-18 Mixed 194427 15613 210040 
    Coronary artery disease (CAD) with myocardial infarction (MI)54 2.20x10-16 Mixed 194427 15613 210040 
    Coronary artery disease (CAD) age >5054 5.00x10-08 Mixed 194427 15613 210040 
    Coronary artery disease (CAD) (females) 54 3.40x10-05 Mixed 194427 15613 210040 
          
rs4129267 1 154426264 IL6R Lung function, predicted forced expiratory flow (FEF)55 7.40x10-06 European 1222 0 1222 
    Plasma C-reactive protein (female)56 2.00x10-08 European 6345 0 6345 
    Soluble IL6R (sIL6R)57 2.50x10-76 European 1200 0 1200 
    C-reactive protein [log (mg/l)]58 4.40x10-04 European 4763 0 4763 
    Plasma fibrinogen (females)59 1.80x10-11 European 17686 0 17686 
    Asthma60 1.90x10-05 European 26475 0 26475 
    Fibrinogen61 8.40x10-07 Mixed 30291 0 30291 
    C-reactive protein (CRP)62 2.10x10-48 European 66185 16540 82725 
    Asthma60 2.40x10-08 European 7197 57800 64997 
    Interleukin-6 (IL-6) levels63 2.40x10-08 European 4694 1392 6086 
    C-reactive protein (CRP)64 1.80x10-05 Mixed 11828 11991 23819 
    Coronary artery disease (CAD)54 1.70x10-08 Mixed 194427 15613 210040 
    Interleukin-6 (IL-6) levels65 1.60x10-21 European 8356 0 8356 
    C-reactive protein (CRP)65 8.80x10-12 European 8356 0 8356 
          
rs1795061 1 214409280 SMYD2 None      
          
rs10757274 9 22096055 ANRIL Coronary heart disease (CHD)66 3.70x10-06 Mixed 634 28047 28681 
    Coronary artery disease (CAD)45 7.00x10-11 Unspecified 8319 10707 19026 
    Coronary artery disease (CAD)67 7.60x10-45 Asian 6534 26932 33466 
    Coronary artery calcification (CAC)68 8.00x10-10 European 4518 0 4518 
35 
 
SNP CHR Position Gene Phenotype P value Ancestry Total Total Replication Total 
    Coronary artery calcification (CAC)69 6.80x10-08 Mixed 1509 3344 4853 
          
rs10985349 9 124425243 DAB2IP None      
          
rs9316871 13 22861921 LINC00540 Body mass index (BMI)70 6.90x10-04 European 5217 0 5217 
    Schizophrenia71 9.40x10-05 European 16161 31375 47536 
    HDL cholesterol change with statins46 7.70x10-04 European 3928 0 3928 
          
rs6511720 19 11202306 LDLR LDL cholesterol41 4.20x10-26 European 8656 11399 20055 
    LDL cholesterol72 2.00x10-51 Mixed 2758 22803 25561 
    LDL cholesterol43 5.20x10-30 European 19840 20623 40463 
    LDL cholesterol exam 1 values43 3.00x10-04 European 19840 20623 40463 
    Total cholesterol (exam 1)43 3.40x10-04 European 19840 20623 40463 
    LDL cholesterol (mmol/l) 58 1.50x10-09 European 4763 0 4763 
    Total cholesterol73 6.80x10-18 European 22562 0 22562 
    APOB (apolipoprotein B)74 7.00x10-18 European 6382 970 7352 
    LDL cholesterol74 5.20x10-15 European 6382 970 7352 
    LDL cholesterol44 7.30x10-24 European 5059 0 5059 
    APOB (apolipoprotein B) 44 6.80x10-15 European 5059 0 5059 
    LDL cholesterol lipoprotein fraction concentration75 2.30x10-31 European/Unspecified 17296 9472 26768 
    LDL cholesterol lipoprotein fraction concentration in fasting sample75 1.50x10-25 European/Unspecified 17296 9472 26768 
    APOB assay lipoprotein fraction concentration75 4.80x10-25 European/Unspecified 17296 9472 26768 
    APOB assay lipoprotein fraction concentration in fasting sample75 2.80x10-18 European/Unspecified 17296 9472 26768 
    LDL cholesterol large lipoprotein fraction concentration75 4.30x10-15 European/Unspecified 17296 9472 26768 
    LDL cholesterol total lipoprotein fraction concentration75 1.90x10-13 European/Unspecified 17296 9472 26768 
    LDL cholesterol large lipoprotein fraction concentration in fasting sample75 3.00x10-12 European/Unspecified 17296 9472 26768 
    VLDL cholesterol small lipoprotein fraction concentration75 1.60x10-10 European/Unspecified 17296 9472 26768 
    LDL cholesterol total lipoprotein fraction concentration in fasting sample75 2.10x10-09 European/Unspecified 17296 9472 26768 
    VLDL cholesterol small lipoprotein fraction concentration in fasting sample75 1.90x10-08 European/Unspecified 17296 9472 26768 
    LDL cholesterol change with statins46 2.80x10-05 European 3928 0 3928 
    LDL cholesterol46 2.80x10-05 European 3928 0 3928 
    LDL cholesterol47 8.60x10-122 Mixed 100184 39875 140059 
    Total cholesterol47 1.70x10-101 Mixed 100184 39875 140059 
    Coronary artery disease (CAD) 47 5.00x10-09 Mixed 100184 39875 140059 
    Height48 5.10x10-04 European 133653 50074 183727 
    LDL cholesterol49 2.00x10-51 African 8090 8849 16939 
    Presence of carotid artery plaque76 8.20x10-08 European 31211 11273 42484 
    Carotid artery plaque76 1.00x10-07 European 31211 11273 42484 
    Coronary artery disease (CAD) 76 2.00x10-04 European 31211 11273 42484 
    LDL cholesterol50 5.00x10-11 European 11683 0 11683 
    Coronary artery disease (CAD)77 1.10x10-08 Mixed 50587 57594 108181 
    LDL cholesterol (baseline) 51 5.20x10-15 European 5244 0 5244 
    Lp-PLA2 activity52 2.60x10-11 European 13664 0 13664 
    Lp-PLA2 mass52 5.50x10-05 European 13664 0 13664 
    Metabolic syndrome domains (Atherogenic Dyslipidemia - PC1)78 5.20x10-30 Mixed 25755 0 25755 
    Metabolic syndrome domains (Multivariate analysis) 78 8.30x10-28 Mixed 25755 0 25755 
    LDL cholesterol79 1.40x10-49 Mixed 44957 0 44957 
    LDL cholesterol (female)79 7.50x10-29 Mixed 44957 0 44957 
    LDL cholesterol (male)79 3.10x10-25 Mixed 44957 0 44957 
    LDL cholesterol53 1.30x10-79 European 66240 25282 91522 
    Total cholesterol53 1.70x10-71 European 66240 25282 91522 
    APOB (apolipoprotein B)80 4.10x10-27 European 3895 14810 18705 
    LDL cholesterol80 3.80x10-25 European 3895 14810 18705 
    APOB (apolipoprotein B) response after 40mg daily simvastatin treatment80 1.40x10-07 European 3895 14810 18705 
    LDL cholesterol response after 40mg daily simvastatin treatment80 4.30x10-07 European 3895 14810 18705 
    LDL cholesterol81 2.60x10-17 Mixed 9813 7000 16813 
    Total cholesterol81 1.80x10-16 Mixed 9813 7000 16813 
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SNP CHR Position Gene Phenotype P value Ancestry Total Total Replication Total 
    Total cholesterol82 4.40x10-04 Hispanic 2240 2121 4361 
          
rs3827066 20 44586023 PCIF1-ZNF335-MMP9 Coronary artery disease (CAD) 54 1.40x10-05 Mixed 194427 15613 210040 
          
rs2836411 21 39819830 ERG None      
          





We performed a phenome-wide association study (PheWAS)83, 84 exploring the association between the 9 AAA-associated SNPs and an extensive group of 
diagnoses to identify novel associations and uncover potential pleiotropy. For the PheWAS we used data from the electronic Medical Records and Genomics 
(eMERGE) Network23 derived from 7 adult sites with a total of 27,077 unrelated patients of European ancestry above 19 years of age. We divided these samples into 
two datasets by proportional sampling based on eMERGE site, sex, and genotyping platform (13,559 and 13,518 individuals in sets 1 and 2, respectively). We 
calculated associations between the 9 AAA-associated SNPs and case or control status based on the extensive set of ICD-9 diagnoses, where for a specific diagnosis, 
individuals with the diagnosis are considered cases. Associations were adjusted for sex, site, genotyping platform and the first 3 principal components to account 
for global ancestry. We considered the identification of previously known associations, such as rs602633 associated with hyperglyceridemia and rs10757274 
associated with CAD, to be indications that the PheWAS approach was robust. The PheWAS results are presented in Online Table XIII. 
 
Online Table XIII: PheWAS Results 
 
      PheWAS dataset 1  PheWAS dataset 2 
Chr Position SNP Locus Gene(s) PheWAS associations ICD-9 Description n cases/controls Beta(SE) P n cases/controls Beta(SE) P 
       
1 214409280 rs1795061 1q32.3 near SMYD2 None        
             
1 154426264 rs4129267 1q21.3 IL6R None  
       
1 109821511 rs602633 1p13.3 CELSR2/SORT1 6 Other and unspecified hyperlipidemia 5467/5722 -0.187 (0.035) 7.86171x10-08 5539/5645 -0.151 (0.035) 1.54x10-05 
      Other and unspecified hyperlipidemia 5467/5722 -0.187 (0.0345) 7.86171x10-08 2506/8687 -0.114 (0.042) 0.006402 
      Pure hypercholesterolemia 2436/8780 -0.116 (0.042) 0.0055185 5539/5645 -0.151 (0.035) 1.54x10-05 
      Pure hypercholesterolemia 2436/8780 -0.116 (0.042) 0.0055185 2506/8687 -0.114 (0.042) 0.006402 
      Mixed hyperlipidemia 1310/11032 -0.141 (0.054) 0.0083104 5539/5645 -0.151 (0.035) 1.54x10-05 
      Mixed hyperlipidemia 1310/11032 -0.141 (0.054) 0.0083104 2506/8687 -0.114 (0.042) 0.006402 
             
9 22096055 rs10757274  9p21 ANRIL 2 
Coronary atherosclerosis of native 
coronary artery 2332/9886 0.210 (0.034) 3.70081x10
-10 2141/9972 0.158 (0.035) 6.9x10-06 
      Coronary atherosclerosis of unspecified type of vessel, native or graft 2167/10004 0.202 (0.035) 4.61186x10
-09 2141/9972 0.158 (0.035) 6.9x10-06 
       
9 124425243 rs10985349 9q33.2 DAB2IP None  
       
13 22861921 rs9316871 13q12.11 LINC00540 None        
             
19 11202306 rs6511720 19p13.2 LDLR 4 Other and unspecified hyperlipidemia 5638/5878 -0.201 (0.046) 1.05931x10-05 2583/8928 -0.218 (0.055) 4.95x10-05 
      Other and unspecified hyperlipidemia 5638/5878 -0.201 (0.046) 1.05931x10-05 5697/5803 -0.173 (0.045) 9.53x10-05 
      Pure hypercholesterolemia 2502/9017 -0.183 (0.056) 0.000948352 2583/8928 -0.218 (0.055) 4.95x10-05 
      Pure hypercholesterolemia 2502/9017 -0.183 (0.056) 0.000948352 5697/5803 -0.173 (0.045) 9.53x10-05 
       
20 44586023 rs3827066 20q13.12 Near PCIF1/MMP9/ZNF335 None        
             
21 39819830 rs2836411 21q22.2 ERG None        
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ANNOTATION OF AAA ASSOCIATED SNPs USING THE UCSC GENOME BROWSER 
 
The 9 AAA-associated loci were manually annotated using the UCSC Genome Browser 
(http://genome.ucsc.edu/cgi-bin/hgGateway) on the hg19 human genome assembly. To annotate a 
gene, the SNP identification number (rs ID) was typed into the browser, and the genomic region 
centered on the SNP was examined. We noted genomic elements within 10 kbp of the SNP and on either 
side of the SNP. Within the browser, there were eleven main tracks that were used to annotate the SNP, 
which displayed gene locations, related literature, full-length public transcriptome data (mRNAs and 
ESTs), regulation, conservation, and repetitive elements. The results of this annotation are presented in 
Online Table XIV. 
Gene Location 
 
We used several UCSC Genome Browser tracks to determine whether a locus was exonic, intronic, or 
intergenic, as well as the identity and classification of the gene, if any, at the locus. One of the tracks 
used was the UCSC Known Genes track. This track displays information on genes and their location, 
including both protein-coding and non-coding RNA genes85. Within this track, NCBI Reference Sequence 
(RefSeq) genes and GenBank genes were aligned to the genome (by the UCSC Genome Bioinformatics 
team) using the BLAST-like alignment tool (BLAT)86-88. In order to be included, genes needed a 98% 
alignment. The track also included gene models from the Consensus CDS (CCDS) project. Predicted 
genes from tRNA and mouse genes from Rfam with synteny to the human genome are also included in 
the track89, 90. The track also reports whether the gene is coding or non-coding. In addition to using the 
NCBI RefSeq to search proteins, UniProt proteins are also reported91. 
Another UCSC track that describes the location of coding and non-coding genes is the NCBI RefSeq track. 
This displays genes that were aligned to genome with at least a 96% match88. We also used ENCODE 
Consortium's Gencode human gene catalog (v19)92. The track combines automatic annotations with 
manual and experimentally validated entries. Another track used to examine gene location is the Broad 
Institute lincRNA track. The long intergenic non-coding RNA (lincRNA) data were collected by RNA 
sequencing (RNA-seq)93. In addition to lincRNAs, the track also displays transcripts of uncertain coding 




The loci were also annotated according to their relationship to other SNPs. The National Human 
Genome Research Institute (NHGRI) has a UCSC track of manually curated loci from published Genome-
Wide Association Studies (GWAS)95with P < 1.0 x 10-5. This track was used to check independent 
previously reported disease or phenotype association of each SNP, and to see if the locus of interest fell 
within a “SNP cloud”, which is an area with several SNPs all significantly associated with complementary 
or biologically similar quantitative traits.  
mRNAs and ESTs 
 
In addition to looking at genes, mRNAs and expressed sequence tags (ESTs) were examined. One track 
used was the human mRNA track. This is comprised of human mRNAs from GenBank aligned to the 
genome using BLAT86, 87. The Human ESTs track was compiled in the same manner, and included both 
spliced and un-spliced ESTs. Both of these tracks contain raw full-length public transcriptome data 
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captured through transcript-to-genome alignments and were used to confirm the presence of genes, to 
interrogate gene expression profiles, to derive comprehensive information on gene structures 
(promoters, splice junctions, 3'ends), and novel transcriptional units absent from gene databases. 
Regulation 
 
There were also several UCSC Browser tracks used to examine epigenetic and post-transcriptional 
regulation in the vicinity of a SNP. One track is the TS miRNA track. This shows 3’ untranslated region 
(UTR) microRNA (miRNA) binding sites predicted using TargetScanHuman version 5.1. First, the UTRs 
were scanned for miRNA sites96. After all the matches were found, they were ranked97. Another track 
that displayed regulatory information was the ENCODE Regulation supertrack, which consists of 7 sub-
tracks. All of the tracks were used in annotating the locus. The first of these sub-tracks is the 
transcription track, which displays ENCODE RNA-seq results from cells representing 9 different tissues98.  
Three of the sub-tracks show information on histone modifications. This was collected by ENCODE using 
chromatin immunoprecipitation sequencing (ChIP-seq) on cells representing seven different tissues99. 
One histone modification is the monomethylation of lysine 4 in the histone 3 protein, referred to as 
H3K4Me1. Another modification is the acetylation of lysine 27 in the same histone protein, referred to 
as H3K27Ac. The presence of either modification suggests an activating regulatory element, and the co-
occurrence of the two modifications indicates a putative enhancer region. IThe third histone 
modification examined is a trimethylation of lysine 4 in the same histone protein, referred to as 
H3K4Me3. This signal indicates the presence of a promoter. 
Another sub-track we used is the DNase hypersensitivity track version 3, which shows areas of open 
chromosome accessibility in 125 different cell lines100. The final two sub-tracks display transcription 
factor binding sites (TFBSs). Both were created using ChIP-Seq and have information for 161 different 
transcription factors in 91 different cell types101. The differentiating factor between the two tracks is 
that one includes information from Factorbook, which displays consensus motifs in binding sites102. 
Conservation 
 
To examine the evolutionary conservation of a locus, the PhyloP Conservation track is used. This displays 
conservation across 100 different species in a human-centric multispecies alignment103.  
Repetitive Elements 
 
The final track used is RepeatMaster, which searches the genome for 10 different forms of repeating 
elements, including long interspersed nuclear elements (LINE), short interspersed nuclear element 
(SINE), and retrotransposons. This track uses information from the Genetic Information Research 
Institute’s (GIRI) Repbase Update library104 and makes it possible to determine whether a SNP resides 





Online Table XIV. Annotation of AAA-Associated SNPs using the UCSC Genome Browser 
(http://genome.ucsc.edu/cgi-bin/hgGateway) 
 
SNP rs# Information Available in UCSC Genome Browser
rs1795061 Intron of one mRNA (AY343912), but no ESTs
~550 bp downstream of CEBP beta binding site with consensus motif 
rs4129267 In a LINE repeat 
NHGRI: associated with CAD, asthma, C-protein levels, and protein quantitative traits.  
Intron of IL6R (involved in immune responses), H3K4Me1 expression 
In a DNase hypersensitivity cluster (83/125) and 7 TFBSs, including one with a consensus site (MYC). 
Low expression level. 
Two ESTs are near the hypersensitivity site, but are not related to any gene/mRNAs. 
rs602633 NHGRI: associated with stroke 
850 bp downstream of 3' end of PSRC1 (involved in mitosis) 
900 bp downstream of large H3K4Me1 peak; high transcription levels 
Associated with a DNase site (9/125) and 3 TFBSs, including a consensus site in EGR1.  
Approximately 1 kb upstream of a DNase hypersensitivity region (125/125, 100% of cell types) with a 
large H3K4Me1 peak and mild H3K27Ac levels. There are 36 TFBSs, 6 with consensus motifs.  
3 kb downstream of CELSR2 (brain expressed cadherin like protein). This region also has high H3K4Me1 
expression and moderate H3K27Ac levels, indicating an enhancer region. There are also high 
transcription levels. There is a DNase hypersensitivity region (62/125) that correlates with 50 TFBSs, 18 
with consensus motifs.  
5 kbp downstream of another DNase hypersensitivity site (20/125) with 6 TFBSs, 4 of which have 
consensus motifs. 
SNP cloud with 9 other SNPs, which have been associated with cholesterol and lipid levels, as well as 
stroke, and CAD 
rs10757274 NHGRI: associated with CAD 
In a LINE and intron of ANRIL 
1.6 kb upstream from high H3K4Me1 and moderate H3K27Ac 
DNase hypersensitivity site (61) and 15 TFBSs (2 consensus motifs) 
7 kbp upstream from a putative enhancer region (high H3K4Me1 and H3K27Ac), associated with DNase 
hypersensitivity (88) and over 50 TFBSs 
rs10985349 Intron of DAB2IP 
In a DNase hypersensitivity cluster (22) and H3K4Me1 peak 
rs9316871 Intergenic 
rs6511720 NHGRI: associated with CAD and aneurysm, as well as with lipid and cholesterol levels 
Intronic to LDLR 
Moderate transcription levels 
High levels of H3K4Me1, H3K4Me3, and H3K27Ac (indicating an enhancer/promoter region) 
In a DNase hypersensitivity cluster of 105/125 with approximately 40 TFBSs (9 consensus motifs) 
rs3827066 Intron of ZNF335 
Moderate transcription levels 
rs2836411 Intron of ERG 
High H3K4Me1 levels, mild H3K27Ac levels 





The lead SNPs at the 4 novel AAA risk loci (Table 1) were identified in the 1000 Genomes phase 3 CEU 
panel. SNPs in LD (r2>0.5) and the lead SNPs were extracted from the 1000 Genomes data and entered 
into Pupasuite v3.1105 (Online Table XV). No non-synonymous, transcript structure, transcript 
processing, transcription factor (TF) binding site (Transfac/Jaspar/Oreganno), miRNA sequence, miRNA 





Online Table XV: Pupasuite 3.1 output for SNPs in LD (r2 > 0.5) with lead SNPs at novel AAA loci. 
*Transcript IDs are shown without the full Ensembl Transcript ID (ENST number) for display purposes. 
This table spans 2 pages. 
 
Lead SNP Chr Position Nearest 
gene(s) 
LD SNPs r2 Location relative to transcript Gene Transcript(s)* 
rs1795061 1 214409280 SMYD2 rs1795065 1 INTERGENIC   
    rs1660364 1 INTERGENIC   
    rs1660365 1 INTERGENIC   
    rs1795064 1 INTERGENIC   
    rs1795063 1 INTERGENIC   
    rs1795062 1 INTERGENIC   
    rs1660368 1 INTERGENIC   
    rs199679227 1 INTERGENIC   
    rs1660371 1 INTERGENIC   
    rs1795060 1 INTERGENIC   
    rs201675223 0.978 INTERGENIC   
    rs1147673 0.912 INTERGENIC   
    rs12745411 0.724 INTERGENIC   
    rs11585945 0.724 INTERGENIC   
    rs61819142 0.724 INTERGENIC   
    rs12754343 0.724 INTERGENIC   
    rs17784245 0.628 INTERGENIC   
    rs1021639 0.609 INTERGENIC   
rs9316871 13 22861921 LINC00540 rs9506822 0.85 INTERGENIC   
    rs9510086 0.763 INTERGENIC   
    rs12863716 0.763 INTERGENIC   
    rs7336555 0.763 INTERGENIC   
    rs12857403 0.763 INTERGENIC   
    rs12866004 0.763 INTERGENIC   
    rs11618858 0.763 INTERGENIC   
    rs7994761 0.763 INTERGENIC   
    rs9506820 0.696 INTERGENIC   
rs3827066 20 44586023 PCIF1-
ZNF335-
MMP9 
rs73128528 0.922 INTRONIC ZNF335 243961 
      INTRONIC ZNF335 322927 
      INTRONIC ZNF335 426788 
    rs17448653 0.629 DOWNSTREAM ZNF335 494955 
      INTRONIC ZNF335 243961 
      INTRONIC ZNF335 322927 
      INTRONIC ZNF335 426788 
      UPSTREAM ZNF335 475002 
      WITHIN_NON_CODING_GENE ZNF335 476822 
rs2836411 21 39819830 ERG rs2836399 0.555 INTRONIC ERG 288319, 357391, 398897, 
398899, 398905, 398907, 
398910, 398911, 398916, 
398919, 415743, 417133, 
429727, 442448, 451178, 
453032 
      WITHIN_NON_CODING_GENE ERG 468474, 473107, 481609, 
492833 
    rs2298336 0.53 INTRONIC ERG 288319, 357391, 398897, 
398899, 398905, 398907, 
398910, 398911, 398916, 
398919, 415743, 417133, 
429727, 442448, 451178, 
453032 
      WITHIN_NON_CODING_GENE ERG 468474, 473107, 481609, 
492833 
    rs2836402 0.53 INTRONIC ERG 288319, 357391, 398897, 
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398899, 398905, 398907, 
398910, 398911, 398916, 
398919, 415743, 417133, 
429727, 442448, 451178, 
453032 
      WITHIN_NON_CODING_GENE ERG 468474, 473107, 481609, 
492833 
    rs2836400 0.519 INTRONIC ERG 288319, 357391, 398897, 
398899, 398905, 398907, 
398910, 398911, 398916, 
398919, 415743, 417133, 
429727, 442448, 451178, 
453032 
      WITHIN_NON_CODING_GENE ERG 468474, 473107, 481609, 
492833 
    rs2836407 0.519 INTRONIC ERG 288319, 357391, 398897, 
398899, 398905, 398907, 
398910, 398911, 398916, 
398919, 415743, 417133, 
429727, 442448, 451178, 
453032 
      UPSTREAM ERG 492833 
      WITHIN_NON_CODING_GENE ERG 468474, 473107, 481609 
    rs2836409 0.519 INTRONIC ERG 288319, 398897, 398899, 
398905, 398907, 398910, 
398911, 398916, 398919, 
417133, 442448, 451178, 
453032 
      UPSTREAM ERG 357391, 415743, 429727, 
492833 






The 9 AAA GWAS SNPs (LeadSNP) were entered into the GWAS3D106 web-portal 
(http://jjwanglab.org/gwas3d), using the following settings: 1. SNP dataset: 1000 Genomes pilot 1, 2. 
Population: EUR, 3. LD threshold: R2 >0.8, 4. Cell type: All; and 5. all ENCODE TF Family Motifs (binding 
site P-value 0.02). 
The predicted lead functional SNP (Fn_SNPID) associations for the 9 AAA SNPs are shown in Figure 4 and 
Online Table XVI. For example, the AAA GWAS SNP rs602633 is in high LD with rs599839, which has 
previously been associated with AAA3.  GWAS3D predicted the rs599839 variant to alter STAT, Ets, p300 
and RFX5 binding affinities.  
The extended list of potential functional variant associations within each locus is shown in Online Table 
XVII. All AAA SNPs were predicted to be associated with transcription factor binding site affinity variants 
and eight map to interactions with distal regions. 
 
Online Table XVI: Lead functional associations for each of the 9 replicated AAA SNPs. 
 
Fn_SNPID Chr:Position Locus Combined P LeadSNP GWAS P R2 Status 
rs4977575 9:22124744 9p21.3 1.70x10-35 rs10757274 1.5x10-33 0.87     
rs73128528 20:44582187 ZNF335 3.72x10-19 rs3827066 2.1x10-17 0.83     
rs73015013 19:11190873 19p13.2 2.58x10-16 rs6511720 7.9x10-14 0.94     
rs4845620 1:154406656 IL6R 9.92x10-15 rs4129267 4.8x10-13 0.87     
rs1660368 1:214407335 1q32.3 4.64x10-14 rs1795061 8.8x10-11 0.97     
rs599839 1:109822166 1p13.3 3.07x10-13 rs602633 6.6x10-09 0.92     
rs9510086 13:22862440 13q12.11 8.33x10-12 rs9316871 4.8x10-10 0.82     
rs10985349 9:124425243 DAB2IP 7.46x10-11 rs10985349 2.4x10-11 1     
rs2836411 21:39819830 ERG 4.72x10-09 rs2836411 5.8x10-09 1     
 
 Leading variant   
 Significant TFBS   
 Mapping on distal interaction  
 Mapping on putative enhancer region  
 Mapping on GERP++ conservation element 
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Online Table XVII:  Significant regulatory variants detected by the GWAS3D algorithm. Status: distal interaction (td), transcription factor binding 
affinity (bda), chromatin modification state (chromhmm), sites under evolutionary constraint (gerp). This table spans 4 pages. 
 
SNPID CHRPOS GENOTYPE LOCUS FINALP LeadSNP LEADSNP_P RSQUARE STATUS
rs4977575 9:22124744 C|G 9p21.3 1.70x10-35 rs10757274 1.54x10-33 0.87 td,bda,enhancer,gerp
rs1333049 9:22125503 G|C 9p21.3 3.13x10-35 rs10757274 1.54x10-33 0.88 td,bda,enhancer
rs1333046 9:22124123 T|A 9p21.3 6.47x10-35 rs10757274 1.54x10-33 0.93 td,bda,enhancer
rs10738610 9:22123766 A|C 9p21.3 4.51x10-34 rs10757274 1.54x10-33 0.93 td,bda,enhancer 
rs7857118 9:22124140 A|T 9p21.3 4.85x10-34 rs10757274 1.54x10-33 0.92 td,bda,enhancer
rs7859362 9:22105927 T|C ANRIL 7.83x10-34 rs10757274 1.54x10-33 0.93 td,bda,enhancer
rs10217586 9:22121349 A|T 9p21.3 9.21x10-34 rs10757274 1.54x10-33 0.81 td,bda,enhancer
rs7859727 9:22102165 C|T ANRIL 1.12x10-33 rs10757274 1.54x10-33 0.97 td,bda,enhancer
rs10811656 9:22124472 C|T 9p21.3 1.19x10-33 rs10757274 1.54x10-33 0.85 td,bda,enhancer
rs1333043 9:22106731 T|A ANRIL 2.16x10-33 rs10757274 1.54x10-33 0.93 td,bda,enhancer
rs2891168 9:22098619 A|G ANRIL 2.44x10-33 rs10757274 1.54x10-33 0.99 td,bda,enhancer
rs10738608 9:22094796 A|C ANRIL 2.72x10-33 rs10757274 1.54x10-33 0.95 td,bda,enhancer
rs10738607 9:22088094 A|G ANRIL 2.72x10-33 rs10757274 1.54x10-33 0.95 td,bda,enhancer
rs6475609 9:22106271 A|G ANRIL 4.57x10-33 rs10757274 1.54x10-33 0.93 td,bda,enhancer
rs2383207 9:22115959 A|G ANRIL 4.60x10-33 rs10757274 1.54x10-33 0.90 td,bda,enhancer
rs1537370 9:22084310 C|T ANRIL 1.19x10-32 rs10757274 1.54x10-33 0.84 td,bda,enhancer
rs10511701 9:22112599 T|C ANRIL 1.39x10-32 rs10757274 1.54x10-33 0.90 td,bda,enhancer
rs1333047 9:22124504 A|T 9p21.3 1.53x10-32 rs10757274 1.54x10-33 0.87 td,bda,enhancer
rs10757275 9:22106225 G|A ANRIL 1.67x10-32 rs10757274 1.54x10-33 0.94 td,bda,enhancer
rs1333048 9:22125347 A|C 9p21.3 1.67x10-32 rs10757274 1.54x10-33 0.94 td,bda,enhancer
rs4977574 9:22098574 A|G ANRIL 2.01x10-32 rs10757274 1.54x10-33 0.99 td,bda,enhancer
rs10757278 9:22124477 A|G 9p21.3 2.25x10-32 rs10757274 1.54x10-33 0.88 td,bda,enhancer
rs1537374 9:22116046 A|G ANRIL 2.27x10-32 rs10757274 1.54x10-33 0.90 td,bda,enhancer
rs1537375 9:22116071 T|C ANRIL 2.66x10-32 rs10757274 1.54x10-33 0.91 td,bda,enhancer
rs7341791 9:22112427 A|G ANRIL 2.69x10-32 rs10757274 1.54x10-33 0.89 td,bda,enhancer
rs10757279 9:22124630 A|G 9p21.3 3.05x10-32 rs10757274 1.54x10-33 0.88 td,bda,enhancer
rs2383206 9:22115026 A|G ANRIL 3.05x10-32 rs10757274 1.54x10-33 0.90 td,bda,enhancer
rs7341786 9:22112241 A|C ANRIL 3.35x10-32 rs10757274 1.54x10-33 0.89 td,bda,enhancer
rs10757272 9:22088260 C|T ANRIL 3.38x10-32 rs10757274 1.54x10-33 0.96 td,bda,enhancer
rs1537376 9:22116220 T|C ANRIL 3.95x10-32 rs10757274 1.54x10-33 0.90 td,bda,enhancer
rs1537373 9:22103341 T|G ANRIL 5.37x10-32 rs10757274 1.54x10-33 0.96 td,bda,enhancer
rs10757274 9:22096055 A|G ANRIL 6.09x10-32 rs10757274 1.54x10-33 1.00 td,bda,enhancer,self
rs2210538 9:22092257 G|A ANRIL 6.51x10-32 rs10757274 1.54x10-33 0.85 td,bda,enhancer
rs1537371 9:22099568 C|A ANRIL 6.84x10-32 rs10757274 1.54x10-33 0.96 td,bda,enhancer
rs10757277 9:22124450 A|G 9p21.3 6.93x10-32 rs10757274 1.54x10-33 0.88 td,bda,enhancer
rs10733376 9:22114469 G|C ANRIL 7.49x10-32 rs10757274 1.54x10-33 0.90 td,bda,enhancer
46 
 
SNPID CHRPOS GENOTYPE LOCUS FINALP LeadSNP LEADSNP_P RSQUARE STATUS 
rs10738606 9:22088090 A|T ANRIL 9.11x10-32 rs10757274 1.54x10-33 0.95 td,bda,enhancer
rs4977757 9:22094330 A|G ANRIL 9.23x10-32 rs10757274 1.54x10-33 0.91 td,bda,enhancer
rs1004638 9:22115589 A|T ANRIL 9.85x10-32 rs10757274 1.54x10-33 0.90 td,bda,enhancer
rs10738609 9:22114495 A|C,G,T ANRIL 1.05x10-31 rs10757274 1.54x10-33 0.91 td,bda,enhancer
rs9644860 9:22090603 C|T ANRIL 1.08x10-31 rs10757274 1.54x10-33 0.81 td,bda,enhancer
rs944797 9:22115286 T|C ANRIL 1.14x10-31 rs10757274 1.54x10-33 0.90 td,bda,enhancer 
rs1556516 9:22100176 G|C ANRIL 1.37x10-31 rs10757274 1.54x10-33 0.96 td,bda,enhancer
rs10116277 9:22081397 G|T ANRIL 1.58x10-31 rs10757274 1.54x10-33 0.85 td,bda,enhancer
rs1412834 9:22110131 T|C ANRIL 1.59x10-31 rs10757274 1.54x10-33 0.91 td,bda,enhancer
rs1333042 9:22103813 A|G ANRIL 1.84x10-31 rs10757274 1.54x10-33 0.95 td,bda,enhancer
rs6475606 9:22081850 C|T ANRIL 2.11x10-31 rs10757274 1.54x10-33 0.85 td,bda,enhancer
rs1970112 9:22085598 T|C ANRIL 2.49x10-31 rs10757274 1.54x10-33 0.86 td,bda,enhancer 
rs73128528 20:44582187 A|T ZNF335 3.72x10-19 rs3827066 2.10x10-17 0.83 bda,enhancer
rs7267295 20:44570683 C|T PCIF1 4.78x10-18 rs3827066 2.10x10-17 0.84 td,bda,enhancer
rs58749629 20:44571317 G|A PCIF1 1.84x10-16 rs3827066 2.10x10-17 0.91 td,bda,enhancer
rs73015013 19:11190873 C|T 19p13.2 2.58x10-16 rs6511720 7.90x10-14 0.94 td,bda,enhancer
rs8124182 20:44608901 G|A 20q13.12 2.86x10-16 rs3827066 2.10x10-17 0.84 td,bda,enhancer
rs7270354 20:44607661 G|A 20q13.12 4.86x10-16 rs3827066 2.10x10-17 0.91 td,bda,enhancer 
chr19:11190074 19:11190074 G|A 19p13.2 1.41x10-15 rs6511720 7.90x10-14 0.96 td,bda,enhancer
chr19:11189272 19:11189272 T|C 19p13.2 1.65x10-15 rs6511720 7.90x10-14 0.94 td,bda,enhancer
chr19:11189937 19:11189937 T|A 19p13.2 1.81x10-15 rs6511720 7.90x10-14 0.96 td,bda,enhancer
rs6511720 19:11202306 G|T LDLR 2.06x10-15 rs6511720 7.90x10-14 1 bda,enhancer,chromhmm,self
rs56289821 19:11188247 G|A 19p13.2 3.84x10-15 rs6511720 7.90x10-14 0.92 td,bda,enhancer
rs8106503 19:11196886 T|C 19p13.2 6.27x10-15 rs6511720 7.90x10-14 0.94 td,bda,enhancer,chromhmm 
rs4845620 1:154406656 A|G IL6R 9.92x10-15 rs4129267 4.76x10-13 0.87 td,bda,enhancer
rs17248720 19:11198187 C|T LDLR 1.87x10-14 rs6511720 7.90x10-14 0.91 td,bda,enhancer,chromhmm
rs1660368 1:214407335 C|T 1q32.3 4.64x10-14 rs1795061 8.80x10-11 0.97 td,bda,enhancer,gerp
rs4537545 1:154418879 C|T IL6R 4.72x10-14 rs4129267 4.76x10-13 0.87 td,bda,enhancer
chr19:11187358 19:11187358 T|G 19p13.2 5.55x10-14 rs6511720 7.90x10-14 0.92 td,bda,enhancer
rs56383622 1:154405024 A|G IL6R 5.67x10-14 rs4129267 4.76x10-13 0.87 td,bda,enhancer 
chr19:11191197 19:11191197 G|A 19p13.2 7.26x10-14 rs6511720 7.90x10-14 0.94 td,bda,enhancer
rs57217136 19:11201124 T|C LDLR 8.82x10-14 rs6511720 7.90x10-14 1 bda,enhancer,chromhmm
rs4129267 1:154426264 C|T IL6R 9.12x10-14 rs4129267 4.76x10-13 1 bda,enhancer,self
rs12151108 19:11197261 G|A 19p13.2 1.10x10-13 rs6511720 7.90x10-14 0.93 td,bda,enhancer
rs17248727 19:11198502 T|C LDLR 1.31x10-13 rs6511720 7.90x10-14 0.92 td,bda,enhancer,chromhmm
rs2228145 1:154426970 A|C,T IL6R 1.39x10-13 rs4129267 4.76x10-13 0.99 bda,enhancer 
chr19:11189205 19:11189205 C|G 19p13.2 1.54x10-13 rs6511720 7.90x10-14 0.94 td,bda,enhancer
chr19:11189980 19:11189980 C|A 19p13.2 1.73x10-13 rs6511720 7.90x10-14 0.96 td,bda,enhancer
chr19:11188899 19:11188899 C|T 19p13.2 1.74x10-13 rs6511720 7.90x10-14 0.94 td,bda,enhancer
rs73015021 19:11192915 A|G 19p13.2 1.91x10-13 rs6511720 7.90x10-14 0.96 td,bda,enhancer
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chr19:11190544 19:11190544 C|T 19p13.2 2.15x10-13 rs6511720 7.90x10-14 0.88 td,bda,enhancer
rs6684439 1:154395839 C|T IL6R 2.51x10-13 rs4129267 4.76x10-13 0.83 td,bda,enhancer
chr19:11191729 19:11191729 C|T 19p13.2 2.95x10-13 rs6511720 7.90x10-14 0.94 td,bda,enhancer
rs599839 1:109822166 G|A 1p13.3 3.07x10-13 rs602633 6.58x10-09 0.92 td,bda,enhancer,gerp
chr19:11190481 19:11190481 G|T 19p13.2 3.15x10-13 rs6511720 7.90x10-14 0.96 td,bda,enhancer
rs10412048 19:11193949 A|G 19p13.2 3.58x10-13 rs6511720 7.90x10-14 0.93 td,bda,enhancer 
rs73015011 19:11189764 T|C 19p13.2 3.78x10-13 rs6511720 7.90x10-14 0.94 td,bda,enhancer
rs4845373 1:154417829 C|T IL6R 4.52x10-13 rs4129267 4.76x10-13 0.87 td,bda,enhancer
rs55997232 19:11188117 C|T 19p13.2 4.98x10-13 rs6511720 7.90x10-14 0.94 td,bda,enhancer
rs56125973 19:11188164 T|C 19p13.2 5.03x10-13 rs6511720 7.90x10-14 0.91 td,bda,enhancer 
chr19:11188850 19:11188850 T|C 19p13.2 6.17x10-13 rs6511720 7.90x10-14 0.93 td,bda,enhancer
rs12126142 1:154425456 G|A IL6R 6.17x10-13 rs4129267 4.76x10-13 1 bda,enhancer
chr19:11187422 19:11187422 T|C 19p13.2 6.25x10-13 rs6511720 7.90x10-14 0.93 td,bda,enhancer
chr19:11190556 19:11190556 T|C 19p13.2 6.99x10-13 rs6511720 7.90x10-14 0.93 td,bda,enhancer
rs10402112 19:11191677 T|A 19p13.2 7.26x10-13 rs6511720 7.90x10-14 0.94 td,bda,enhancer
rs11265613 1:154418415 T|C IL6R 7.93x10-13 rs4129267 4.76x10-13 0.88 td,bda,enhancer 
chr19:11187324 19:11187324 C|G 19p13.2 8.25x10-13 rs6511720 7.90x10-14 0.93 td,bda,enhancer
rs55791371 19:11188153 A|C 19p13.2 8.67x10-13 rs6511720 7.90x10-14 0.93 td,bda,enhancer
rs1147673 1:214402313 A|G 1q32.3 9.07x10-13 rs1795061 8.80x10-11 0.93 td,bda,enhancer
rs61194703 19:11192193 A|T 19p13.2 9.20x10-13 rs6511720 7.90x10-14 0.94 td,bda,enhancer
chr19:11190292 19:11190292 T|C 19p13.2 1.03x10-12 rs6511720 7.90x10-14 0.94 td,bda,enhancer
rs4845622 1:154411419 A|C IL6R 1.13x10-12 rs4129267 4.76x10-13 0.87 td,bda,enhancer 
rs73015024 19:11197598 G|T 19p13.2 1.13x10-12 rs6511720 7.90x10-14 0.94 td,bda,enhancer
rs12133641 1:154428283 A|G IL6R 1.32x10-12 rs4129267 4.76x10-13 0.97 bda,enhancer
chr19:11190534 19:11190534 G|A 19p13.2 1.36x10-12 rs6511720 7.90x10-14 0.93 td,bda,enhancer
chr19:11190110 19:11190110 A|G 19p13.2 1.44x10-12 rs6511720 7.90x10-14 0.96 td,bda,enhancer
chr19:11190549 19:11190549 G|A 19p13.2 1.50x10-12 rs6511720 7.90x10-14 0.93 td,bda,enhancer
rs73015016 19:11191300 G|A 19p13.2 1.56x10-12 rs6511720 7.90x10-14 0.94 td,bda,enhancer 
rs12730935 1:154419892 G|A IL6R 1.60x10-12 rs4129267 4.76x10-13 0.86 td,bda
chr19:11192831 19:11192831 A|G 19p13.2 1.88x10-12 rs6511720 7.90x10-14 0.94 td,bda,enhancer
rs73015020 19:11192550 G|A 19p13.2 1.98x10-12 rs6511720 7.90x10-14 0.93 td,bda,enhancer
rs4576655 1:154418749 C|T IL6R 2.56x10-12 rs4129267 4.76x10-13 0.88 td,bda,enhancer
rs4845621 1:154409730 G|A IL6R 2.95x10-12 rs4129267 4.76x10-13 0.87 td,bda
rs4393147 1:154414037 C|T IL6R 3.16x10-12 rs4129267 4.76x10-13 0.87 td,bda,enhancer 
rs12753254 1:154416935 G|A IL6R 3.49x10-12 rs4129267 4.76x10-13 0.87 td,bda,enhancer
rs4845372 1:154415396 C|A IL6R 4.58x10-12 rs4129267 4.76x10-13 0.83 td,bda,enhancer
rs6664201 1:154414296 C|T IL6R 5.08x10-12 rs4129267 4.76x10-13 0.87 td,bda,enhancer
rs4845623 1:154415777 A|G IL6R 5.10x10-12 rs4129267 4.76x10-13 0.83 td,bda,enhancer
rs7521458 1:154407713 T|C IL6R 5.55x10-12 rs4129267 4.76x10-13 0.87 td,bda
rs12730036 1:154416969 C|T IL6R 6.86x10-12 rs4129267 4.76x10-13 0.87 td,bda,enhancer 
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rs9510086 13:22862440 G|C 13q12.11 8.33x10-12 rs9316871 4.80x10-10 0.81 td,bda,enhancer
rs7518199 1:154407419 A|C IL6R 8.49x10-12 rs4129267 4.76x10-13 0.87 td,bda,enhancer
rs4453032 1:154414086 A|G IL6R 8.54x10-12 rs4129267 4.76x10-13 0.87 td,bda,enhancer
rs1795065 1:214405194 G|A 1q32.3 1.75x10-11 rs1795061 8.80x10-11 0.97 td,bda,enhancer
rs1795060 1:214410021 C|T 1q32.3 1.90x10-11 rs1795061 8.80x10-11 1 bda,enhancer
rs12740374 1:109817590 G|T CELSR2 2.07x10-11 rs602633 6.58x10-09 0.90 td,bda,enhancer,chromhmm,gerp 
rs904320 1:214408457 A|T 1q32.3 4.93x10-11 rs1795061 8.80x10-11 0.98 td,bda,enhancer
rs1795061 1:214409280 T|C 1q32.3 5.62x10-11 rs1795061 8.80x10-11 1 td,bda,enhancer,self
rs629301 1:109818306 G|T CELSR2 7.32x10-11 rs602633 6.58x10-09 0.90 td,bda,enhancer,chromhmm,gerp
rs10985349 9:124425243 C|T DAB2IP 7.46x10-11 rs10985349 2.40x10-11 1 td,bda,enhancer,self
rs10985350 9:124429196 A|C DAB2IP 1.67x10-10 rs10985349 2.40x10-11 0.81 td,bda,enhancer
rs660240 1:109817838 T|C CELSR2 1.88x10-10 rs602633 6.58x10-09 0.96 td,bda,enhancer,chromhmm,gerp 
rs7528419 1:109817192 A|G CELSR2 4.03x10-10 rs602633 6.58x10-09 0.90 td,bda,enhancer,chromhmm,gerp
rs1795064 1:214406272 C|T 1q32.3 5.07x10-10 rs1795061 8.80x10-11 0.97 td,bda,enhancer
rs1795062 1:214406721 T|C 1q32.3 5.73x10-10 rs1795061 8.80x10-11 0.97 td,bda,enhancer
rs1660371 1:214409248 T|A 1q32.3 9.29x10-10 rs1795061 8.80x10-11 0.97 td,bda,enhancer
rs1795063 1:214406508 G|A 1q32.3 9.72x10-10 rs1795061 8.80x10-11 0.97 td,bda,enhancer
rs9316871 13:22861921 A|G 13q12.11 1.26x10-09 rs9316871 4.80x10-10 1 td,bda,enhancer,self 
rs9506822 13:22862220 A|G 13q12.11 1.89x10-09 rs9316871 4.80x10-10 0.87 td,bda,enhancer




BIOINFORMATIC IDENTIFICATION OF CANDIDATE AAA GENES AND PATHWAYS USING DEPICT 
 
An integrated gene function analysis was performed using the DEPICT version 1.1 tool108.  DEPICT 
was installed, tested and run using meta-GWAS summary statistics following the recommended 
procedure outlined at https://github.com/perslab/depict.  Two separate runs were performed using 
either all independent SNPs with discovery metaGWAS P<5x10-6 or just those 10 SNPs which reached 
P<1x10-6 in the combined analysis. Results are shown in Online Table XVIII and the full dataset is 
available in the online data supplement. 
 
Online Table XVIII, DEPICT gene enrichment sets (nominal P<0.05) based on the top 10 validated 
loci. 
There is a notable presence of descriptions associated with transforming growth factor beta 
regulation, lipoprotein metabolism, inflammation induced extracellular matrix remodelling (eg. 
RFX1), vascular smooth muscle cell function, vascular injury (including haemorrhage), immune cell 
function (particularly T & B cells), acute phase response (including IL6 secretion), apoptosis, 
hyperglycemia and the PIK3K, JNK and MAPK cascades.  In addition, there are several descriptions 
associated with long bone size, an observation which may be consistent with previous reports linking 
height with cardiovascular disease risk. All gene sets had a false discovery rate > 0.2 with the 
exception of the most significant gene set, MP:0006396 (decreased long bone epiphyseal plate size), 
where the FDR was <0.2. This table spans 11 pages. 
 
Original gene set 
ID 
Original gene set description DEPICT 
Nominal 
P-value 
MP:0006396 decreased long bone epiphyseal plate size 1.14x10-9 
GO:0034381 plasma lipoprotein particle clearance 5.22x10-7 
ENSG00000205250 E2F4 PPI subnetwork 1.27x10-6 
ENSG00000132005 RFX1 PPI subnetwork 2.28x10-6 
MP:0000708 thymus hyperplasia 6.32x10-6 
ENSG00000167553 TUBA1C PPI subnetwork 3.18x10-5 
ENSG00000170421 KRT8 PPI subnetwork 9.59x10-5 
MP:0003645 increased pancreatic beta cell number 1.12x10-4 
ENSG00000166866 MYO1A PPI subnetwork 2.32x10-4 
REACTOME REACTOME_apoptotic_execution__phase 2.92x10-4 
MP:0008182 decreased marginal zone B cell number 3.06x10-4 
GO:0008375 acetylglucosaminyltransferase activity 3.62x10-4 
ENSG00000131941 RHPN2 PPI subnetwork 3.75x10-4 
ENSG00000169710 FASN PPI subnetwork 4.55x10-4 
REACTOME Reactome_apoptotic_cleavage_of_cellular_proteins 5.46x10-4 
ENSG00000013297 CLDN11 PPI subnetwork 6.28x10-4 
ENSG00000070159 PTPN3 PPI subnetwork 6.56x10-4 
ENSG00000091409 ITGA6 PPI subnetwork 7.26x10-4 
ENSG00000178209 PLEC PPI subnetwork 8.57x10-4 
REACTOME Reactome_p75_ntr_receptor:mediated_signalling 1.07x10-3 
GO:0001890 placenta development 1.08x10-3 
ENSG00000164344 KLKB1 PPI subnetwork 1.09x10-3 
MP:0002136 abnormal kidney physiology 1.17x10-3 
MP:0002655 abnormal keratinocyte morphology 1.45x10-3 
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ENSG00000143375 CGN PPI subnetwork 1.48x10-3 
MP:0005595 abnormal vascular smooth muscle physiology 1.55x10-3 
ENSG00000122641 INHBA PPI subnetwork 1.79x10-3 
MP:0002764 short tibia 1.79x10-3 
MP:0003662 abnormal long bone epiphyseal plate proliferative zone 2.01x10-3 
ENSG00000169047 IRS1 PPI subnetwork 2.21x10-3 
ENSG00000125503 PPP1R12C PPI subnetwork 2.23x10-3 
MP:0001179 thick pulmonary interalveolar septum 2.30x10-3 
GO:0043256 laminin complex 2.33x10-3 
ENSG00000116809 ZBTB17 PPI subnetwork 2.46x10-3 
GO:0050431 transforming growth factor beta binding 2.47x10-3 
ENSG00000039560 RAI14 PPI subnetwork 2.60x10-3 
ENSG00000164733 CTSB PPI subnetwork 2.64x10-3 
ENSG00000139567 ACVRL1 PPI subnetwork 2.75x10-3 
MP:0005590 increased vasodilation 3.45x10-3 
GO:0071813 lipoprotein particle binding 3.51x10-3 
GO:0071814 protein-lipid complex binding 3.51x10-3 
MP:0002082 postnatal lethality 3.53x10-3 
GO:0071902 positive regulation of protein serine/threonine kinase activity 3.87x10-3 
ENSG00000130147 SH3BP4 PPI subnetwork 3.91x10-3 
GO:0005178 integrin binding 4.08x10-3 
ENSG00000133056 PIK3C2B PPI subnetwork 4.40x10-3 
ENSG00000172725 CORO1B PPI subnetwork 4.45x10-3 
ENSG00000136286 MYO1G PPI subnetwork 4.65x10-3 
ENSG00000078142 PIK3C3 PPI subnetwork 4.72x10-3 
MP:0005095 decreased T cell proliferation 4.84x10-3 
ENSG00000145715 RASA1 PPI subnetwork 4.96x10-3 
ENSG00000104725 ENSG00000104725 PPI subnetwork 5.08x10-3 
KEGG_PATHWAYS KEGG_PATHWAYS_IN_CANCER 5.17x10-3 
GO:0008194 UDP-glycosyltransferase activity 5.46x10-3 
ENSG00000078747 ITCH PPI subnetwork 5.48x10-3 
ENSG00000149257 SERPINH1 PPI subnetwork 5.79x10-3 
ENSG00000114062 UBE3A PPI subnetwork 5.85x10-3 
ENSG00000139144 PIK3C2G PPI subnetwork 5.85x10-3 
ENSG00000143393 PI4KB PPI subnetwork 5.87x10-3 
ENSG00000148498 PARD3 PPI subnetwork 6.00x10-3 
ENSG00000196455 PIK3R4 PPI subnetwork 6.19x10-3 
ENSG00000148660 CAMK2G PPI subnetwork 6.48x10-3 
ENSG00000034152 MAP2K3 PPI subnetwork 6.58x10-3 
ENSG00000123124 WWP1 PPI subnetwork 6.95x10-3 
MP:0008813 decreased common myeloid progenitor cell number 7.37x10-3 
ENSG00000204175 GPRIN2 PPI subnetwork 7.39x10-3 
GO:0001772 immunological synapse 7.40x10-3 
REACTOME Reactome_caspase:mediated_cleavage_of_cytoskeletal_proteins 7.46x10-3 
ENSG00000017427 IGF1 PPI subnetwork 7.51x10-3 
MP:0001954 respiratory distress 7.56x10-3 
GO:0016051 carbohydrate biosynthetic process 7.65x10-3 
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GO:0043406 positive regulation of MAP kinase activity 7.65x10-3 
REACTOME Reactome_cell_death_signalling_via_nrage_nrif_and_nade 7.67x10-3 
MP:0000180 abnormal circulating cholesterol level 7.71x10-3 
ENSG00000170759 KIF5B PPI subnetwork 7.79x10-3 
ENSG00000180530 NRIP1 PPI subnetwork 7.86x10-3 
ENSG00000138771 SHROOM3 PPI subnetwork 7.89x10-3 
ENSG00000065882 TBC1D1 PPI subnetwork 7.97x10-3 
ENSG00000138592 USP8 PPI subnetwork 7.99x10-3 
MP:0001915 intracranial hemorrhage 8.00x10-3 
ENSG00000131746 TNS4 PPI subnetwork 8.01x10-3 
MP:0004883 abnormal vascular wound healing 8.15x10-3 
ENSG00000091073 ENSG00000091073 PPI subnetwork 8.22x10-3 
ENSG00000081189 MEF2C PPI subnetwork 8.24x10-3 
ENSG00000154415 PPP1R3A PPI subnetwork 8.33x10-3 
ENSG00000188313 PLSCR1 PPI subnetwork 8.55x10-3 
MP:0004933 abnormal epididymis epithelium morphology 8.61x10-3 
ENSG00000147065 MSN PPI subnetwork 8.64x10-3 
ENSG00000165409 TSHR PPI subnetwork 8.64x10-3 
ENSG00000106992 AK1 PPI subnetwork 8.69x10-3 
GO:0007292 female gamete generation 8.93x10-3 
ENSG00000144061 NPHP1 PPI subnetwork 8.95x10-3 
MP:0003419 delayed endochondral bone ossification 8.98x10-3 
ENSG00000110880 CORO1C PPI subnetwork 9.04x10-3 
ENSG00000197879 MYO1C PPI subnetwork 9.22x10-3 
ENSG00000176476 CCDC101 PPI subnetwork 9.31x10-3 
ENSG00000176108 CHMP6 PPI subnetwork 9.44x10-3 
REACTOME Reactome_integrin_cell_surface_interactions 9.47x10-3 
GO:0016758 transferase activity, transferring hexosyl groups 9.49x10-3 
ENSG00000103197 TSC2 PPI subnetwork 9.49x10-3 
MP:0003909 increased eating behavior 9.57x10-3 
MP:0000716 abnormal immune system cell morphology 9.63x10-3 
MP:0008803 abnormal placental labyrinth vasculature morphology 9.67x10-3 
ENSG00000137801 THBS1 PPI subnetwork 9.71x10-3 
ENSG00000130522 JUND PPI subnetwork 9.72x10-3 
GO:0005088 Ras guanyl-nucleotide exchange factor activity 9.78x10-3 
ENSG00000170581 STAT2 PPI subnetwork 9.79x10-3 
ENSG00000173757 STAT5B PPI subnetwork 9.84x10-3 
GO:0043277 apoptotic cell clearance 9.98x10-3 
GO:0006917 induction of apoptosis 0.01 
MP:0001828 abnormal T cell activation 0.01 
ENSG00000171241 SHCBP1 PPI subnetwork 0.01 
REACTOME REACTOME_apoptosis 0.01 
MP:0011106 partial embryonic lethality before somite formation 0.01 
GO:0030169 low-density lipoprotein particle binding 0.01 
MP:0003731 abnormal retinal outer nuclear layer morphology 0.01 
MP:0009400 decreased skeletal muscle fiber size 0.01 
ENSG00000137693 YAP1 PPI subnetwork 0.01 
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REACTOME Reactome_nrage_signals_death_through_jnk 0.01 
ENSG00000145794 MEGF10 PPI subnetwork 0.01 
MP:0008478 increased spleen white pulp amount 0.01 
MP:0005079 defective cytotoxic T cell cytolysis 0.01 
ENSG00000141506 PIK3R5 PPI subnetwork 0.01 
GO:0000989 transcription factor binding transcription factor activity 0.01 
MP:0002161 abnormal fertility/fecundity 0.01 
GO:0040029 regulation of gene expression, epigenetic 0.01 
ENSG00000115963 RND3 PPI subnetwork 0.01 
GO:0043236 laminin binding 0.01 
ENSG00000211660 ENSG00000211660 PPI subnetwork 0.01 
ENSG00000211653 ENSG00000211653 PPI subnetwork 0.01 
ENSG00000160310 PRMT2 PPI subnetwork 0.01 
ENSG00000127688 GAN PPI subnetwork 0.01 
ENSG00000167711 SERPINF2 PPI subnetwork 0.01 
GO:0043491 protein kinase B signaling cascade 0.01 
ENSG00000136068 FLNB PPI subnetwork 0.01 
GO:0002020 protease binding 0.01 
ENSG00000198053 SIRPA PPI subnetwork 0.01 
ENSG00000182319 SGK223 PPI subnetwork 0.01 
ENSG00000174292 TNK1 PPI subnetwork 0.01 
ENSG00000132825 PPP1R3D PPI subnetwork 0.01 
GO:0051015 actin filament binding 0.01 
ENSG00000140443 IGF1R PPI subnetwork 0.01 
MP:0000281 abnormal interventricular septum morphology 0.01 
ENSG00000067560 RHOA PPI subnetwork 0.01 
MP:0006094 increased fat cell size 0.01 
ENSG00000197555 SIPA1L1 PPI subnetwork 0.01 
ENSG00000183386 FHL3 PPI subnetwork 0.01 
MP:0003229 abnormal vitelline vasculature morphology 0.01 
MP:0001231 abnormal epidermis stratum basale morphology 0.01 
MP:0000511 abnormal intestinal mucosa morphology 0.01 
KEGG KEGG_ACUTE_MYELOID_LEUKEMIA 0.01 
GO:0007254 JNK cascade 0.01 
GO:0008624 induction of apoptosis by extracellular signals 0.01 
GO:0000988 protein binding transcription factor activity 0.02 
MP:0002452 abnormal antigen presenting cell physiology 0.02 
ENSG00000185950 IRS2 PPI subnetwork 0.02 
KEGG KEGG_leukocyte_transendothelial_migration 0.02 
GO:0051568 histone H3-K4 methylation 0.02 
ENSG00000165516 KLHDC2 PPI subnetwork 0.02 
REACTOME Reactome_cell_surface_interactions_at_the_vascular_wall 0.02 
ENSG00000198838 RYR3 PPI subnetwork 0.02 
MP:0001711 abnormal placenta morphology 0.02 
GO:0014910 regulation of smooth muscle cell migration 0.02 
ENSG00000104960 PTOV1 PPI subnetwork 0.02 
GO:0001968 fibronectin binding 0.02 
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GO:0012502 induction of programmed cell death 0.02 
ENSG00000100364 KIAA0930 PPI subnetwork 0.02 
ENSG00000165410 CFL2 PPI subnetwork 0.02 
MP:0004994 abnormal brain wave pattern 0.02 
MP:0001552 increased circulating triglyceride level 0.02 
ENSG00000116141 MARK1 PPI subnetwork 0.02 
GO:0032403 protein complex binding 0.02 
ENSG00000179364 PACS2 PPI subnetwork 0.02 
MP:0001559 hyperglycemia 0.02 
ENSG00000105851 PIK3CG PPI subnetwork 0.02 
MP:0004031 insulitis 0.02 
MP:0010124 decreased bone mineral content 0.02 
ENSG00000165197 FIGF PPI subnetwork 0.02 
ENSG00000126561 STAT5A PPI subnetwork 0.02 
ENSG00000136156 ITM2B PPI subnetwork 0.02 
ENSG00000164327 RICTOR PPI subnetwork 0.02 
ENSG00000159166 LAD1 PPI subnetwork 0.02 
MP:0001716 abnormal placenta labyrinth morphology 0.02 
MP:0002427 disproportionate dwarf 0.02 
ENSG00000105371 ICAM4 PPI subnetwork 0.02 
ENSG00000165476 REEP3 PPI subnetwork 0.02 
GO:0046625 sphingolipid binding 0.02 
MP:0000585 kinked tail 0.02 
MP:0000889 abnormal cerebellar molecular layer 0.02 
ENSG00000105699 LSR PPI subnetwork 0.02 
GO:0005545 1-phosphatidylinositol binding 0.02 
MP:0001134 absent corpus luteum 0.02 
ENSG00000100097 LGALS1 PPI subnetwork 0.02 
MP:0002079 increased circulating insulin level 0.02 
ENSG00000150093 ITGB1 PPI subnetwork 0.02 
GO:0001871 pattern binding 0.02 
GO:0030247 polysaccharide binding 0.02 
ENSG00000126934 MAP2K2 PPI subnetwork 0.02 
ENSG00000110395 CBL PPI subnetwork 0.02 
ENSG00000179151 EDC3 PPI subnetwork 0.02 
ENSG00000154162 CDH12 PPI subnetwork 0.02 
ENSG00000184363 PKP3 PPI subnetwork 0.02 
ENSG00000020577 SAMD4A PPI subnetwork 0.02 
MP:0004139 abnormal gastric parietal cell morphology 0.02 
ENSG00000168476 REEP4 PPI subnetwork 0.02 
ENSG00000110651 CD81 PPI subnetwork 0.02 
ENSG00000134184 GSTM1 PPI subnetwork 0.02 
ENSG00000105376 ICAM5 PPI subnetwork 0.02 
ENSG00000196954 CASP4 PPI subnetwork 0.02 
MP:0003704 abnormal hair follicle development 0.02 
ENSG00000050820 BCAR1 PPI subnetwork 0.02 
ENSG00000151748 SAV1 PPI subnetwork 0.02 
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GO:0003714 transcription corepressor activity 0.02 
ENSG00000115904 SOS1 PPI subnetwork 0.02 
ENSG00000175793 SFN PPI subnetwork 0.02 
ENSG00000100345 MYH9 PPI subnetwork 0.02 
GO:0035091 phosphatidylinositol binding 0.02 
ENSG00000149930 TAOK2 PPI subnetwork 0.02 
GO:0042054 histone methyltransferase activity 0.02 
MP:0000689 abnormal spleen morphology 0.02 
GO:0001892 embryonic placenta development 0.02 
ENSG00000130294 KIF1A PPI subnetwork 0.02 
ENSG00000148965 SAA4 PPI subnetwork 0.02 
GO:0034774 secretory granule lumen 0.02 
ENSG00000166483 WEE1 PPI subnetwork 0.02 
ENSG00000110237 ARHGEF17 PPI subnetwork 0.02 
GO:0032608 interferon-beta production 0.02 
ENSG00000152518 ZFP36L2 PPI subnetwork 0.02 
MP:0010792 abnormal stomach mucosa morphology 0.02 
ENSG00000189319 FAM53B PPI subnetwork 0.02 
ENSG00000117461 PIK3R3 PPI subnetwork 0.02 
GO:0034362 low-density lipoprotein particle 0.02 
ENSG00000134072 CAMK1 PPI subnetwork 0.02 
ENSG00000163362 C1orf106 PPI subnetwork 0.02 
MP:0002816 colitis 0.02 
GO:0050900 leukocyte migration 0.03 
GO:0044304 main axon 0.03 
ENSG00000071909 MYO3B PPI subnetwork 0.03 
ENSG00000100714 MTHFD1 PPI subnetwork 0.03 
ENSG00000198836 OPA1 PPI subnetwork 0.03 
ENSG00000197442 MAP3K5 PPI subnetwork 0.03 
ENSG00000206306 HLA-DRB1 PPI subnetwork 0.03 
ENSG00000206240 HLA-DRB1 PPI subnetwork 0.03 
GO:0031983 vesicle lumen 0.03 
KEGG KEGG_regulation_of_actin_cytoskeleton 0.03 
GO:0004713 protein tyrosine kinase activity 0.03 
GO:0006953 acute-phase response 0.03 
GO:0003712 transcription cofactor activity 0.03 
MP:0000295 trabecula carnea hypoplasia 0.03 
ENSG00000105647 PIK3R2 PPI subnetwork 0.03 
GO:0060205 cytoplasmic membrane-bounded vesicle lumen 0.03 
ENSG00000107566 ERLIN1 PPI subnetwork 0.03 
ENSG00000114270 COL7A1 PPI subnetwork 0.03 
ENSG00000135930 EIF4E2 PPI subnetwork 0.03 
MP:0006413 increased T cell apoptosis 0.03 
ENSG00000211949 ENSG00000211949 PPI subnetwork 0.03 
ENSG00000125731 SH2D3A PPI subnetwork 0.03 
MP:0000414 alopecia 0.03 
ENSG00000160691 SHC1 PPI subnetwork 0.03 
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MP:0001282 short vibrissae 0.03 
MP:0003996 clonic seizures 0.03 
ENSG00000019991 HGF PPI subnetwork 0.03 
MP:0010025 decreased total body fat amount 0.03 
GO:0007568 aging 0.03 
GO:0042809 vitamin D receptor binding 0.03 
MP:0005331 insulin resistance 0.03 
GO:0045682 regulation of epidermis development 0.03 
MP:0001923 reduced female fertility 0.03 
MP:0001219 thick epidermis 0.03 
ENSG00000068615 REEP1 PPI subnetwork 0.03 
ENSG00000171219 CDC42BPG PPI subnetwork 0.03 
MP:0009583 increased keratinocyte proliferation 0.03 
ENSG00000105810 CDK6 PPI subnetwork 0.03 
ENSG00000105662 CRTC1 PPI subnetwork 0.03 
MP:0003957 abnormal nitric oxide homeostasis 0.03 
KEGG KEGG_small_cell_lung_cancer 0.03 
GO:0030669 clathrin-coated endocytic vesicle membrane 0.03 
ENSG00000100030 MAPK1 PPI subnetwork 0.03 
GO:0046328 regulation of JNK cascade 0.03 
GO:0014070 response to organic cyclic compound 0.03 
GO:0033500 carbohydrate homeostasis 0.03 
GO:0042593 glucose homeostasis 0.03 
REACTOME Reactome_ptm_gamma_carboxylation_hypusine_formation_and_arylsulfatase_activation 0.03 
REACTOME Reactome_regulation_of_signaling_by_cbl 0.03 
MP:0002418 increased susceptibility to viral infection 0.03 
MP:0003721 increased tumor growth/size 0.03 
GO:0071845 cellular component disassembly at cellular level 0.03 
GO:0030518 intracellular steroid hormone receptor signaling pathway 0.03 
ENSG00000116824 CD2 PPI subnetwork 0.03 
MP:0003566 abnormal cell adhesion 0.03 
GO:0034061 DNA polymerase activity 0.03 
ENSG00000141968 VAV1 PPI subnetwork 0.03 
GO:0001701 in utero embryonic development 0.03 
MP:0000166 abnormal chondrocyte morphology 0.03 
MP:0003400 kinked neural tube 0.03 
GO:0000790 nuclear chromatin 0.03 
ENSG00000197102 DYNC1H1 PPI subnetwork 0.03 
GO:0043566 structure-specific DNA binding 0.03 
ENSG00000075413 MARK3 PPI subnetwork 0.03 
GO:0000271 polysaccharide biosynthetic process 0.03 
REACTOME Reactome_cell:cell_communication 0.03 
MP:0000410 waved hair 0.03 
ENSG00000154556 SORBS2 PPI subnetwork 0.03 
ENSG00000104368 PLAT PPI subnetwork 0.03 
GO:0043123 positive regulation of I-kappaB kinase/NF-kappaB cascade 0.03 
ENSG00000156127 BATF PPI subnetwork 0.03 
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ENSG00000132470 ITGB4 PPI subnetwork 0.03 
GO:0038024 cargo receptor activity 0.03 
ENSG00000100014 SPECC1L PPI subnetwork 0.03 
ENSG00000163083 INHBB PPI subnetwork 0.03 
ENSG00000110931 CAMKK2 PPI subnetwork 0.03 
MP:0002088 abnormal embryonic growth/weight/body size 0.03 
GO:0016571 histone methylation 0.03 
GO:0033559 unsaturated fatty acid metabolic process 0.03 
MP:0005350 increased susceptibility to autoimmune disorder 0.03 
ENSG00000136111 TBC1D4 PPI subnetwork 0.03 
REACTOME Reactome_nephrin_interactions 0.03 
ENSG00000182195 LDOC1 PPI subnetwork 0.03 
ENSG00000123685 BATF3 PPI subnetwork 0.03 
ENSG00000215699 ENSG00000215699 PPI subnetwork 0.03 
GO:0005720 nuclear heterochromatin 0.03 
ENSG00000092969 TGFB2 PPI subnetwork 0.03 
KEGG KEGG_ECM_receptor_interaction 0.03 
MP:0001201 translucent skin 0.03 
GO:0016278 lysine N-methyltransferase activity 0.03 
GO:0016279 protein-lysine N-methyltransferase activity 0.03 
ENSG00000196586 MYO6 PPI subnetwork 0.03 
GO:0004702 receptor signaling protein serine/threonine kinase activity 0.03 
ENSG00000072518 MARK2 PPI subnetwork 0.03 
ENSG00000165025 SYK PPI subnetwork 0.03 
MP:0002109 abnormal limb morphology 0.03 
ENSG00000157764 BRAF PPI subnetwork 0.03 
ENSG00000152256 PDK1 PPI subnetwork 0.03 
ENSG00000065618 COL17A1 PPI subnetwork 0.04 
ENSG00000169220 RGS14 PPI subnetwork 0.04 
ENSG00000100311 PDGFB PPI subnetwork 0.04 
ENSG00000134202 GSTM3 PPI subnetwork 0.04 
ENSG00000142515 KLK3 PPI subnetwork 0.04 
MP:0002619 abnormal lymphocyte morphology 0.04 
ENSG00000161395 PGAP3 PPI subnetwork 0.04 
ENSG00000145431 PDGFC PPI subnetwork 0.04 
ENSG00000170962 PDGFD PPI subnetwork 0.04 
ENSG00000153879 CEBPG PPI subnetwork 0.04 
ENSG00000077380 DYNC1I2 PPI subnetwork 0.04 
ENSG00000197122 SRC PPI subnetwork 0.04 
MP:0004399 abnormal cochlear outer hair cell morphology 0.04 
ENSG00000174996 KLC2 PPI subnetwork 0.04 
MP:0002376 abnormal dendritic cell physiology 0.04 
MP:0000709 enlarged thymus 0.04 
MP:0008706 decreased interleukin-6 secretion 0.04 
MP:0004686 decreased length of long bones 0.04 
GO:0050810 regulation of steroid biosynthetic process 0.04 
ENSG00000138396 ENSG00000138396 PPI subnetwork 0.04 
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ENSG00000148400 NOTCH1 PPI subnetwork 0.04 
ENSG00000137171 KLC4 PPI subnetwork 0.04 
ENSG00000196396 PTPN1 PPI subnetwork 0.04 
ENSG00000148672 GLUD1 PPI subnetwork 0.04 
GO:0000975 regulatory region DNA binding 0.04 
GO:0001067 regulatory region nucleic acid binding 0.04 
GO:0022411 cellular component disassembly 0.04 
ENSG00000026025 VIM PPI subnetwork 0.04 
ENSG00000061273 HDAC7 PPI subnetwork 0.04 
ENSG00000104067 TJP1 PPI subnetwork 0.04 
MP:0004813 absent linear vestibular evoked potential 0.04 
ENSG00000091136 LAMB1 PPI subnetwork 0.04 
KEGG KEGG_renal_cell_carcinoma 0.04 
KEGG KEGG_focal_adhesion 0.04 
GO:0031581 hemidesmosome assembly 0.04 
ENSG00000141068 KSR1 PPI subnetwork 0.04 
MP:0004214 abnormal long bone diaphysis morphology 0.04 
ENSG00000123836 PFKFB2 PPI subnetwork 0.04 
ENSG00000168090 COPS6 PPI subnetwork 0.04 
ENSG00000132356 PRKAA1 PPI subnetwork 0.04 
GO:0031093 platelet alpha granule lumen 0.04 
GO:0048545 response to steroid hormone stimulus 0.04 
MP:0003109 short femur 0.04 
ENSG00000113758 DBN1 PPI subnetwork 0.04 
GO:0008276 protein methyltransferase activity 0.04 
MP:0003383 abnormal gluconeogenesis 0.04 
ENSG00000162614 NEXN PPI subnetwork 0.04 
ENSG00000162614 NEXN PPI subnetwork 0.04 
ENSG00000169641 LUZP1 PPI subnetwork 0.04 
MP:0002152 abnormal brain morphology 0.04 
ENSG00000204257 HLA-DMA PPI subnetwork 0.04 
ENSG00000206229 ENSG00000206229 PPI subnetwork 0.04 
ENSG00000206293 ENSG00000206293 PPI subnetwork 0.04 
ENSG00000138439 FAM117B PPI subnetwork 0.04 
GO:0006636 unsaturated fatty acid biosynthetic process 0.04 
ENSG00000176444 CLK2 PPI subnetwork 0.04 
MP:0000703 abnormal thymus morphology 0.04 
REACTOME Reactome_zinc_transporters 0.04 
ENSG00000125952 MAX PPI subnetwork 0.04 
GO:0046456 icosanoid biosynthetic process 0.04 
ENSG00000132964 CDK8 PPI subnetwork 0.04 
MP:0008688 decreased interleukin-2 secretion 0.04 
ENSG00000196218 RYR1 PPI subnetwork 0.04 
MP:0004770 abnormal synaptic vesicle recycling 0.04 
ENSG00000121879 PIK3CA PPI subnetwork 0.04 
ENSG00000196735 HLA-DQA1 PPI subnetwork 0.04 
MP:0009355 increased liver triglyceride level 0.04 
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MP:0009399 increased skeletal muscle fiber size 0.04 
ENSG00000160678 S100A1 PPI subnetwork 0.04 
ENSG00000064999 ANKS1A PPI subnetwork 0.04 
ENSG00000173327 MAP3K11 PPI subnetwork 0.04 
GO:0051183 vitamin transporter activity 0.04 
GO:0006690 icosanoid metabolic process 0.04 
ENSG00000134363 FST PPI subnetwork 0.04 
GO:0060053 neurofilament cytoskeleton 0.04 
ENSG00000151914 DST PPI subnetwork 0.04 
ENSG00000189079 ARID2 PPI subnetwork 0.04 
ENSG00000065559 MAP2K4 PPI subnetwork 0.05 
ENSG00000120709 FAM53C PPI subnetwork 0.05 
MP:0002110 abnormal digit morphology 0.05 
GO:0005976 polysaccharide metabolic process 0.05 
ENSG00000054523 KIF1B PPI subnetwork 0.05 
ENSG00000100906 NFKBIA PPI subnetwork 0.05 
ENSG00000136518 ACTL6A PPI subnetwork 0.05 
GO:0004709 MAP kinase kinase kinase activity 0.05 
GO:0060711 labyrinthine layer development 0.05 
KEGG_ KEGG_circadian_rhythm_mammal 0.05 
REACTOME Reactome_classical_antibody:mediated_complement_activation 0.05 
ENSG00000211979 ENSG00000211979 PPI subnetwork 0.05 
ENSG00000211973 ENSG00000211973 PPI subnetwork 0.05 
ENSG00000172534 HCFC1 PPI subnetwork 0.05 
ENSG00000136270 TBRG4 PPI subnetwork 0.05 
GO:0032648 regulation of interferon-beta production 0.05 
GO:0034375 high-density lipoprotein particle remodeling 0.05 
ENSG00000185811 IKZF1 PPI subnetwork 0.05 
ENSG00000198802 ENSG00000198802 PPI subnetwork 0.05 
MP:0006262 testis tumor 0.05 
ENSG00000171992 SYNPO PPI subnetwork 0.05 
ENSG00000213341 CHUK PPI subnetwork 0.05 
ENSG00000175197 DDIT3 PPI subnetwork 0.05 
MP:0005150 cachexia 0.05 
GO:0043122 regulation of I-kappaB kinase/NF-kappaB cascade 0.05 
GO:0097006 regulation of plasma lipoprotein particle levels 0.05 
ENSG00000162772 ATF3 PPI subnetwork 0.05 
GO:0000122 negative regulation of transcription from RNA polymerase II promoter 0.05 
GO:0005858 axonemal dynein complex 0.05 
ENSG00000051382 PIK3CB PPI subnetwork 0.05 
GO:0043405 regulation of MAP kinase activity 0.05 
MP:0008722 abnormal chemokine secretion 0.05 
KEGG KEGG_chronic_myeloid_leukemia 0.05 
REACTOME Reactome_regulated_PROTEOLYSIS_OF_P75NTR 0.05 
GO:0043588 skin development 0.05 
GO:0010627 regulation of intracellular protein kinase cascade 0.05 
GO:0044212 transcription regulatory region DNA binding 0.05 
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GO:0030027 lamellipodium 0.05 
ENSG00000105976 MET PPI subnetwork 0.05 
MP:0002792 abnormal retinal vasculature morphology 0.05 
MP:0000069 kyphoscoliosis 0.05 
GO:0034339 regulation of transcription from RNA polymerase II promoter by nuclear hormone receptor 0.05 
ENSG00000141551 CSNK1D PPI subnetwork 0.05 
MP:0005108 abnormal ulna morphology 0.05 
MP:0002419 abnormal innate immunity 0.05 
GO:0016757 transferase activity, transferring glycosyl groups 0.05 
ENSG00000161800 RACGAP1 PPI subnetwork 0.05 
MP:0006387 abnormal T cell number 0.05 
GO:0005089 Rho guanyl-nucleotide exchange factor activity 0.05 
ENSG00000117984 CTSD PPI subnetwork 0.05 
ENSG00000105971 CAV2 PPI subnetwork 0.05 
ENSG00000115085 ZAP70 PPI subnetwork 0.05 
MP:0004609 vertebral fusion 0.05 
ENSG00000135862 LAMC1 PPI subnetwork 0.05 
MP:0003449 abnormal intestinal goblet cell morphology 0.05 
MP:0002687 oligozoospermia 0.05 
MP:0000714 increased thymocyte number 0.05 
ENSG00000133030 MPRIP PPI subnetwork 0.05 
ENSG00000079841 RIMS1 PPI subnetwork 0.05 
ENSG00000130638 ATXN10 PPI subnetwork 0.05 
MP:0002656 abnormal keratinocyte differentiation 0.05 
ENSG00000129691 ASH2L PPI subnetwork 0.05 
MP:0002650 abnormal ameloblast morphology 0.05 
ENSG00000135503 ACVR1B PPI subnetwork 0.05 
GO:0004715 non-membrane spanning protein tyrosine kinase activity 0.05 
ENSG00000001497 LAS1L PPI subnetwork 0.05 
GO:0018024 histone-lysine N-methyltransferase activity 0.05 
GO:0000792 heterochromatin 0.05 
ENSG00000111961 SASH1 PPI subnetwork 0.05 
MP:0008840 abnormal spike wave discharge 0.05 
ENSG00000139514 SLC7A1 PPI subnetwork 0.05 





Functional effects of SNPs at AAA loci 
 
1: Expression SNP database lookup (Online Table XIX) 
Evidence for functional effects of AAA associated SNPs/loci was sought in two eQTL datasets curated 
by Andrew Johnson at the NIH National Heart Lung and Blood Institute, Framingham, USA. Firstly, 
index and proxy SNPs were queried in a collected database of expression SNP (eSNP) results. The 
collected eSNP results met criteria for statistical thresholds for association with gene transcript 
levels as described in the original papers. A general overview of a subset of >50 eQTL studies has 
been published109, with specific citations for >100 studies included in the current query following 
here: 
Blood cell related eQTL studies included fresh lymphocytes110, fresh leukocytes111 , leukocyte 
samples in individuals with Celiac disease112, whole blood samples113-126, lymphoblastoid cell lines 
(LCL) derived from asthmatic children127, 128, HapMap LCL from 3 populations129, a separate study on 
HapMap CEU LCL130, additional LCL population samples131-136, CD19+ B cells137, primary PHA-
stimulated T cells133, 135, CD4+ T cells138, peripheral blood monocytes137, 139, 140 and CD14+ monocytes 
before and after stimulation with LPS or interferon-gamma141, CD11+ dendritic cells before and after 
Mycobacterium tuberculosis infection142 and a separate study of dendritic cells before or after 
stimulation with LPS, influenza or interferon-beta143. Micro-RNA QTLs144 and DNase-I QTLs145 were 
also queried for LCL. 
Non-blood cell tissue eQTLs searched included omental and subcutaneous adipose115, 134, 146, 147, 
stomach147, endometrial carcinomas148, ER+ and ER- breast cancer tumor cells149, liver147, 150-153, 
osteoblasts154, intestine155 and normal and cancerous colon156, skeletal muscle157, breast tissue 
(normal and cancer)158, 159, lung146, 160, 161, skin134, 146, 162, primary fibroblasts133, 135, 163, sputum164, 
pancreatic islet cells165 and heart tissue from left ventricles146, 166 and left and right atria167. Micro-
RNA QTLs were also queried for gluteal and abdominal adipose168 and liver169. Further mRNA and 
micro-RNA QTLs were queried from ER+ invasive breast cancer samples, colon-, kidney renal clear-, 
lung- and prostate-adenocarcinoma samples170. 
Brain eQTL studies included brain cortex139, 171, 172, cerebellar cortex173, cerebellum172, 174-177, frontal 
cortex173, 175, 176, gliomas178, hippocampus173, 176, inferior olivary nucleus (from medulla)173, 
intralobular white matter173, occiptal cortex173, parietal lobe174, pons175, pre-frontal cortex176, 177, 179, 
180, putamen (at the level of anterior commussure)173, substantia nigra173, temporal cortex172, 173, 175, 
176, thalamus176 and visual cortex177. 
Secondly, additional eQTL data were integrated from online sources including ScanDB, the Broad 
Institute GTex browser, and the Pritchard Lab (eqtl.uchicago.edu). Cerebellum, parietal lobe and 
liver eQTL data was downloaded from ScanDB and cis-eQTLs were limited to those with P<1.0x10-6 
and trans-eQTLs with P<5.0x10-8. The top 1000 eQTL results were downloaded from the GTex 
Browser at the Broad Institute for 9 tissues on 11/26/2013: thyroid, leg skin (sun exposed), tibial 
nerve, tibial artery, skeletal muscle, lung, heart (left ventricle), whole blood, and subcutaneous 
adipose146. All GTex results had associations with P<8.4x10-7. 
2: eQTL lookup in the Advanced Study of Aortic Pathology (Online Table XX and Online Figure III) 
eQTL data were obtained from the Advanced Study of Aortic Pathology (ASAP) dataset which has 
previously been described181. Tissue samples were selected from individuals undergoing aortic valve 
surgery. Five tissue types were collected from each patient: mammary artery, liver, aorta intima-
media, aorta adventitia, and heart. RNA was extracted from tissues and hybridised to Affymetrix ST 
1.0 exon arrays (Santa Clara, CA, USA) and data were robust multiarray average normalised before 
log2 transformation. DNA extracted from whole blood was genotyped on the Illumina 610w-Quad 
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bead array (San Diego, CA, USA) platform. SNPs with >95% call rate were used for imputation, and 
imputed SNPs with quality scores of MACH <0.3 were excluded from analysis. An additive model for 
associations between SNPs and gene expression was assumed. Genotypes for 5 of the 10 lead SNPs 
at AAA risk loci were directly genotyped on Illumina 610wQuad arrays.  
 
3: RNA-seq (Online Table XXI) 
RNA-seq data were obtained from the Stockholm-Tartu Atherosclerosis Reverse Network 
Engineering Task (STARNET) database182 (http://www.mountsinai.org/profiles/johan-bjorkegren). 
These consist of RNA-seq data from 9 cardiovascular tissues from up to 600 CAD patients obtained 
during coronary artery by-pass grafting surgery. Gene expression was measured with a standard 
RNA-seq protocol, followed by normalization of raw read counts to adjust for library size and batch 
effects. Adjusted read counts were subsequently log2-transformed, and the association between 
genotype and expression was tested using a linear model. Permutation was used to assess the 
statistical significance. Significant results for the lead SNPs at each AAA risk locus are shown in 
Online Table XX. 
 
4: Peripheral blood monocyte eQTL analysis (Online Table XXII) 
Data from an eQTL analysis of peripheral blood monocytes was obtained from the Cardiogenics 
Consortium 183, 184. The description of the cohort sample collection and processing and the eQTL 
analysis have previously been described in detail. Briefly, genome-wide expression and genotype 
data were obtained from peripheral blood monocytes from 363 patients with CAD or myocardial 
infarction and 395 healthy individuals. Expression profiling was performed using the Illumina 
HumanRef-8 v3 beadchip array (Illumina Inc., San Diego, CA) containing 24,516 probes 
corresponding to 18,311 distinct genes and 21,793 Ref Seq annotated transcripts. Genome-wide 
genotyping was carried out using two Illumina arrays, the Sentrix Human Custom 1.2M array and the 
Human 610 Quad Custom array. SNP analysis was restricted to autosomal SNPs with MAF >0.01, call 
rate >0.95 and HWE testing P>1x10−5. After quality control, 522,603 SNPs were used for association 
analyses with expression. All replicated AAA associated SNPs were tested for association with 
regional gene expression. Significant results are shown in Online Table XXII.
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Online Table XIX: eQTL data (1). This table spans 2 pages. 
 
Locus Lead AAA SNP Gene Tissue Transcript Proxy SNP looked up in eQTL database Peak regional SNP in eQTL database 
     Proxy SNP r2 to AAA SNP eQTL P-Value for lead AAA SNP or proxy Peak SNP r2 (Peak SNP to AAA SNP) eQTL P-Value for peak SNP 
1q21.3 rs4129267 IL6R Average in 10 brain regions [PMID 
25174004] 
INTS3 rs4576655 1 5.59x10-06 rs12068901 NA 3.32x10-42 
   Average in 10 brain regions [PMID 
25174004] 
SLC39A1 rs4845372 0.965 4.75x10-06 rs4845372 0.965 4.75x10-06 
   Average in 10 brain regions [PMID 
25174004] 
PYGO2 rs6684439 0.839 2.96x10-06 rs6684439 0.839 2.96x10-06 
   CD14+ monocytes (untreated) [PMID 
24604202] 
IL6R   6.64x10-04 rs7518199 0.965 5.27x10-04 
   Intestine (normal ileum) [PMID 23474282] IL6R   8.81x10-06 rs7553796 0.49 8.20x10-11 
   Lymph [PMID 17873875] IL6R rs4537545 1 2.63x10-03 rs4845623 0.965 1.88x10-03 
   Prefrontal cortex (all samples) [PMID 
23622250] 
MUC1 rs8192284 0.982 6.33x10-05 rs8192284 0.982 6.33x10-05 
   Whole blood (Battle) [PMID 24092820] IL6R rs4537545 1 2.62x10-20 rs4537545 1 2.62x10-20 
   Whole blood (CHARGE) [PMID 24013639] IL6R   3.15x10-27 rs4537545 1 2.02x10-29 
   Whole blood (CHARGE) [PMID 24013639] UBE2Q1   9.75x10-08 rs6660775 0.058 3.93x10-21 
1p13.3 rs602633 CELSR2/SORT1 CD14+ monocytes (24h LPS stimulated) 
[PMID 24604202] 
PSRC1 rs599839 1 9.50x10-05 rs646776 0.895 3.53x10-05 
   CD14+ monocytes (IFNg stimulated) [PMID 
24604202] 
PSRC1 rs599839 1 4.25x10-13 rs646776 0.895 7.40x10-14 
   CD14+ monocytes (untreated) [PMID 
24604202] 
PSRC1 rs599839 1 7.31x10-44 rs599839 1 7.31x10-44 
   Cerebellum (all samples) [PMID 23622250] PSRC1   9.12x10-06 rs602633 Same SNP 9.12x10-06 
   Cerebellum (Huntington's) [PMID 
23622250] 
PSRC1 rs646776 0.895 5.19x10-05 rs646776 0.895 5.19x10-05 
   Liver (ScanDB) SORT1 rs646776 0.895 3.18x10-43 rs646776 0.895 3.18x10-43 
   Liver (ScanDB) PSRC1 rs646776 0.895 2.92x10-37 rs646776 0.895 2.92x10-37 
   Liver (ScanDB) CELSR2 rs646776 0.895 4.48x10-24 rs646776 0.895 4.48x10-24 
   Liver(Greenawalt) [PMID 21602305] SORT1 rs646776 0.895 5.20x10-88 rs646776 0.895 5.20x10-88 
   Liver(Greenawalt) [PMID 21602305] PSRC1 rs646776 0.895 3.05x10-86 rs646776 0.895 3.05x10-86 
   Liver(Greenawalt) [PMID 21602305] CELSR2 rs646776 0.895 6.27x10-68 rs646776 0.895 6.27x10-68 
   Liver(Schroder) [PMID 22006096] SORT1 rs646776 0.895 2.14x10-27 rs646776 0.895 2.14x10-27 
   Liver(Schroder) [PMID 22006096] CELSR2 rs646776 0.895 3.66x10-22 rs646776 0.895 3.66x10-22 
   Liver(Schroder) [PMID 22006096] PSRC1 rs646776 0.895 8.72x10-17 rs646776 0.895 8.72x10-17 
   Liver(UChicago) [PMID 21637794] CELSR2 rs12740374 0.895 <1x10-16 rs12740374 0.895 <1e-16 
   Liver(UChicago) [PMID 21637794] SORT1 rs12740374 0.895 <1x10-16 rs12740374 0.895 <1e-16 
   Liver(UWash) [PMID 21637794] SORT1 rs12740374 0.895 2.86x10-22 rs12740374 0.895 2.86x10-22 
   Liver(UWash) [PMID 21637794] CELSR2 rs12740374 0.895 5.31x10-11 rs12740374 0.895 5.31x10-11 
   Lymph [PMID 17873875] PSRC1 rs646776 0.895 2.10x10-08 rs646776 0.895 2.10x10-08 
   Monocytes (CD14+) [PMID 22446964] PSRC1 rs599839 1 6.65x10-18 rs599839 1 6.65x10-18 
   Monocytes [PMID 20502693] PSRC1 rs599839 1 5.30x10-55 rs629301 0.895 2.34x10-56 
   Muscle_Skeletal [PMID 23715323] CELSR2 rs12740374 0.895 1.40x10-08 rs12740374 0.895 1.40x10-08 
   Prefrontal cortex (all samples) [PMID 
23622250] 
CELSR2 rs646776 0.895 4.10x10-10 rs646776 0.895 4.10x10-10 
   Prefrontal cortex (all samples) [PMID 
23622250] 
PSRC1 rs646776 0.895 1.67x10-09 rs646776 0.895 1.67x10-09 
   Prefrontal cortex (Alzheimer's) [PMID 
23622250] 
PSRC1 rs646776 0.895 7.93x10-08 rs646776 0.895 7.93x10-08 
   Prefrontal cortex (Alzheimer's) [PMID 
23622250] 
CELSR2 rs646776 0.895 3.24x10-05 rs646776 0.895 3.24x10-05 
   Prefrontal cortex (Huntington's) [PMID 
23622250] 
CELSR2   1.52x10-06 rs602633 Same SNP 1.52x10-06 
   PrefrontalCortex [PMID 20351726] PSRC1 rs599839 1 2.62x10-06 rs599839 1 2.62x10-06 
   SchadtLiver [PMID 18462017] SORT1 rs599839 1 1.52x10-56 rs599839 1 1.52x10-56 
   SchadtLiver [PMID 18462017] CELSR2 rs646776 0.895 3.09x10-24 rs646776 0.895 3.09x10-24 
   SubCutAdipose(Greenawalt) [PMID 
21602305] 
CELSR2   2.93x10-08 rs602633 Same SNP 2.93x10-08 
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   Visual cortex (all samples) [PMID 
23622250] 
PSRC1 rs646776 0.895 7.66x10-11 rs646776 0.895 7.66x10-11 
   Visual cortex (Alzheimer's) [PMID 
23622250] 
PSRC1 rs646776 0.895 1.44x10-09 rs646776 0.895 1.44x10-09 
   Whole blood (Battle) [PMID 24092820] PSRC1 rs599839 1 4.93x10-87 rs599839 1 4.93x10-87 
   Whole blood (Schramm et al.) [PMID 
24740359] 
PSRC1 rs599839 1 1.23x10-24 rs599839 1 1.23x10-24 
   Whole blood (Wright, n=4,647) [PMID 
24728292] 
CELSR2 rs629301 0.895 6.73x10-18 rs629301 0.895 6.73x10-18 
9p21 rs10757274 ANRIL SubCutAdipose(Greenawalt) [PMID 
21602305] 
CDKN2B rs1537370 0.901 1.48x10-04 rs1537370 Same SNP 1.48x10-04 
   Omental adipose [PMID 21602305] CDKN2B rs2383207 0.846 3.10x10-07 rs2383207 Same SNP 3.10x10-07 
9q33.2 rs10985349 DAB2IP CD14+ monocytes (2h LPS stimulated) 
[PMID 24604202] 
GGTA1   6.64x10-04 rs10985349 Same SNP 6.64x10-04 
20q13.12 rs3827066 Near 
PCIF1/MMP9/ZNF335 
Bcells (CD19+) [PMID 22446964] PLTP   2.98x10-09 rs394643 0.229 9.89x10-40 
   CD14+ monocytes (24h LPS stimulated) 
[PMID 24604202] 
PLTP   2.46x10-11 rs3827066 Same SNP 2.46x10-11 
   CD14+ monocytes (24h LPS stimulated) 
[PMID 24604202] 
DNTTIP1   8.41x10-09 rs2664529 0.108 1.02x10-63 
   CD14+ monocytes (2h LPS stimulated) [PMID 
24604202] 
PLTP   3.89x10-11 rs3843763 0.506 2.46x10-13 
   CD14+ monocytes (2h LPS stimulated) [PMID 
24604202] 
DNTTIP1   9.56x10-10 rs2664529 0.108 1.60x10-63 
   CD14+ monocytes (IFNg stimulated) [PMID 
24604202] 
PLTP   2.20x10-43 rs3827066 Same SNP 2.20x10-43 
   CD14+ monocytes (IFNg stimulated) [PMID 
24604202] 
DNTTIP1   2.68x10-10 rs6032531 0.148 8.85x10-76 
   CD14+ monocytes (IFNg stimulated) [PMID 
24604202] 
PLTP   8.25x10-07 rs3827066 Same SNP 2.20x10-43 
   CD14+ monocytes (untreated) [PMID 
24604202] 
DNTTIP1   3.69x10-09 rs6032531 0.148 1.11x10-49 
   CD14+ monocytes (untreated) [PMID 
24604202] 
CD40   4.03x10-04 rs745307 0.086 4.24x10-88 
   LCL (MuTHER) [PMID 22941192] PLTP   1.20x10-06 rs441346 0.214 1.64x10-37 
   Liver(UChicago) [PMID 21637794] NEURL2   2.29x10-06 rs3827066 Same SNP 2.29x10-06 
   Liver(UChicago) [PMID 21637794] C20orf165 rs7270354 1 1.22x10-03 rs7270354 1 1.22x10-03 
   Liver(UWash) [PMID 21637794] NEURL2   1.02x10-03 rs3827066 Same SNP 1.02x10-03 
   Peripheral artery plaque [PMID 24973796] NEURL2 rs7270354 1 2.51x10-08 rs7270354 1 2.51x10-08 
   Skin (MuTHER) [PMID 22941192] WFDC3   2.60x10-12 rs2664529 0.108 5.47x10-74 
   Subc adipose (MuTHER) [PMID 22941192] PLTP   6.67x10-11 rs6104410 0.486 2.62x10-11 
   Subc adipose (MuTHER) [PMID 22941192] NEURL2   9.51x10-09 rs3827066 Same SNP 9.51x10-09 
   Subc adipose (MuTHER) [PMID 22941192] WFDC3   1.26x10-05 rs6032544 0.11 5.99x10-36 
   Whole blood (CHARGE) [PMID 24013639] TNNC2   3.98x10-19 rs6104350 0.11 3.33x10-63 
   Whole blood (CHARGE) [PMID 24013639] DNTTIP1   2.52x10-14 rs6104350 0.11 7.89x10-71 
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Online Table XX: eQTL from the Advanced Study of Aortic Pathology181. 
 
Chr SNP Position Imputed (quality score) Genes Aortic Adventitia Aortic Media Heart Liver LIMA
     (Effect, P, Quartile) (Effect, P, Quartile) (Effect, P, Quartile) (Effect, P, Quartile) (Effect, P, Quartile) 
1 rs1795061 214409280 Yes (0.7908) PROX1 0.0264, 0.764, 2 -0.008, 0.82, 1 -0.0534, 0.449, 4 0.0132, 0.801, 4 0.0565, 0.234, 1
    SMYD2 0.0597, 0.237, 2 -0.0871, 0.0694, 2 0.0254, 0.643, 4 -0.0408, 0.285, 3 -0.0632, 0.302, 2 
    PTPN14 -0.071, 0.116, 4 -0.0158, 0.736, 4 0.024, 0.663, 3 0.0299, 0.251, 2 0.00447, 0.933, 4 
1 rs4129267 154426264  UBAP2L 0.00819, 0.814, 4 -0.000356, 0.993, 4 0.0361, 0.579, 4 0.0467, 0.106, 4 0.046, 0.3, 4 
    HAX1 0.115, 0.0484, 3 -0.0725, 0.223, 4 0.0377, 0.547, 4 0.0398, 0.291, 4 -0.0667, 0.253, 4
    RNU6-239P nd nd nd nd nd
    RNU6-121P nd nd nd nd nd 
    AQP10 -0.00947, 0.769, 1 -0.0213, 0.494, 1 -0.00645, 0.832, 2 -0.00193, 0.931, 1 0.0217, 0.579, 1 
    ATP8B2 0.0769, 0.161, 4 0.0443, 0.32, 4 -0.0216, 0.588, 3 0.0223, 0.446, 3 0.08, 0.161, 4
    IL6R -0.0261, 0.55, 2 -0.0277, 0.45, 2 -0.028, 0.294, 2 0.0292, 0.49, 4 -0.0128, 0.698, 2
    PSMD8P1 nd nd nd nd nd
    SHE nd nd nd nd nd 
    TDRD10 -0.0646, 0.146, 2 -0.0249, 0.465, 2 -0.0246, 0.49, 2 -0.00838, 0.779, 2 0.0332, 0.429, 2 
    UBE2Q1 0.0798, 0.0377, 4 -0.0194, 0.636, 4 -0.0343, 0.483, 4 0.0769, 0.0323, 4 0.0562, 0.198, 4 
    UBE2Q1-AS1 nd nd nd nd nd
    CHRNB2 0.0103, 0.758, 2 0.0322, 0.367, 2 -0.0525, 0.17, 2 0.00361, 0.898, 2 0.00785, 0.856, 2 
    ADAR 0.0195, 0.674, 4 0.000942, 0.986, 4 0.0382, 0.559, 4 0.055, 0.107, 4 0.0846, 0.146, 4 
1 rs602633 109821511 Yes (0.51863) TMEM167B nd nd nd nd nd
    SCARNA2 nd nd nd nd nd
    C1orf194 nd nd nd nd nd 
    KIAA1324 0.0254, 0.3, 1 0.00596, 0.762, 1 0.0279, 0.189, 1 -0.0172, 0.26, 1 -0.00434, 0.868, 1 
    SARS -0.0594, 0.2, 4 -0.0245, 0.546, 4 -0.0825, 0.2, 4 0.0736, 0.0725, 4 0.0937, 0.087, 4
    CELSR2 0.00668, 0.806, 3 -0.0101, 0.643, 3 0.0198, 0.46, 3 0.0522, 0.0139, 3 -0.0384, 0.208, 3
    PSRC1 0.00324, 0.91, 2 -0.0272, 0.36, 2 0.0288, 0.343, 2 0.281,  9.67x10-13, 2 0.0057, 0.877, 2
    MYBPHL nd nd nd Nd nd 
    SORT1 -0.145, 0.135, 4 -0.0409, 0.532, 4 -0.203, 0.009, 4 1.25, 2.35x10-24, 3 0.0304, 0.648, 4 
    PSMA5 -0.137, 0.0753, 3 -0.0474, 0.489, 3 -0.145, 0.0884, 4 0.102, 0.0705, 4 0.131, 0.191, 3
    SYPL2 -0.0904, 0.0412, 1 -0.0385, 0.461, 2 -0.211, 0.0312, 2 0.0977, 0.0336, 2 -0.0657, 0.28, 2
9 rs10757274 22096055 Yes (0.78299) MTAP 0.0276, 0.416, 3 0.0231, 0.403, 3 0.0554, 0.142, 3 -0.0111, 0.668, 3 0.0137, 0.702, 3 
    ERVFRD-3 nd nd nd nd nd 
    CDKN2A-AS1 nd nd nd nd nd
    CDKN2A 0.0379, 0.215, 2 0.0337, 0.296, 2 -0.0227, 0.449, 2 -0.00872, 0.68, 2 0.022, 0.515, 2
    ANRIL nd nd nd nd nd 
    CDKN2B 0.0101, 0.728, 3 -0.0237, 0.405, 3 0.000812, 0.979, 3 0.0047, 0.82, 3 0.0369, 0.325, 3 
    UBA52P6 nd nd nd nd nd
9 rs10985349 124425243 Yes (0.58069) GGTA1P nd nd nd nd nd
    RN7SL187P nd nd nd nd nd 
    HMGB1P37 nd nd nd nd nd 
    DAB2IP 0.0586, 0.13, 3 0.0653, 0.11, 3 -0.0288, 0.571, 3 -0.0159, 0.547, 3 -0.0644, 0.0833, 3
    TTLL11 0.0213, 0.64, 3 0.0515, 0.163, 3 -0.0772, 0.0168, 3 0.0161, 0.445, 3 -0.0992, 0.00289, 4
13 rs9316871 22861921  LINC00540 nd nd nd nd nd 
    NME1P1 nd nd nd nd nd 
    MTND3P1 nd nd nd nd nd
19 rs6511720 11202306  CARM1 0.00983, 0.861, 3 -0.0297, 0.577, 3 -0.00125, 0.987, 3 -0.0163, 0.662, 3 0.0162, 0.744, 3
    YIPF2 0.00883, 0.881, 3 -0.00788, 0.863, 3 -0.0105, 0.871, 3 -0.0461, 0.237, 3 0.0308, 0.624, 3 
    C19orf52 -0.0462, 0.458, 3 0.0269, 0.58, 3 -0.023, 0.717, 3 -0.0214, 0.559, 3 -0.0201, 0.772, 3 
    SMARCA4 0.0288, 0.569, 3 -0.105, 0.0407, 3 -0.018, 0.787, 3 -0.0268, 0.393, 3 -0.0647, 0.323, 3
    LDLR 0.164, 0.118, 3 0.19, 0.112, 3 -0.0297, 0.634, 3 0.0024, 0.982, 4 0.221, 0.177, 3
    MIR6886 nd nd nd nd nd 
    SPC24 -0.0229, 0.651, 1 0.0159, 0.721, 2 0.0378, 0.507, 2 -0.0246, 0.459, 1 0.0153, 0.781, 2 
    KANK2 -0.0233, 0.851, 4 -0.00958, 0.911, 4 0.0425, 0.71, 4 -0.0695, 0.141, 3 -0.0716, 0.395, 4
    DOCK6 -0.018, 0.749, 3 -0.0289, 0.469, 3 -0.0386, 0.526, 3 -0.0229, 0.523, 3 -0.0288, 0.513, 3
    C19orf80 nd nd nd nd nd
20 rs3827066 44586023 Yes (0.6275) WFDC3 0.0626, 0.15, 2 0.0772, 0.0433, 2 -0.00286, 0.961, 2 -0.0196, 0.542, 2 0.0407, 0.375, 2 
    RNU6ATAC38P nd nd nd nd nd
    DNTTIP1 -0.0666, 0.132, 3 -0.0711, 0.0606, 3 -0.0573, 0.316, 3 -0.0781, 0.00627, 3 -0.0715, 0.0459, 3 
    UBE2C 0.0147, 0.729, 2 0.0206, 0.616, 2 -0.0565, 0.219, 2 0.0164, 0.538, 2 0.0859, 0.025, 2
    TNNC2 -0.0322, 0.621, 2 0.059, 0.304, 2 0.0675, 0.431, 2 0.007, 0.872, 2 0.121, 0.082, 2 
    SNX21 -0.0545, 0.228, 3 0.00543, 0.875, 3 -0.0359, 0.544, 3 -0.00772, 0.773, 3 0.0266, 0.539, 3 
    ACOT8 -0.00969, 0.816, 3 0.0458, 0.17, 3 -0.1, 0.277, 3 0.0303, 0.313, 3 -0.024, 0.53, 3
    ZSWIM3 0.0582, 0.209, 1 0.0493, 0.187, 1 -0.0382, 0.563, 1 0.0258, 0.402, 1 -0.00447, 0.922, 1
    ZSWIM1 -0.0458, 0.427, 2 -0.0743, 0.123, 2 -0.0861, 0.374, 2 -0.0159, 0.655, 2 0.0164, 0.78, 2 
    SPATA25 nd nd nd nd nd 
    NEURL2 nd nd nd nd nd
    CTSA 0.0231, 0.616, 4 -0.0716, 0.321, 4 0.0481, 0.487, 4 0.105, 0.0111, 4 -0.141, 0.101, 4
    PLTP 0.513, 0.0118, 4 -0.00838, 0.958, 4 0.0306, 0.832, 4 0.0375, 0.587, 4 -0.0865, 0.561, 3
    PCIF1 -0.0435, 0.361, 3 -0.0633, 0.0975, 3 -0.000238, 0.998, 3 -0.0277, 0.278, 3 -0.042, 0.389, 3 
    ZNF335 -0.0467, 0.107, 3 0.0401, 0.123, 3 0.0213, 0.631, 3 0.0105, 0.608, 3 -0.0174, 0.579, 3 
    FTLP1 nd nd nd nd nd
    MMP9 0.107, 0.333, 2 0.168, 0.0796, 2 0.0236, 0.623, 2 0.0107, 0.79, 2 0.0262, 0.566, 2
    SLC12A5 -0.0409, 0.175, 2 -0.00016, 0.995, 2 0.0189, 0.654, 2 -0.00367, 0.866, 1 -0.0206, 0.544, 2 
    NCOA5 -0.00203, 0.962, 3 -0.0311, 0.449, 4 -0.0941, 0.29, 3 -0.0339, 0.424, 3 -0.0258, 0.597, 4 
    RPL13P2 nd nd nd nd nd
    CD40 -0.0309, 0.531, 2 -0.0095, 0.813, 2 -0.0416, 0.391, 2 0.0104, 0.681, 2 0.0118, 0.755, 2
21 rs2836411 39819830  KCNJ15 -0.00282, 0.958, 2 -0.0161, 0.634, 1 -0.00692, 0.809, 1 -0.0181, 0.635, 2 -0.0407, 0.236, 1 
    LINC01423 nd nd nd nd nd 
    ERG -0.0351, 0.636, 4 -0.0324, 0.573, 4 0.0247, 0.648, 3 0.0276, 0.309, 3 -0.106, 0.0762, 4
    SNRPGP13 nd nd nd nd nd
65 
 
Online Figure III: Significant eQTL plots for data from ASAP study. Each column of plots 
represents data for the SNP and tissue stated at the bottom of each column. The gene for which 







Online Table XXI: eQTL results based on RNA seq data 
 
Chr Position SNP Locus Gene(s) Tissue gene for RNA-Seq index SNP index SNP beta index SNP P Lead SNP in 
region
Lead SNP beta Lead SNP P index SNP effect 
independent
1 109821511 rs602633 1p13.3 CELSR2/SORT1 Blood PSRC1 rs602633 0.640465606 4.49x10-17 rs629301 0.61412198 1.03x10-15 Yes
     LIV PSRC1 rs602633 -1.292449889 9.43x10-108 rs7528419 1.26797503 4.33x10-103 Yes
     LIV SARS rs602633 0.495537791 2.37x10-12 rs1277930 0.49333558 2.97x10-12 Yes
     LIV SORT1 rs602633 -1.365654087 2.98x10-130 rs7528419 1.33525433 1.79x10-122 Yes
     LIV CELSR2 rs602633 1.298741331 1.79x10-109 rs629301 1.27447629 8.75x10-105 Yes
1 154426264 rs4129267 1q21.3 IL6R MAM IL6R rs4129267 0.652344491 1.97x10-26 rs7518199 0.63498045 3.78x10-24 Yes
13 22861921 rs9316871 13q12.11 LINC00540 MAM FGF9 rs9316871 -0.699526462 1.76x10-23 rs9506822 -0.7027035 2.44x10-23 Yes
20 44586023 rs3827066 20q13.12 Near 
PCIF1/MMP9/ZNF335
AOR PLTP rs3827066 -0.756619944 1.65x10-21 rs7267295 -0.7193854 5.40x10-18 Yes 
     SF PLTP rs3827066 -0.905646216 4.93x10-29 rs7270354 -0.8474133 2.10x10-26 Yes
     SKLM PLTP rs3827066 -0.484882963 2.76x10-09 rs7267295 -0.4860579 1.40x10-08 Yes
     VAF PLTP rs3827066 -0.610415837 1.39x10-12 rs8124182 -0.5513566 1.48x10-10 Yes
21 39819830 rs2836411 21q22.2 ERG MAM ERG rs386574671 0.271607451 1.88x10-05 rs386574671 0.27160745 1.88x10-05 Yes
 
Online Table XXII: Peripheral blood monocyte eQTLs 
 
Chr Position SNP Locus Gene(s) Probe_ID ILMN_Gene beta beta_se P FDR Cell type 
1 109821511 rs602633 1p13.3 CELSR2/SORT1 ILMN_1671843 PSRC1 -0.2202 0.0195 7.91x10-27 1.08x10-23 Macrophage 
     ILMN_2315964 PSRC1 -0.0763 0.0168 6.32x10-06 8.65x10-04 Macrophage 
     ILMN_1671843 PSRC1 -0.1512 0.0121 1.96x10-32 2.33x10-29 Monocyte 
     ILMN_2315964 PSRC1 -0.1261 0.0158 4.72x10-15 1.83x10-12 Monocyte 
     ILMN_1711208 CELSR2 -0.0696 0.0139 7.41x10-07 1.23x10-04 Macrophage 
     ILMN_1707077 SORT1 -0.0752 0.0183 4.38x10-05 4.95x10-03 Macrophage 
     ILMN_1671843 PSRC1 -0.2202 0.0195 7.91x10-27 1.08x10-23 Macrophage 
     ILMN_1711208 CELSR2 -0.0696 0.0139 7.41x10-07 1.23x10-04 Macrophage 
     ILMN_2315964 PSRC1 -0.0763 0.0168 6.32x10-06 8.65x10-04 Macrophage 
     ILMN_1707077 SORT1 -0.0752 0.0183 4.38x10-05 4.95x10-03 Macrophage 
     ILMN_1671843 PSRC1 -0.1512 0.0121 1.96x10-32 2.33x10-29 Monocyte 
     ILMN_2315964 PSRC1 -0.1261 0.0158 4.72x10-15 1.83x10-12 Monocyte 
20 44586023 rs3827066 20q13.12 Near 
PCIF1/MMP9/ZNF335
ILMN_1777113 NEURL2 -0.1058 0.0255 3.86x10-05 3.11x10-03 Macrophage 
     ILMN_1773389 PLTP -0.3127 0.0796 9.57x10-05 6.86x10-03 Macrophage 
     ILMN_1711748 PLTP -0.2266 0.0587 1.27x10-04 8.82x10-03 Macrophage 
     ILMN_2367818 CD40 0.0828 0.0245 7.75x10-04 4.08x10-02 Macrophage 
     ILMN_1691117 DNTTIP1 0.0741 0.0109 1.95x10-11 3.13x10-09 Monocyte 
     ILMN_2367818 CD40 0.0752 0.0176 2.20x10-05 1.45x10-03 Monocyte 
     ILMN_1779257 CD40 0.1136 0.0317 3.63x10-04 1.74x10-02 Monocyte 
21 39819830 rs2836411 21q22.2 ERG ILMN_1757074 GNG10 -0.0626 0.0138 6.84x10-06 5.28x10-01 Monocyte 
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VALIDATION OF GWAS3D RESULTS USING mRNA EXPRESSION DATA FOR AAA AND CONTROL AORTA 
 
To determine the potential utility of the GWAS3D chromatin state analysis to identify trans interactions, 
a validation analysis was performed comparing mRNA expression of putative genes in abdominal aortic 
tissue.  Relative mRNA expression profiles of candidate genes, indicated by either SNP proximity (cis-
acting regulatory variant) or GWAS3D predicted distal interaction, was derived using the Biros et al 2015 
(GSE57691) dataset (Online Table XXIII). The composition and analysis of this dataset has been 
previously described107. All genes at AAA loci (Table 1) were included in this analysis. Case (49 AAA, 
including 29 large and 20 small) and control (10 organ donor) abdominal aortic samples were compared 
using data generated from the Illumina HumanHT-12 V4.0 expression beadchip (GPL10558).  
Several of the GWAS3D predicted distal gene interactions appeared to have differential case/ control 
gene expression (Online Table XXIII and Online Figure IV).  For example, not only was the mRNA 
expression of SORT1 (which is within the locus suggested by rs602633) significantly different between 
cases and controls, but predicted distal interactions in BCAR3 and NOTCH2 also had altered expression.  
The predicted distal interaction between rs4129267 (IL6R locus) and TDRD10 also appeared concordant 
with an observed differential gene expression profile.  The intergenic SNP rs9316871 (closest gene 
LINC0540) had a predicted interaction with FGF9 which also had increased expression in AAA versus 
control aortic tissue. 
It should be noted that absence of differential gene expression in this analysis does not specifically 
preclude a role in AAA pathogenesis.  Many genes will have temporal expression and may, for example, 
only be differentially expressed in specific phases of the pathology.  In addition, other genes may have 
significantly altered expression in other tissues (such as the liver, kidney or circulating leukocytes) the 
results of which may have indirect effects on the aortic wall.  Nevertheless, these results appear to, at 
least in part, validate the potential utility of chromatin state-based analysis to identify functional 




Online Table XXIII:  AAA tissue mRNA expression for genes in close proximity to validated SNPs or having 
predicted distal gene interactions based on GWAS3D analysis. 
 
  






metaGWAS SNP proximity  ANRIL 9p21.3 1030 0.0025  increased 
GWAS3D predicted distal interaction (SORT1) BCAR3 1p22.1 8412 1.8x10-4 decreased 
metaGWAS SNP proximity  CDKN2A 9p21.3 1029 0.217   
metaGWAS SNP proximity  CDKN2BAS1 9p21.3 100048912 0.266   
metaGWAS SNP proximity CELSR2 1p13.3 1952 0.479   
metaGWAS SNP proximity  CHRNB2 1q21.3 1141 0.829   
metaGWAS SNP proximity CTSA 20q13.12 5476 0.174   
metaGWAS SNP proximity  DAB2IP 9q33.1 153090 0.213   
metaGWAS SNP proximity  ERG 21q21.3 2078 0.095   
GWAS3D predicted distal interaction (LINC00540) FGF9 13q11 2254 0.002 increased 
metaGWAS SNP proximity IL6R 1q21 3570 0.087   
metaGWAS SNP proximity KANK2 19p13.2 25959 0.132   
metaGWAS SNP proximity LDLR 19p13.2 3949 0.197   
metaGWAS SNP proximity  LRP1 12q13.3 4035 0.0084 decreased 
metaGWAS SNP proximity MMP9 20q13.12 4318 0.132   
metaGWAS SNP proximity MYBPHL 1p13.3 343263 0.897   
metaGWAS SNP proximity  NAB2 12q13.3 4665 1.1x10-5 decreased 
metaGWAS SNP proximity NEURL2 20q13.12 140825 0.576   
GWAS3D predicted distal interaction (LDLR) NEUROG1 5q23 4762 0.138   
GWAS3D predicted distal interaction (SORT1) NOTCH2 1p12 4853 4.6x10-7 increased  
metaGWAS SNP proximity PCIF1 20q13.12 63935 0.968   
metaGWAS SNP proximity PLTP 20q13.12 5360 0.011 increased 
metaGWAS SNP proximity PSRC1 1p13.3 84722 0.440   
metaGWAS SNP proximity SARS 1p13.3 6301 0.095   
GWAS3D predicted distal interaction (LDLR) SHANK1 19p13.3 50944 0.567   
metaGWAS SNP proximity SHE 1q21.3 126669 0.396   
metaGWAS SNP proximity SLC12A5 20q13.12 57468 0.329   
metaGWAS SNP proximity SMYD2 1q41 56950 0.317   
metaGWAS SNP proximity SORT1 1p13.3 6272 1.1x10-4 decreased 
metaGWAS SNP proximity SPC24 19p13.2 147841 0.211   
metaGWAS SNP proximity  STAT6 12q13.3 6778 0.423   
GWAS3D predicted distal interaction (IL6R) TDRD10 1q21.3 126668 0.006 increased 
GWAS3D predicted distal interaction (IL6R) TYW1 7q11.21 55253 0.320   
metaGWAS SNP proximity  UBE2Q1 1q21.3 55585 0.157   
GWAS3D predicted distal interaction (CDKN2B-AS1) UBE2W 8q21.11 55284 0.0292 increased 
metaGWAS SNP proximity ZNF335 20q13.12 63925 0.205   
GWAS3D predicted distal interaction (LDLR) ZNF440 19p13.2 126070 0.406   
metaGWAS SNP proximity ZSWIM3 20q13.12 140831 0.235   
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Online Figure IV:  Box and whiskers plots of gene expression in AAA tissue and control tissue for genes in close proximity to validated SNPs or 
having predicted distal gene interactions based on GWAS3D analysis. Significant differences between AAA and controls are highlighted. Gene 






LOOK-UP FOR TRANSCRIPTION FACTOR BINDING SITES IN GENES HARBORING AAA-ASSOCIATED 
VARIANTS 
 
We previously performed a chromatin-immunoprecipation (ChIP) study using AAA and control aorta 
tissue for the TFs ELF1, ETS2, RUNX1 and STAT5185. These TFs were chosen because they were enriched 
in genes differentially expressed between AAA and control aorta; ELF1, ETS2, and RUNX1 were identified 
as relevant to most upregulated genes186 and STAT5 was a driver for genes in the complement 
cascade187.  
The TF binding data were obtained from tables published in a paper by Pahl et al.185, which describes 
ChIP-chip for TFs ELF1, ETS2, RUNX1 and STAT5 using human aortic tissue (AAA and control aorta). We 
performed a lookup in these data for evidence supporting that the genes near the SNPs identified by the 
meta-GWAS are relevant to AAA pathobiology. Lack of evidence in these data does not preclude 
involvement in AAA, but presence of evidence is a useful indicator that the gene is likely involved. This is 
especially useful for genes with little or no annotation in the major databases such as SMYD2 and ERG. 
The results are summarized in Online Table XXIV. Chromatin enriched regions (cher) with binding sites 
for the TF ETS2 were found in SMYD2 and SORT1. TF STAT5 had binding sites with chers in CDKN2B-
AS1ANRIL, ERG and DAB2IP, and TF ELF1 had multiple binding sites in ERG. None of the TF binding sites 




Online Table XXIV: ChIP-chip data on human aortic tissue for the genes harbouring AAA-associated 
SNPs. Genome-wide ChIP-chip data were available on 4 transcription factors: ETS2, ELF1, STAT5 and 
RUNX1. For details, see Pahl et al. 2015185. AAA, aortic tissue from abdominal aortic aneurysm; cher, 
chromatin enriched region; CTL, control abdominal aorta; TFBS, transcription factor binding site as 
defined by Transfac®. 
 
SNP Chr Position Gene(s) Gene Symbol Cher for TF (tissue source) TFBS in cher
rs602633 1 109821511 PSRC1-CELSR2-SORT1 CELSR2 None  
    SORT1 ETS2 (CTL) ETS2 (1 site)
    PSRC None  
rs4129267 1 154426264 IL6R IL6R None  
rs1795061 1 214409280 SMYD2 SMYD2 ETS2 (AAA) ETS2 (4 sites)
rs10757274 9 22096055 ANRIL ANRIL STAT5 (CTL) STAT5 (1 site)
rs10985349 9 124425243 DAB2IP DAB2IP STAT5 (CTL) STAT5 (1 site)
rs9316871 13 22861921 LINC00540 LINC00540 None  
rs6511720 19 11202306 LDLR LDLR None  
rs3827066 20 44586023 PCIF1-ZNF335-MMP9 PCIF1 None  
    MMP9 None  
    ZNF335 None  
rs2836411 21 39819830 ERG ERG STAT5 (AAA) STAT5 (1 site)
    ELF1 (AAA) ELF1 (4 sites)








We investigated whether most of the loci could be connected into a single network through 
intermediate nodes and interactions. A network integrating most of the loci would suggest mechanisms 
by which the loci could act in concert, whether synergistically or antagonistically, to affect the 
phenotype. The network(s) would also provide hypotheses for future investigation. Potential 
interactions between molecules encoded by genes harboring AAA-associated SNPs were analyzed using 
two independent analysis tools: Ingenuity Pathway Analysis® (IPA) tool version 9.0 (Qiagen’s Ingenuity 
Systems, Redwood City, CA, USA; www.ingenuity.com) and ConsensusPathDB 
(http://cpdb.molgen.mpg.de/CPDB)188-191. The analyzed gene set had 14 genes: 2 loci identified by the 9 
AAA-associated SNPs included clusters of 3 genes (see Online Table XIV for SNP annotations), we also 
included TNF since recent literature indicated that SMYD2 suppresses IL6 and TNF production192, 193 and 
this had been published since the latest database update for each pathway analysis tool used. The gene 
symbols included in the network analyses were: CDKN2BAS1, CELSR2, DAB2IP, ERG, IL6R, LDLR, 
LINC00540, MMP9, PCIF1, PSRC1, SMYD2, SORT1, ZNF335, and TNF. 
The parameters for the IPA were: 1. the Ingenuity Knowledge Base was used as a reference set; 2. both 
direct and indirect relationships were considered; and 3. only relationships that were either 
experimentally observed or had predictions with high confidence were considered. The relationships 
displayed as direct interactions mean that the two molecules make physical contact with each other 
such as binding or phosphorylation, and those displayed as indirect interactions do not require physical 
contact between the two molecules, such as signaling events. The IPA network generation algorithm has 
been described previously194. The IPA’s Core Analysis generated 2 networks, (1) “cardiovascular disease, 
cellular movement, developmental disorders” (P=1x10-21; 8/12 molecules), and (2) “cell signalling, 
nucleic acid metabolism, small molecular biochemistry” (P=1x10-7; 3/12 molecules). We merged the two 
networks into an interaction figure (Online Figure V). This identified that ERG, IL6R and LDLR were 
predicted modifiers of MMP9, with a direct interaction between ERG and MMP9. SORT and LDLR appear 
coupled via ERK and LDL. IL6R affects DAB2IP which in turn regulates NFKB. Several gene products, such 
as ANRIL, CELSR2, ZNF335 and SMYD2 have poorly defined functions at present, and LINC00540, a long 
non-coding RNA expressed in the hippocampus and lacking annotation information, did not belong to 
either of the 2 networks. The long non-coding RNA ANRIL, our strongest hit in the genome (Figure 1), 
has been reported in numerous studies as a GWAS hotspot and a candidate gene for CAD, intracranial 
aneurysms, and diverse cardiometabolic disorders195. 
The same gene list was submitted to the ConsensusPathDB web-based tool for generating an inferred 
network. ConsensusPathDB-human integrates interaction networks in Homo sapiens including binary 
and complex protein-protein, genetic, metabolic, signaling, gene regulatory and drug-target 
interactions, as well as biochemical pathways. Data currently originate from 32 public resources for 
interactions and interactions that have been curated from the literature. The interaction data are 
integrated in a manner to avoid redundancies, resulting in an interaction network containing different 
types of interactions. When the analysis was carried out, the database contained the following 
annotations: 158,523 unique physical entities; 458,570 unique interactions (17,098 gene regulation, 
261,085 protein interaction, 443 genetic, 21,070 biochemical reactions, and 158,874 drug-target 
interactions), and 4,593 pathways. ConsensusPathDB infers a network to include proteins or metabolites 
that are not in the user-supplied input list, but associate two or more nodes (gene/protein/metabolite) 
on the input list with each other. These nodes are termed intermediate nodes and are ranked according 
to the significance of association with the input nodes given their overall connectivity in the background 
network. This is quantified by a z-score calculated for each intermediate node with the binomial 
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proportions test. The default z-score was used. The network was visualized using CytoScape (version 
3.4.0).  
Four genes from the input list did not map to known entities in ConsensusPathDB: ANRIL and LINC00540 
are long non-coding RNAs and not represented; similarly PCIF1 and ZNF335 are poorly annotated and 
not currently represented in source databases (Online Figure VI). The inferred network generated by 
ConsensusPathDB is largely similar to that produced by IPA, although it lacks the interaction between 
SMYD2 and IL6R, and SMYD2 and TNF. The absence of these interactions could be due to the recent 
elucidation as well as the unknown mechanism by which the SMYD2 suppression of TNF and IL6 occurs. 
The number of interactions of a node is a function of the true number of interactions as well as how well 
studied the protein or gene is. In the network (Online Figure VI) MMP9 and TNF have a large number of 
interactions. Interestingly LDLR and SMYD2 both have indirect interactions with MMP9 and TNF through 
CREBP, and could have synergistic effects on the AAA phenotype. Additionally CREBP has an interaction 
with NFKB complex and ETS1. Inhibition of NFKB and ETS1 was shown to reduce AAA in a rat model196 
and their promoter binding sites were enriched in the promoters of genes upregulated in human AAA197. 
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Online Figure V. Potential interactions between gene products of AAA related genes. This figure shows IPA networks 1 and 2 merged together. 
Molecules are represented as nodes, and the biological relationship between two nodes as a line. Solid lines represent direct and dashed lines 
indirect interactions. All lines are supported by at least one literature citation or are from canonical information stored in the Ingenuity Pathways 
Knowledge Base (Qiagen’s Ingenuity Systems). Nodes are displayed using various shapes that represent the functional class of the gene product. 
Molecules in orange are encoded by genes harboring AAA-associated variants. Red dashed lines indicate new information on SMYD2, IL6 and 
TNF found in recent literature192, 193 
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Online Figure VI: Induced network generated by ConsensusPathDB from 14 input genes. The network comprises, genes, gene products 
(proteins), protein complexes, and metabolites, represented as nodes of different colors: pink, protein; light-blue, gene; medium blue, protein 
complexes; yellow, metabolite; and light green, unknown complex. Node shape indicates whether the node was on the input list: octagons, 
input list; rhomboids, induced nodes. Interactions are represented as edges, with color indicating interaction type: blue, protein interaction; red, 
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